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8 General introduction  
General introduction 
Cardiovascular disease (CVD) is one of the leading causes of death in industrialized 
countries. In 2012, 28% of deaths in women and 27% of deaths in men were due to 
CVD 
1
. In addition, it is estimated that the prevalence of CVD in the United States in 
2008 was 82.6 million individuals (36.2% of the total population above 20 years) 
2
. 
Although the absolute number of deaths due to CVD has decreased during the last 
decades, the public health burden from CVD remains high 
1;2
. With increasing age, 
the proportion of deaths caused by CVD increases; in women and men between 55 
and 85 years 25-26 % of the deaths can be contributed to CVD, compared to 32-35% 
in men and women aged 85 years and older 
1
.  
A high low-density lipoprotein (LDL)-cholesterol level is one of the most important 
risk factors for CVD. Accumulation of lipids and fibrous elements in the large arteries 
results in atherosclerosis, a progressive disease and an important contributor to CVD 
3
. Analysis of 68 prospective studies including over 300,000 participants has shown a 
strong association between high LDL-cholesterol levels and increased risk for 
coronary heart disease 
4
. Therefore, lowering LDL-cholesterol levels is a primary 
therapy to reduce CVD risk. 
HMG-CoA reductase inhibitors, better known as statins, are the most prescribed class 
of drugs worldwide and are widely used in the prevention of CVD.  Statin therapy has 
been proven to lower LDL-cholesterol levels up to 55% 
5
 and reduce the incidence of 
CVD events by 20-30% 
6
. Despite the clinical effectiveness of statins, there is large 
variability in clinical response to statin therapy. For example, within the PROSPER 
trial, 13% of the subjects allocated to statin treatment did not reach >10% LDL-
cholesterol lowering after 36 months of pravastatin treatment 
7
. In recent years, 
several studies have shown that genetic factors may influence the inter-individual 
variation in response to statin therapy 
8;9
.  
Pharmacogenetic studies are used to assess whether genetic variation contributes to 
the variability in clinical response to drug therapy. The aim of pharmacogenetic 
studies is to develop better patient- or disease-specific health care 
10
. In the past, 
pharmacogenetic studies were mainly performed by investigating only one genetic 
variant at a time. These candidate gene studies focused on genes hypothesized to be 
involved in the disease or drug response. Nowadays more and more genome-wide 
associations studies (GWAS) are performed. Unlike candidate gene approaches, 
GWAS can link multiple genetic variants with no a priori assumptions, thereby 
facilitating new discoveries 
11
. Pharmacogenetic studies with regard to statin therapy 
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have mainly focused on the lipid lowering response to statins. Several studies have 
shown that genetic variation within the APOE and LPA genes are associated with the 
level of LDL-cholesterol lowering after statin therapy 
12-14
.  Less is known about 
genetic variation associated with variability in clinical event reduction and side 
effects in response to statin therapy.  
Besides improving CVD treatment by identifying genetic variants associated with the 
variability in statin response, another option would be to develop new treatment 
options. One of the promising new LDL-cholesterol lowering drugs are the proprotein 
convertase subtilisin-like/kexin type 9 (PCSK9) inhibitors. PCSK9 is a protein involved 
in the LDL-cholesterol metabolism by promoting the degradation of LDL receptors 
15
. 
Several phase I and II clinical trials have shown that inhibiting PCSK9 by monoclonal 
antibodies is very effective in lowering LDL-cholesterol levels 
16
. Phase III trials 
including more participants followed over a longer period are currently ongoing to 
assess the effects of the inhibitors on CVD and other adverse events 
16
.  
The aim of the PROSPER trial was to investigate the effectiveness of pravastatin in 
the elderly.  Pravastatin reduced the LDL-cholesterol levels by 34% and reduced the 
incidence of CVD by 15%, and was thereby shown to be effective even in the elderly 
7
. However, the association between LDL-cholesterol and CVD and mortality risk at 
older ages is controversial. Observational studies including elderly participants have 
shown no or inverse associations 
17
. This might be explained by the observation that 
at old age, LDL-cholesterol levels in plasma may not reflect their life-time LDL-
cholesterol levels due to comorbidities 
18
. The use of genetic variants, associated 
with LDL-cholesterol levels, provides a possibility to investigate the association 
between LDL-cholesterol and CVD and mortality in the elderly free of biases.  
Outline of this thesis 
In this thesis, several of the issues described above are addressed, with the aim to 
give more insight in the (pharmaco) genetics of lipid metabolism in cardiovascular 
disease. In the first four chapters the focus will be on the pharmacogenetics of statin 
therapy. In chapter 2 an extensive overview is given of the literature on candidate 
gene studies and GWAS investigating the pharmacogenetic effects on statin therapy. 
In chapter 3 we describe the PHArmacogenetic study of Statins in the Elderly at risk 
(PHASE), the GWAS performed in the PROSPER study. This GWAS is used in 
pharmacogenetic studies within PROSPER to identify genetic variation responsible for 
individual variation in drug response to pravastatin. In addition, we used the GWAS 
on baseline LDL-cholesterol levels to validate the use of the GWAS for future genetic 
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studies. In chapter 4 the first results of the analyses performed for the Genomic 
Investigation of Statin Therapy (GIST) consortium are shown. Collaboration in large 
consortia is needed to increase the power of pharmacogenetic analysis. In this 
chapter we present the results of the pharmacogenetic meta-analysis of GWAS of 
LDL-cholesterol response to statins, with the aim of determining whether additional 
loci influence LDL-cholesterol response to statins. In chapter 5 we performed a 
GWAS in the PROSPER/PHASE study to investigate whether there are genetic variants 
associated with a clinically meaningful differential event reduction by pravastatin 
treatment.  
In chapter 6 we tried to distinguish between non-responders and non-adherers to 
statin therapy in the PROSPER study. In pharmacogenetic studies, genetic variation in 
non-responders and high-responders are compared with the goal to identify genetic 
loci associated with the inter-individual variation in drug response. However, in this 
context it is an important question whether the non-responders are true non-
responders or whether they are actually non-adherent. In chapter 7 we shortly 
discuss the usage of statins worldwide and whether there are indications that they 
would work differently in different parts of the world.  
In chapter 8 a genetic risk score was created based on genetic variants associated 
with variation in LDL-cholesterol levels. We used this genetic risk score to assess the 
unconfounded associations between LDL-cholesterol and mortality and longevity in 
three Dutch cohorts.  
Since LDL-cholesterol is an important risk factor of CVD, even at old age, the aim is to 
develop new treatment approaches to decrease LDL-cholesterol levels. One of these 
are the PCSK9 inhibitors. Since it is not known whether these inhibitors will have an 
influence on cognitive performance or clinical events, we assessed in chapter 9 the 
relation between genetic variants within the PCSK9 gene and cognitive function and 
non-cardiovascular events in the participants of the PROSPER study.    
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Abstract 
Statins are the most commonly prescribed class of drug worldwide and therapy is 
highly effective in reducing low-density lipoprotein cholesterol levels and 
cardiovascular events. However, there is large variability in clinical response to statin 
treatment. Recent research provides evidence that genetic variation contributes to 
this variable response to statin treatment. Until recently, pharmacogenetic studies 
have used mainly candidate gene approaches to investigate these effects. Since 
candidate gene studies explain only a small part of the observed variation and results 
have often been inconsistent, genome-wide association (GWA) studies may be a 
better approach. In this paper the most important candidate gene studies and the 
first published GWA studies assessing statin response are discussed. Moreover, we 
describe the PHASE study, an EU-funded GWA study that will investigate the genetic 
variation responsible for the variation in response to pravastatin in a large 
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Introduction 
Cardiovascular disease is the leading cause of death in industrialized countries 
1
. The 
HMG-CoA reductase (HMGCR) inhibitors, also known as statins, are the most 
prescribed class of drug worldwide and are widely used in the prevention of 
cardiovascular disease. Statin therapy is generally associated with a low-density 
lipoprotein (LDL) cholesterol lowering up to 55% 
2
 and a reduction of cardiovascular 
events by 20-30% 
3
. Despite the clinical effectiveness of statins, there is large 
variability in clinical response to statin treatment. For example, within the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial, a large 
randomized clinical trial assessing the effectiveness of pravastatin in elderly, 
compliance with study medication was high, yet 13.3% of the subjects allocated to 
pravastatin did not reach 10% LDL-cholesterol lowering after 36 months of 
pravastatin treatment 
4
. Many studies from the past years provide evidence that 
genetic factors contribute to this inter-individual variation in drug response 
5;6
. The 
genetic variation associated with lipid lowering in response to statin therapy has 
been investigated mainly by previous pharmacogenetic studies.  Relatively little is 
known about the genetic variation associated with variability in clinical events and 
side effects in response to statin therapy. The aim of this paper is to give an overview 
of the literature on candidate gene studies and the more recent performed genome-
wide association (GWA) studies of pharmacogenetics of statins and to introduce the 
PHArmacogenetic study of Statin in the Elderly at risk (PHASE). 
Pharmacogenetic studies investigating variable lipid-lowering response after statin 
therapy 
Pharmacogenetic studies are performed to assess whether genetic variation accounts 
for the variability in clinical response to drug therapy. Meaningful candidate genes 
for investigating statin response are genes that belong to lipid metabolism, 
inflammation, thrombosis, and endothelial function as well as pharmacodynamic 
target genes, disease-modifying genes, and genes involved in uptake, distribution 
and metabolism of statins (see Figure 1 for the pharmacodynamic and 
pharmacokinetic statin pathways) 
5
.  More than 40 candidate genes have been 
described with respect to the variable effect of statins in lipid-lowering abilities, and 
the variable effect on the risk of clinical endpoints including myocardial infarctions 
and cardiovascular death 
6
.  
HMGCR is the rate limiting enzyme in cholesterol synthesis. Statins are competitive 
inhibitors of HMGCR and therefore this gene is an interesting target for 
pharmacogenetic studies. The largest reported pharmacogenetic study investigating 
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genetic variation in various candidate genes was performed in 1536 participants of 
the PRINCE study 
7
. One hundred and forty eight single nucleotide polymorphisms 
(SNPs) in 10 candidate genes known to be involved in cholesterol synthesis and statin 
metabolism were investigated. After correcting for multiple testing, two common 
intronic SNPs (chromosome 5 position 74726928 and 74739571, Human genome July 
2003 UCSC version hg16, based on build 34) in the HMGCR gene were significantly 
associated with a reduced response to pravastatin therapy. Those SNPs were tightly 
linked (linkage disequilibrium r
2
=0.90) and the results of the two SNPs were 
equivalent. Carriers of one copy of the minor allele of one of the SNPs had a 22% less 
relative reduction in total cholesterol levels and 19% less relative reduction in LDL-
cholesterol compared with participants homozygous for the major allele of one of 
the SNPs. Interestingly, no differences in baseline lipid levels were seen between the 
genotypes.  
Genetic variation of APOE, and in particular the ε2/ε3/ε4 variants (coded by rs7412 
and rs429358), have been investigated extensively 
8
. ApoE has various roles in lipid 
and lipoprotein metabolism and thus a clear impact on plasma lipid and lipoprotein 
levels. It has been shown in many studies that the APOE ε4 and ε2 alleles associate 
B A 
Figure 1. Pharmacokinetic (a) and pharmacodynamics (b) pathways of statins 
Abbreviations: FA: Fatty acid; HDL: High-density lipoprotein; IDL: Intermediate-density lipoprotein; LDL: 
Low-density lipoprotein; VLDL: Very low-density lipoprotein. 
Reproduced from McDonagh et al. 
55
. Used with permission of PharmGKB and Stanford University. 
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with higher and lower concentrations of total cholesterol, LDL-cholesterol and ApoB, 
respectively, compared with the ε3 allele 
9-11
.  The results of studies on APOE SNPs 
and statin therapy response are equivocal, which has been summarized in a review 
by Nieminen et al. 
8
. Several studies report less effect of statins in ε4 carriers for 
lowering cholesterol levels, compared with ε3 carriers, whereas carriers of the ε2 
allele have a larger reduction of cholesterol levels during statin therapy compared 
with ε3 carriers. Nevertheless, several studies found no significant associations for 
APOE SNPs and lipid levels during statin therapy 
8
. A recent meta-analysis did also 




Other pharmacogenetic studies have investigated genetic variation in LDL-cholesterol 
related candidate genes, for example the LDL-receptor gene 
13
. However, most of the 
results from studies investigating changes in lipid levels and cardiovascular event 
responses are difficult to interpret, because of strong influences of the genetic 
variation on baseline lipid levels 
5
.  Also several genes have been investigated for 
their pharmacokinetic and dynamic influences on statins. Two of those genes are 
SLCO1B1, the gene encoding the solute carrier organic anion transporter family 
member 1B1 (OATP1B1) influx, and ATP-binding cassette sub-family B member 1 
(ABCB1) efflux transporter. The group of Niemi et al. showed that ABCB1 haplotypes 
(rs1045642, rs2032582 and rs1128503) affected the pharmacokinetics of the active 
acid forms of simvastatin and atorvastatin 
14
. In vivo pharmacokinetic studies have 
shown associations between SLCO1B1 variations and statin plasma concentrations. 
Those pharmacokinetic features could only be translated to cholesterol-lowering 
abilities in small in vivo pharmacodynamic studies, results from larger studies are 
contradictory 
15
. Other genes involved in the metabolism of statins are for example 
CYP3A4 and ABCG2, but research has not been able to produce definitive results to 
show the possible role of these genes in the pharmacogenetics of statins 
16
.    
Pharmacogenetic studies investigating variation in clinical events after statin 
therapy 
Kinesin-like protein 6 (KIF6) is a member of the molecular motor superfamily 
involved in intracellular transport of several important molecules, including mRNA 
17
. 
Several studies have shown an association between the Trp719Arg (rs20455) SNP in 
the KIF6 gene and coronary heart disease 
18-23
. Furthermore, analyses in four large 
clinical trials have shown a substantially increased benefit of statin therapy in 
carriers of this SNP compared with non-carriers 
18;19;24
. In the WOSCOPS study, a 
primary prevention statin trial, the absolute risk reduction of coronary heart disease 
by statin therapy was 5.5% in carriers of the SNP compared with 0.1% in noncarriers 
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19
. In the secondary prevention trials PROSPER, CARE, and PROVE IT - TIMI 22, the 
absolute risk reduction by statin therapy ranged from 5% to 10% in carriers of the 
SNP compared with 0.4% to 1.2% in noncarriers. The endpoints of interest in those 
studies were respectively: coronary events, myocardial infarction, and death or 
major cardiovascular events 
18;19;24
.  However, those results are equivocal; an 
accompanying editorial in the Journal of the American College of Cardiology 
expressed their doubts about the validity of those studies 
25
. Moreover, a recent 
meta-analysis of 19 case-control studies (in total 17,000 coronary artery disease 
(CAD) cases and 39,369 controls) reported no association between the KIF6 SNP and 
the risk of clinical CAD 
17
. Furthermore, within the 18,348 participants from the HPS 
study, the KIF6 SNP was not associated with the risk of incident vascular events 
among placebo treated participants, and reductions in the risk of vascular events 
during statin therapy were similar across KIF6 genotypes 
26
.  
Another gene that has been analyzed comprehensively is the CETP gene. CETP is 
involved in cholesterol metabolism by transporting cholesteryl ester back into the 
liver and functions to transport triglycerides from LDL and very low-density to high-
density lipoprotein (HDL) cholesterol 
27
. The most investigated SNP in CETP is the 
Taq1B variant (rs708272), a SNP in the first intron of the CETP gene. Initial studies 
associated the B2B2 genotype of the CETP gene with lower CETP levels 
28
, higher 
HDL-cholesterol levels, and a lower risk of progression of CAD, compared with the 
B1B1 CETP genotype 
29-32
. However, when patients with the B1B1 genotype were 
treated with statins, they showed a lower progression of CAD compared with B2B2 
carriers. In addition, long-term results from the REGRESS study, the first study to 
report the possible pharmacogenetic interactions between the CETP SNP and statin 
treatment 
33
, demonstrated significantly higher 10-year mortality in statin-treated 
male B2 carriers, compared with carriers of the B1B1 genotype 
34
. Therefore, 
although untreated B2B2 patients have a lower risk of CAD progression, statin 
treatment is more beneficial in patients with the B1B1 genotype, denying the initial 
advantage of the B2 allele in CAD. A large meta-analysis including 13,677 subjects 
confirmed the association between the Taq1B SNP and HDL-cholesterol levels and 




SNPs in the APOE gene have also been assessed in the relation with progression of 
coronary heart disease during statin therapy
8
. Gerdes et al. analyzed data of 5.5 
years of follow-up from 966 Danish and Finnish myocardial infarction survivors 
enrolled in the Scandinavian Simvastatin Survival Study (4S) 
36
. Carriers of the APOE 
ε4 allele had nearly twofold higher mortality compared with noncarriers of the ε4 
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allele during simvastatin therapy. However, the results found in the 4S trial are 
equivocal; analyses in almost 8000 participants from the Rotterdam Study and in 815 
men in the REGRESS study could not confirm the pharmacogenetic effect of statins 
on cardiovascular endpoints 
37;38
.   
Two another genes investigated in relation with statin therapy and clinical events are 
SLCO1B1 and ABCB1. Peters et al. tested 24 tagging SNPs in the two genes in 668 
cases with myocardial infarction and 1217 controls from the population-based 
PHARMO study 
39
. They found two SNPs within ABCB1 (rs3789244 and rs1922242) to 
interact significantly with statin therapy. In addition, they observed a non-significant 
interaction between the SLCO1B1*1A haplotype and statin treatment; odds ratio 
(OR) homozygote carriers 0.49 (95% CI 0.34-0.79) compared with 0.31 (95% CI 0.24-
0.41) for heterozygous or noncarriers of the *1A allele 
39
. 
GWA studies  
As shown in the previous paragraphs, various studies have assessed the association 
between genetic polymorphisms and response to statin therapy. At least two reviews 
have given an elaborate overview of the pharmacogenetic candidate genes and their 
genotype effects related to statin therapy 
5;6
. Table 1 shows a brief overview of the 
most important investigated candidate genes in their relation to efficiency and 
clinical effectiveness after statin therapy. Based on these data, candidate genes 
regulating pharmacokinetic and pharmacodynamic properties of statins appear to be 
the most promising target genes (see figure 1). Although the genetic variation in 
these pharmacokinetic and pharmacodynamic pathways has received much attention 
over the past years, it only explains a small part of the observed variation, and the 
results are often inconsistent. Therefore, it is now important to investigate which 
other genetic pathways are responsible for the remaining genetic variation in statin 
response.  
GWA studies are another approach to investigate pharmacogenetic effects. Unlike 
candidate gene approaches, GWA studies can link multiple SNPs to drug response 
with no a priori assumptions, thereby facilitating new discoveries. At present, only 
three GWA studies investigating genetic variants and variation in response to statin 
therapy have been published, focusing on lipid lowering and adverse effects of statin 
therapy 
40-42
. The first published GWA study on statin response was performed in the 
TNT study. This study used a combination of a genome-wide and candidate gene 
approach. Using only the GWA study in 1984 individuals, no SNPs were genome-wide 
significantly associated with statin response. However, by analyzing the candidate 
genes in the genotyped participants, they found the SNP rs7412 in the APOE gene  
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Table 1. Overview of a selection of the genes investigated for associations with statin treatment and 
several outcomes 
Gene Main outcome parameter 
of the study 
Statin Study type Results Ref 
HMGCR Plasma lipids Pravastatin, 
simvastatin, 
atorvastatin 
Candidate gene SNPs associated with LDLC and TC 
lowering 
7,40,56 
APOE Plasma lipids Pravastatin Candidate gene No association 7 
 Plasma lipids, coronary 
events 
Atorvastatin Candidate gene 
and GWAS 
SNP associated with LDLC response 
but not with clinical events 
40 
 Plasma lipids Various  Meta-analysis No association 12 
 Death or major coronary 
event 
Simvastatin Candidate gene SNP associated with mortality but 
not with major coronary events 
36 
 Plasma lipids, coronary 
angiography 
Pravastatin Candidate gene SNP associated with lipids but not 
with angiography 
37 
 MI, stroke and mortality Various Candidate gene No association 38 




SNPs affect the pharmacokinetics   14 
 Myocardial infarction Various Candidate gene Interaction between SNPs and statin 
treatment 
39 
SLCO1B1 Pharmacokinetics Various Candidate gene, 
in vivo 
SNPs affect the pharmacokinetics   15 
 Myopathy Simvastatin GWAS SNP associated with risk for 
myopathy 
41 
 Myopathy Simvastatin, 
atorvastatin 
Candidate gene SNP associated with myopathy in 
simva users, but not in atorva users 
43 
 Myocardial infarction Various Candidate gene Non-significant interaction between 
haplotype and statin treatment 
39 
KIF6 Coronary events Pravastatin, 
atorvastatin 
Candidate gene Association between SNP and events 18,19,24 
 Coronary events Simvastatin Candidate gene No association 26 
CETP Lipid lowering Pravastatin Candidate gene No association 7 
 CAD Pravastatin Candidate gene SNP associated with CAD 
progression 
29 
 CV events Various  Candidate gene SNP associated with risk of CV 
events 
57 
 CV events Pravastatin Candidate gene, 
meta-analysis 
No treatment interaction 30,35 
 Mortality Pravastatin Candidate gene SNP associated with 10-yr mortality 34 





SNP associated with TC lowering 42 
Abbreviations: SNP, Single nucleotide polymorphism; LDLC, low-density lipoprotein cholesterol; TC, total 
cholesterol; GWAS, Genome-wide association study; MI, Myocardial infarction; CAD, coronary artery 
disease; CV, cardio vascular. 
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significantly associated with statin response (p=3.65 x 10
-9
). The rs7412 SNP was not 
present on the platform used for the GWA scan used in the TNT study and was not in 
linkage disequilibrium with any of the SNPs in the GWA scan 
40
.  
The second published GWA study on statin response was a meta-analysis performed 
in approximately 4,000 subjects from three statin trials; the CAP trial, the PRINCE 
study, and the TNT study. An association between the gene CLMN, encoding calmin, 
and the reduction in total cholesterol levels after statin treatment was observed. The 
function of calmin is unknown and has not been implicated in cholesterol 
metabolism before. The combined analysis of these three studies found an 84% 
posterior probability that the CLMN SNP (rs8014194) was genuinely associated with 
statin-mediated change in total cholesterol (p=1.9 x 10
-8
). On average across the 
three studies, carriers with two copies of the minor allele of rs8014194 had a 3% 
lower total cholesterol reduction compared with noncarriers 
42
. Nevertheless, further 
(functional) studies are needed to replicate this finding and explore the function of 
calmin.  
The third published GWA study investigated genetic variation in relation with statin-
induced myopathy, an adverse side effect of statin therapy. This GWA study included 
85 subjects with definite or incipient myopathy and 90 controls, all taking 80 mg 
simvastatin daily. The SNP rs4363657 located within the SLCO1B1 gene, which 
encoded the polypeptide OATP1B1, which mediates the hepatic uptake of most 
statins, was found to be associated with myopathy (p=4.1 x 10
-9
). The noncoding 
rs4363657 SNP was in nearly complete linkage disequilibrium with the non-
synonymous rs4149056 SNP (Val174Ala; r
2
=0.97), which was also located within the 
SLCO1B1 gene and has been linked to statin metabolism. The OR for myopathy was 
4.3 per copy of the rs4363657 C allele (minor allele frequency: 0.13) and 17.4 in 
homozygote carriers of the CC variant compared with homozygote carriers of the 
common variant (TT) 
41
. This is the strongest effect found until now from a 
pharmacogenetic effect in relation to the response to statin therapy. Brunham et al. 
have performed a study aiming to replicate the association of rs4149056 and statin-
induced myopathy is a cohort of patients using various statin types 
43
. In this small 
study, including 25 cases of severe statin-induced myopathy and 83 controls, the SNP 
was not associated with myopathy in the complete group. However, stratifying 
patients by statin type, the SNP was significantly associated with myopathy in 
simvastatin users (OR: 3.2, p=0.042), but not in atorvastatin treated patients (OR: 
4.5, p=0.48). These different results between different statin types indicate the 
presence of possible statin type-specific pharmacogenetic effects.  
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Pharmacogenetic study of Statin in the Elderly at risk, a large GWA study 
Results of pharmacogenetic candidate gene studies are often inconsistent and 
explain only a small part of the observed variation in statin response. Furthermore, 
GWA studies enable detection of novel and less obvious genes. Since there are 
currently only three GWA studies on statin response published with only very low 
subject numbers, we have initiated the PHArmacogenetic study of Statin in the 
Elderly at risk (PHASE) 
44
. PHASE is a EU sponsored GWA study in the participants of 
the PROSPER study 
4
 investigating the genetic variation responsible for the individual 
variation in drug response. The PROSPER study provides a good population to study 
pharmacogenetics. First, PROSPER is an investigator-driven, prospective multi-
national randomized placebo-controlled trial including 5,804 subjects aged 70-82 
years at baseline of whom more than 50% was female. Plasma levels of LDL-
cholesterol as well as other levels of plasma lipoproteins were measured at baseline 
and prospectively during follow-up for a mean of 3.2 years (range 2.8-4.0). Second, 
within the PHASE study 557,192 SNPs in 5,244 subjects are available for analysis, and 
to maximize the availability of genetic data and coverage of the genome those SNPs 
have been imputed up to 2.5 million SNPs. A GWA study for LDL-cholesterol was used 
as proof-of-principle analysis in the PROSPER/PHASE study. With this GWA study five 
of the previously found genetic associations with LDL-cholesterol were confirmed 




The large number of statistical tests performed in a GWA analysis requires large 
sample sizes to provide adequate statistical power to detect small effect sizes. For 
this purpose it is necessary to cooperate with other studies. To investigate genetic 
loci affecting statin response and adverse effects the PHASE study is involved in the 
Genomic Investigation of Statin Therapy (GIST) consortium. GIST is a large 
international consortium formed to conduct a combined meta-analysis of GWA and 
replication studies, including several randomized controlled trials (RCT) of statin 
therapy and several non-trial cohorts of statin recipients with GWA data.  Most of 
the large RCTs are participating in the GIST consortium, including the 
PROSPER/PHASE study, the CAP trial, the PRINCE study, the TNT study, the CARDS 
study 
45
, and the ASCOT trial 
46
.  Together those studies provide data of 
approximately 10,000 statin treated subjects. The non-trial cohorts involved in the 
GIST consortium are the cohorts of the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium 
47
. The studies from CHARGE are 
supplemented with the MESA study 
48
, the HABC study 
49





, and the biobank of the Vanderbilt University (BioVu) 
52
. With 
those studies participating in GIST there is observational data available of 
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approximately 10,000 statin treated subjects. The first plan for the GIST consortium 
is to conduct a meta-analysis of GWA studies and replication studies to identify novel 
loci influencing statin response. For this aim every participating study will perform 
their own analysis assuming an additive genetic model. To overcome the less 
certainty of imputed SNPs, regression analysis onto expected allele dosages will be 
performed. The meta-analysis will be performed with the random effects model. To 
correct for multiple testing, we will use a p-value threshold of 5.0x10
-8
 for statistical 
significance. To conclude, with the GIST consortium we have data of approximately 
20,000 statin treated subjects, which gives the opportunity to assess the genetic 
variation responsible for the variable response to statin treatment in a large 
consortium. 
Future perspective 
Over previous years, substantive effort has been made in investigating the 
pharmacogenetics of the variable response to statin treatment. With the GWA 
analysis performed in the PHASE study and the meta-analysis in the GIST consortium 
we hope to identify novel genes and pathways involved in the variation in statin 
response. Expanding the knowledge about the genes and pathways associated with 
the variation in statin response might lead to substantial improvements in the use of 
cardiovascular drug therapy, through selection of the most appropriate drug therapy 
based on an individual’s genetic make-up 
53;54
. With the results of the PHASE study 
and the GIST consortium we aim to identify nonresponders or subjects who will 
experience adverse effects by their genetic variation. 
However, with the GWAS study performed in the PROSPER/PHASE study and the GIST 
consortium only common variants associated with statin response will be detected. 
Within the PROSPER/PHASE study we will perform an exome sequencing study to 
identify also rare variants associated with statin response. High responders to statin 
therapy will be compared with low or nonresponders in order to find the biological 
pathways involved in pharmacogenetics of statin therapy. Moreover, epigenetic 
studies will be executed to investigate the epigenetic mechanisms involved in the 
interindividual variation in response to statin treatment. All genetic or epigenetic 
variation that will be identified by these studies will be further tested in a clinical 
setting to investigate their use in clinical practice. 
  
 
24 Pharmacogenetics of statins 
Acknowledgements and Funding 
The research leading to these results has received funding from the European 
Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 
HEALTH-F2-2009-223004. For a part of the genotyping we received funding from the 
Netherlands Consortium of Healthy Aging (NGI: 05060810). This work was performed 
as part of an ongoing collaboration of the PROSPER study group in the universities of 
Leiden, Glasgow and Cork. Prof. Dr. J.W. Jukema is an Established Clinical Investigator 
of the Netherlands Heart Foundation (2001 D 032).  
 
25 Chapter 2 
References 
 (1)  McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. Recent trends 
in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The 
Minnesota Heart Survey Investigators. N Engl J Med 1996 Apr 4;334(14):884-90. 
 (2)  Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 
2004 Sep;47(2):73-104. 
 (3)  Ballantyne CM. Achieving greater reductions in cardiovascular risk: lessons from statin therapy 
on risk measures and risk reduction. Am Heart J 2004 Jul;148(1 Suppl):S3-S8. 
 (4)  Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in 
elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 
2002 Nov 23;360(9346):1623-30. 
 (5)  Schmitz G, Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 
2006 Feb;44(2):75-89. 
 (6)  Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, et al. A 
systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical 
application? Eur Heart J 2011 Jul 30;33(2):165-75. 
 (7)  Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Jr., Ridker PM. 
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004 Jun 
16;291(23):2821-7. 
 (8)  Nieminen T, Kahonen M, Viiri LE, Gronroos P, Lehtimaki T. Pharmacogenetics of apolipoprotein 
E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. 
Pharmacogenomics 2008 Oct;9(10):1475-86. 
 (9)  Lehtimaki T, Moilanen T, Viikari J, Akerblom HK, Ehnholm C, Ronnemaa T, et al. Apolipoprotein 
E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res 1990 
Mar;31(3):487-95. 
 (10)  Lehtimaki T, Moilanen T, Nikkari T, Solakivi T, Porkka K, Ehnholm C, et al. Regional differences 
in apolipoprotein E polymorphism in Finland. Ann Med 1991 Feb;23(1):61-6. 
 (11)  Ilveskoski E, Loimaala A, Mercuri MF, Lehtimaki T, Pasanen M, Nenonen A, et al. 
Apolipoprotein E polymorphism and carotid artery intima-media thickness in a random sample 
of middle-aged men. Atherosclerosis 2000 Nov;153(1):147-53. 
 (12)  Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G. APOE gene polymorphisms and response 
to statin therapy. Pharmacogenomics J 2009 Aug;9(4):248-57. 
 (13)  Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase 
inhibitors: exploring the potential for genotype-based individualization of coronary heart 
disease management. Atherosclerosis 2004 Dec;177(2):219-34. 
 (14)  Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the 
pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin 
Pharmacol Ther 2008 Oct;84(4):457-61. 
 
26 Pharmacogenetics of statins 
 (15)  Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene 
polymorphisms on response to statin therapy. Pharmacogenomics J 2010 Feb;10(1):1-11. 
 (16)  Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin 
treatment. Pharmacogenomics J 2006 Nov;6(6):360-74. 
 (17)  Assimes TL, Holm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, et al. Lack of 
association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery 
disease in 19 case-control studies. J Am Coll Cardiol 2010 Nov 2;56(19):1552-63. 
 (18)  Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, et al. Polymorphism 
in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE 
IT-TIMI 22 study. J Am Coll Cardiol 2008 Jan 29;51(4):449-55. 
 (19)  Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR, et al. 
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction 
and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll 
Cardiol 2008 Jan 29;51(4):435-43. 
 (20)  Li Y, Iakoubova OA, Shiffman D, Devlin JJ, Forrester JS, Superko HR. KIF6 polymorphism as a 
predictor of risk of coronary events and of clinical event reduction by statin therapy. Am J 
Cardiol 2010 Oct 1;106(7):994-8. 
 (21)  Shiffman D, Chasman DI, Zee RY, Iakoubova OA, Louie JZ, Devlin JJ, et al. A kinesin family 
member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am 
Coll Cardiol 2008 Jan 29;51(4):444-8. 
 (22)  Bare LA, Morrison AC, Rowland CM, Shiffman D, Luke MM, Iakoubova OA, et al. Five common 
gene variants identify elevated genetic risk for coronary heart disease. Genet Med 2007 
Oct;9(10):682-9. 
 (23)  Shiffman D, O'Meara ES, Bare LA, Rowland CM, Louie JZ, Arellano AR, et al. Association of gene 
variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler 
Thromb Vasc Biol 2008 Jan;28(1):173-9. 
 (24)  Iakoubova OA, Robertson M, Tong CH, Rowland CM, Catanese JJ, Blauw GJ, et al. KIF6 
Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the 
PROSPER study. Eur J Cardiovasc Prev Rehabil 2010 Aug;17(4):455-61. 
 (25)  Marian AJ. Surprises of the genome and "personalized" medicine. J Am Coll Cardiol 2008 Jan 
29;51(4):456-8. 
 (26)  Hopewell JC, Parish S, Clarke R, Armitage J, Bowman L, Hager J, et al. No impact of KIF6 
genotype on vascular risk and statin response among 18,348 randomized patients in the heart 
protection study. J Am Coll Cardiol 2011 May 17;57(20):2000-7. 
 (27)  Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the 
effects of statins. Drug Saf 2011 Jan 1;34(1):1-19. 
 (28)  Kuivenhoven JA, de KP, Boer JM, Smalheer HA, Botma GJ, Seidell JC, et al. Heterogeneity at the 
CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. 
Arterioscler Thromb Vasc Biol 1997 Mar;17(3):560-8. 
 (29)  Kuivenhoven JA, Jukema JW, Zwinderman AH, de KP, McPherson R, Bruschke AV, et al. The role 
of a common variant of the cholesteryl ester transfer protein gene in the progression of 
 
27 Chapter 2 
coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 
1998 Jan 8;338(2):86-93. 
 (30)  Freeman DJ, Samani NJ, Wilson V, McMahon AD, Braund PS, Cheng S, et al. A polymorphism of 
the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in 
the West of Scotland Coronary Prevention Study. Eur Heart J 2003 Oct;24(20):1833-42. 
 (31)  Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, et al. Association of 
cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses 
and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000 
May;20(5):1323-9. 
 (32)  Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, et al. A prospective 
study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk 
of myocardial infarction in middle-aged men. Atherosclerosis 2002 Apr;161(2):469-74. 
 (33)  Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of 
lipid lowering by pravastatin on progression and regression of coronary artery disease in 
symptomatic men with normal to moderately elevated serum cholesterol levels. The 
Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995 May 15;91(10):2528-
40. 
 (34)  Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, et al. CETP 
genotype predicts increased mortality in statin-treated men with proven cardiovascular 
disease: an adverse pharmacogenetic interaction. Eur Heart J 2008 Nov;29(22):2792-9. 
 (35)  Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, et al. Cholesteryl 
ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular 
risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. 
Circulation 2005 Jan 25;111(3):278-87. 
 (36)  Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The 
apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin 
in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival 
study. Circulation 2000 Mar 28;101(12):1366-71. 
 (37)  Maitland-van der Zee AH, Jukema JW, Zwinderman AH, Hallman DM, De BA, Kastelein JJ, et al. 
Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery 
disease (REGRESS). Acta Cardiol 2006 Jun;61(3):327-31. 
 (38)  Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, et al. 
The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the 
elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics 2002 Nov;12(8):647-
53. 
 (39)  Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, van't Slot R, et al. Pharmacogenetic 
interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the 
prevention of myocardial infarction. Pharmacogenomics 2010 Aug;11(8):1065-76. 
 (40)  Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, et al. Comprehensive whole-
genome and candidate gene analysis for response to statin therapy in the Treating to New 
Targets (TNT) cohort. Circ Cardiovasc Genet 2009 Apr;2(2):173-81. 
 
28 Pharmacogenetics of statins 
 (41)  Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-
induced myopathy--a genomewide study. N Engl J Med 2008 Aug 21;359(8):789-99. 
 (42)  Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al. Genome-wide 
association of lipid-lowering response to statins in combined study populations. PLoS One 
2010;5(3):e9763. 
 (43)  Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, et al. Differential effect of the 
rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. 
Pharmacogenomics J 2011 Jan 18. 
 (44)  Trompet S, de Craen AJ, Postmus I, Ford I, Sattar N, Caslake M, et al. Replication of LDL GWAs 
hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Med Genet 
2011;12(1):131. 
 (45)  Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, et al. 
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 
diabetes. Diabet Med 2002 Mar;19(3):201-11. 
 (46)  Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Rationale, design, 
methods and baseline demography of participants of the Anglo-Scandinavian Cardiac 
Outcomes Trial. ASCOT investigators. J Hypertens 2001 Jun;19(6):1139-47. 
 (47)  Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, et al. Cohorts for Heart 
and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective 
meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2009 
Feb;2(1):73-80. 
 (48)  Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic study 
of atherosclerosis: objectives and design. Am J Epidemiol 2002 Nov 1;156(9):871-81. 
 (49)  Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, et al. Inflammatory 
markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung 
disease in well functioning elderly subjects. Thorax 2006 Jan;61(1):10-6. 
 (50)  Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of 
myocardial infarction associated with antihypertensive drug therapies. JAMA 1995 Aug 
23;274(8):620-5. 
 (51)  Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, et al. Variation in 
TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007 
Aug;56(8):2178-82. 
 (52)  Wilke RA. High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank 
cohorts to characterize clinical and genetic predictors of treatment outcome. 
Pharmacogenomics J 2011 Jun;11(3):162-73. 
 (53)  Seo D, Ginsburg GS, Goldschmidt-Clermont PJ. Gene expression analysis of cardiovascular 
diseases: novel insights into biology and clinical applications. J Am Coll Cardiol 2006 Jul 
18;48(2):227-35. 
 (54)  Meisel C, Gerloff T, Kirchheiner J, Mrozikiewicz PM, Niewinski P, Brockmoller J, et al. 
Implications of pharmacogenetics for individualizing drug treatment and for study design. J 
Mol Med (Berl) 2003 Mar;81(3):154-67. 
 
29 Chapter 2 
 (55)  McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic 
knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic 
biomarker resource. Biomark Med 2011 Dec;5(6):795-806. 
 (56)  Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, et al. Variation in the 3-
hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in 
low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008 Mar 
25;117(12):1537-44. 
 (57)  Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, et al. The cholesteryl 
ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in 











Replication of LDL GWAS hits in PROSPER/PHASE as 
validation for future (pharmaco)genetic analyses 
Stella Trompet, Anton JM de Craen, Iris Postmus, Ian Ford, Naveed Sattar, 
 Muriel Caslake, David J Stott, Brendan M Buckley, Frank Sacks, 
 James J Devlin, P Eline Slagboom, Rudi GJ Westendorp, J Wouter Jukema 
 on behalf of the PROSPER study group 
BMC Med Genet. 2011;12:131 
 
32 The PHASE study 
Abstract 
The PHArmacogenetic study of Statins in the Elderly at risk (PHASE) is a genome wide 
association study in the PROspective Study of Pravastatin in the Elderly at risk for 
vascular disease (PROSPER) that investigates the genetic variation responsible for the 
individual variation in drug response to pravastatin. Statins lower LDL cholesterol in 
general by 30%, however not in all subjects. Moreover, clinical response is highly 
variable and adverse effects occur in a minority of patients. In this report we first 
describe the rationale of the PROSPER/PHASE project and second show that the 
PROSPER/PHASE study can be used to study pharmacogenetics in the elderly. The 
genome wide association study (GWAS) was conducted using the Illumina 660K-Quad 
beadchips following manufacturer’s instructions. After a stringent quality control 
557,192 SNPs in 5,244 subjects were available for analysis. To maximize the 
availability of genetic data and coverage of the genome, imputation up to 2.5 million 
autosomal CEPH HapMap SNPs was performed with MACH imputation software. The 
GWAS for LDL cholesterol is assessed with an additive linear regression model in 
PROBABEL software, adjusted for age, sex, and country of origin to account for 
population stratification. Forty-two SNPs reached the GWAS significant threshold of 
p=5.0e-08 in 5 genomic loci (APOE/APOC1; LDLR; FADS2/FEN1; HMGCR; 
PSRC1/CELSR5). The top SNP (rs445925, chromosome 19) with a p-value of p=2.8e-30 
is located within the APOC1 gene and near the APOE gene. The second top SNP 
(rs6511720, chromosome 19) with a p-value of p=5.22e-15 is located within the LDLR 
gene. All 5 genomic loci were previously associated with LDL cholesterol levels, no 
novel loci were identified. Replication in WOSCOPS and CARE confirmed our results. 
With the GWAS in the PROSPER/PHASE study we confirm the previously found 
genetic associations with LDL cholesterol levels. With this proof-of-principle study we 
show that the PROSPER/PHASE study can be used to investigate genetic associations 
in a similar way to population based studies. The next step of the PROSPER/PHASE 
study is to identify the genetic variation responsible for the variation in LDL 
cholesterol lowering in response to statin treatment in collaboration with other large 
trials.  
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Introduction 
Cardiovascular disease is the leading cause of death in industrialized countries at old 
age. Advancing age is one of the most important risk factors for cardiovascular 
disease 
1
. With the rising number of elderly people in our society cardiovascular 
disease has a major impact on healthcare 
2
. The prevention of cardiovascular disease 
is critically dependent on lipid lowering therapy including the 3-hydroxymethyl-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Statins are the 
most prescribed class of drugs worldwide and therapy is generally associated with a 
reduction of cardiovascular events by 20-30%. However, clinical response is highly 
variable and adverse effects occur in a minority of patients 
3
. Recent research 




Pharmacogenomics focuses on unraveling the genetic determinants of such variable 
drug responses, both in intended, beneficial effects and unintended, adverse effects 
5
. Therefore, we here present the PHArmacogenetic study of Statin in the Elderly at 
risk (PHASE) a genome wide association study (GWAS) in the PROspective Study of 
Pravastatin in the Elderly at Risk for vascular disease (PROSPER)
6
 investigating the 
genetic variation responsible for the individual variation in drug response funded by 
the European Union's Seventh Framework Programme. To validate the GWAS 
performed in the PHASE study, we executed a proof-of-principle study to investigate 
the underlying genetic variation in LDL cholesterol levels.  
Recent GWA studies have identified several new loci that influence circulating levels 
of blood lipids with around 95 loci showing statistical associations with circulating 
total cholesterol levels, HDL cholesterol, LDL cholesterol, and triglycerides 
7
. These 
GWA studies are executed in population based studies with various age groups, 
however the elderly (age >75 years) are rarely represented in these studies. With this 
proof-of-principle study we provide a testing frame to show that the PROSPER/PHASE 
study has sufficient statistical power to find genome wide statistical significant 
associations in quantitative traits such as LDL cholesterol in an elderly population. 
We replicated our findings from the PROSPER/PHASE study in two independent 
cohorts to validate that our results contain no false positive findings.  
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Methods 
Study population 
PROSPER was an investigator-driven, prospective multi-national randomized placebo-
controlled trial to assess whether treatment with pravastatin diminishes the risk of 
major vascular events in the elderly 
6;8
. Between December 1997 and May 1999, we 
screened and enrolled subjects in Scotland, Ireland, and the Netherlands. Men and 
women aged 70-82 years were recruited if they had pre-existing vascular disease or 
were at increased risk of such disease because of smoking, hypertension, or diabetes. 
A total number of 5804 subjects, of whom more than 50% was female, were 
randomly assigned to pravastatin or placebo. Various clinical laboratory 
measurements were carried out like inflammatory markers (CRP and various 
cytokines) and other biochemical substrates (e.g. glucose, leptin) at baseline and 
during follow-up. The protocol of the PROSPER study meets the criteria of the 
Declaration of Helsinki and was approved by the Medical Ethics Committees of each 
participating institution. Written informed consent was obtained from all 
participating subjects. 
LDL cholesterol 
Plasma lipids and lipoproteins were measured twice during the
 
screening phase, i.e. 
at the beginning and end of the single-blind,
 
placebo "run-in" phase according to the 
standardized Lipid
 
Research Clinics protocol. Baseline LDL cholesterol levels were 
taken as the
 
average of these 2 determinations prior to randomization to statin 
treatment.  Total cholesterol (TC), HDL cholesterol, and triglycerides were assessed 





The genotyping was conducted using the Illumina 660-Quad beadchips following 
manufacturer’s instructions. These beadchips contain 657,366 single nucleotide 
polymorphism (SNP) and copy number variants (CNV) probes. After genotyping, 
samples and genetic markers were subjected to a stringent quality control protocol. 
From the 5763 samples with DNA available that underwent genotyping, 519 samples 
(9%) were excluded during the quality control (figure 1).  Excluded were 18 
duplicated samples, 219 samples with a call rate <97.5%, 11 samples with an excess 
for heterozygosity, 40 samples of non-caucasian origin, 170 samples with familiar 
relationships (IBD>0.35), and 61 samples with a gender mismatch. From the 657,366 
probes on the beadchips, 95,876 probes were filtered based on CNV intensity. 
Moreover, 4,298 SNPs were excluded with a call rate < 95%, leaving us with 557,192 
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SNPs for analysis. To maximize the availability of genetic data and coverage of the 
genome, imputation up to 2.5 million autosomal CEPH HapMap SNPs was performed 
with MACH imputation software based on the HapMap built II release 23. To assess 
accuracy of the imputed genotypes, we compared the imputation output with SNPs 
that had been previously genotyped on other platforms.  
 
Figure 1. Flow chart of the Quality Control of the PROSPER/PHASE study 
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Statistical Analysis 
Genome wide association analysis was performed with PROBABEL software 
specialized in genetic association analysis with imputed data taking the probability of 
the genotype into account (http://www.genabel.org/). With analyzing imputed 
genotypes, the observed allele count is replaced by the imputation’s estimated 
dosage. For the continuous trait, baseline LDL cholesterol levels, an additive linear 
regression model was used to assess estimates and standard errors. The model was 
adjusted for sex and age, and country to correct for the within-study population 
structure. Standard errors for the regression estimates were calculated with model-
robust methods. The analysis of 2.5 million SNPs at once poses a multiple testing 
problem. After the use of a Bonferroni correction, the threshold for genome wide 
significant results was set at 5.0e-08. 
Replication 
Associations with a genome-wide significant p-value of 5.0e-08 were replicated in 
two independent cohorts, the West of Scotland Coronary Prevention Study 
(WOSCOPS) 
9
 and the Cholesterol and Recurrent Events (CARE) trial 
10
. The WOSCOPS 
study was a double blind randomized placebo-controlled clinical trial in which 6595 
men (age range 45-64 years)with hypercholesterolemia and no history of myocardial 
infarction were treated with 40 mg pravastatin (N=3302) or placebo (N=3293). GWAS 
data and baseline LDL cholesterol levels were available for 431 subjects. The CARE 
study was a double blind randomized placebo-controlled clinical trial in which 4159 
patients (age range 21-75 years) were treated with 40 mg pravastatin (N=2081) or 
placebo (N=2078). GWAS data and baseline LDL cholesterol levels were available for 
751 subjects. The significance level for the replication SNPs was set at p-value < 0.05.  
Results 
Table 1 shows the baseline characteristics of the subjects participating in the 
PROSPER and the PROSPER/PHASE study. This table shows that the genotyped 
subjects in the PROSPER/PHASE study are representative of the total study 
population of the PROSPER study, since no major discrepancies exist between the 
two study sets. The mean age of all subjects at study entry was 75.3 years and about 
50% of the participants were female. 
In Figure 2 the QQ-plot of the genome-wide association study with baseline LDL 
levels within the PROSPER/PHASE study is shown. In this plot it is shown that no 
genomic inflation has occurred in this analyses (lambda=1.077) and that population 
stratification is sufficiently controlled for. In figure 3 the results of the genome-wide  
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Table 1. Baseline characteristics of the PROSPER/PHASE study 
 PROSPER study (n=5804) PROSPER/PHASE study (n=5244) 
Continuous variables (mean, SD) 
   Age (years) 
   Education (years) 
   Systolic blood pressure (mmHg) 
   Diastolic blood pressure (mmHg) 
   Height (cm) 
   Weight (kg) 
   Body mass index (kg/m
2
) 
   Total cholesterol
 
(mmol/L) 
   LDL cholesterol (mmol/L) 
   HDL cholesterol (mmol/L) 

























Categorical variables (n, %) 
   Males 
   Current smoker 
   History of diabetes 
   History of hypertension 
   History of angina 
   History of claudication 
   History of myocardial infarction 
   History of stroke or TIA 





















*Any of stable angina, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, 
peripheral artery disease surgery, or amputation for vascular disease more than 6 months before study 
entry.  
Table 2. Genomic loci with a genome wide significant p-value <= 5.0e-08 in the association with baseline 
LDL cholesterol levels 
Chr. Gene Nr of SNPs Top SNP Variant MAF Beta SE p-value Ref* 
19 APOE/APOC1 17 rs445925 G>A 0.11 -0.33 0.03 2.8e-30 7;11-14;18;19 
19 LDLR 5 rs6511720 G>T 0.13 -0.19 0.02 5.2e-15 7;11;13;14;19 
5 HMGCR 5 rs258494 G>C 0.38 0.10 0.02 1.3e-09 7;11;13;14;19 
11 FADS2/FEN1 14 rs174541 C>T 0.38 -0.10 0.02 1.1e-08 7;11;13;19 
1 PSRC1/CELSR5 1 rs602633 G>T 0.23 -0.11 0.02 5.0e-08 7;11-14;16-19 
Abbreviations: SNP, Single Nucleotide Polymorphism; Chr, Chromosome; MAF, minor allele frequency; 
SE, standard error. * A list of references in which the same loci were found. 
Table 3. Replication of the 5 significant loci in the WOSCOPS trial and CARE study in association with 
baseline LDL cholesterol levels 
   WOSCOPS (n=431)  CARE (n=751) 
SNP Gene Chr. beta se p-value  beta se p-value 
rs445925 APOE/ APOC1 19 0.07 0.05 0.164  -0.10 0.04 0.006 
rs6511720 LDLR 19 -0.03 0.05 0.657  -0.03 0.03 0.411 
rs258494*
1
 HMGCR 5 0.06 0.03 0.044  0.03 0.02 0.147 
rs174541*
2
 FADS2/FEN1 11 -0.04 0.03 0.264  -0.03 0.02 0.134 
rs602633*
3
 PSRC1/CELSR5 1 -0.09 0.04 0.026  -0.05 0.02 0.035 
* A proxy for this SNP was used in both replication cohorts, for 
1
 the proxy SNP was rs7715806 with a r
2
 
of 0.93, for 
2
 the proxy SNP was rs174545 with a r
2
 of 0.90, and for 
3
 the proxy SNP was rs660240 with a 
r
2
 of 0.88. 
Abbreviations: SNP, Single Nucleotide Polymorphism; Chr, Chromosome. 
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association study with baseline LDL cholesterol levels within the PROSPER/PHASE 
study are depicted in a Manhattan plot. Forty-two SNPs in five genomic loci, 
APOE/APOC1, LDLR, FADS2/FEN1, HMGCR, and PSRC1/CELSR5, reached the genome-
wide significant p-value of 5.0e-08. In table 2 a summary of the five genomic loci and 
their corresponding SNPs is given. The top SNP (rs445925, Chr. 19) with a p-value of 
p=2.8e-30 is located within the APOC1 gene and near the APOE gene. Sixteen other 
SNPs in the same genomic region were also found to be associated with LDL 
cholesterol levels. The second top SNP (rs6511720, Chr. 19) with a p-value of 
p=5.22e-15 is located within the LDLR gene. The three other genomic regions 
included the HMGCR (Chr.5), FADS2/FEN1 (Chr. 11), PSRC1/CELSR5 (Chr. 1) genes. All 
5 genomic loci were previously found in association with LDL cholesterol levels and 
no novel loci were identified. 
We replicated the positive associations with genome-wide significant p-values in two 
independent cohorts, the WOSCOPS study and the CARE trial (table 3). Of our five 
genomic loci that were significantly associated with baseline LDL cholesterol levels 
we selected the top SNP for replication in both replication cohorts. If the SNP was 
not genotyped in their GWAS analysis, we chose a proxy in high linkage 
disequilibrium (r2>0.5%) for that SNP. These SNPs were associated with baseline LDL 
levels before randomisation to statin treatment in both studies. Three out of the five 
loci (APOE/APOC1; HMGCR; PSRC1/CELSR5) replicated in one or two replication 
cohorts (p<0.05). The two other loci (LDLR and FADS2/FEN1) showed similar trends 
as shown in the discovery cohort, although they did not reach statistical significance 
(table 3).  
Figure 3. Manhattan plot for the GWAS on baseline 
LDL cholesterol in the PROSPER/PHASE study. 
Figure 2. QQ-plot for the GWAS on baseline LDL 
cholesterol in the PROSPER/PHASE study. 
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Discussion 
With this first proof-of principle study we show that the PROSPER/PHASE GWAS can 
confirm previously found genetic associations with LDL cholesterol levels. This proof-
of-principle study indicates that the PROSPER/PHASE study is likely to be capable of 
detecting genomic regions responsible for the variation in various other quantitative 
traits. With almost 6000 samples in the PROSPER/PHASE study and access to various 
replication studies, the PROSPER/PHASE study can provide a good testing frame to 
identify the genetic variation responsible for the variation in LDL cholesterol lowering 
in response to statin treatment.  
The main locus responsible for the person-to-person variation in LDL cholesterol 
levels is the chromosome 19 locus, which contains the APOE, APOC1, and LDLR 
genes. Other important loci included the HMGCR locus on chromosome 5, 
FADS2/FEN1 locus on chromosome 11, and the PSRC1/CELSR5 locus on chromosome 
1. The five genomic loci that were associated with variation in LDL cholesterol levels 
in the PHASE GWAS study were all genomic regions that were previously reported 
with LDL cholesterol variation 
7;11-19
. Three out of the five loci were replicated in the 
WOSCOPS study and the CARE trial. The LDLR and FADS2/FEN1 loci were not 
replicated, however these loci were repeatedly found to be associated with LDL 
cholesterol levels in various other studies with large number of participants 
7;11-
14;16;19
. Moreover, both the WOSCOPS and CARE studies had genotype data available 
in a small number of subjects. Therefore, the lack of replication of these loci in 
WOSCOPS and CARE was most likely due to lack of statistical power. Finally, since we 
used in the replication studies a proxy SNP for some of the topSNPs, this may have 
diluted the effect.  
Conclusions 
With this proof-of-principle study we show that the PROSPER/PHASE study can be 
used to investigate genetic associations in a similar way to population based studies. 
Moreover, we can also assume from these results that the PROSPER/PHASE study is 
likely to have sufficient power to detect genome-wide significant hits with large 
effects for other quantitative traits. The next step of the PROSPER/PHASE study is to 
identify the genetic variation responsible for the variation in LDL cholesterol lowering 
in response to statin treatment.   
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Abstract 
Statins effectively lower LDL cholesterol levels in large studies and the observed 
inter-individual response variability may be partially explained by genetic variation. 
Here we perform a pharmacogenetic meta-analysis of genome-wide association 
studies (GWAS) in studies addressing the LDL cholesterol response to statins, 
including up to 18,596 statin-treated subjects. We validate the most promising 
signals in a further 22,318 statin recipients and identify two loci, 
SORT1/CELSR2/PSRC1 and SLCO1B1, not previously identified in GWAS. Moreover, we 
confirm the previously described associations with APOE and LPA. Our findings 
advance the understanding of the pharmacogenetic architecture of statin response. 
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Introduction 
The 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
also known as statins, are widely prescribed and are highly effective in the 
management and prevention of cardiovascular disease. Statin therapy results in a 
lowering of low-density lipoprotein cholesterol (LDL-C) levels by up to 55% 
1
 and a 
20-30% reduction of cardiovascular events 
2
. Despite the clinical efficacy of statins in 
a wide range of patients 
2
, inter-individual variability exists with regard to LDL-C 
lowering response as well as efficacy in reducing major cardiovascular events 
3
. The 
suggestion that some of this variability may be due, in part, to common 
pharmacogenetic variation is supported by previous studies that have identified 
genetic variants associated with differential LDL-C response to statin therapy 
4-6
.  
A small number of genome-wide association studies (GWAS) have previously 
identified loci associated with statin response on a genome-wide level. A GWAS in 
the JUPITER trial identified three genetic loci, ABCG2 (rs2199936), LPA (rs10455872), 
and APOE (rs7412), that were associated with percentage LDL-C reduction following 
rosuvastatin therapy 
7
. In the CARDS and ASCOT studies, single nucleotide 
polymorphisms (SNPs) at LPA (rs10455872) and APOE (rs445925 and rs4420638) 
were associated with LDL-C response to atorvastatin treatment 
8
. A combined GWAS 
in three statin trials identified a SNP within CLMN (rs8014194) that is associated with 
the magnitude of statin-induced reduction in plasma cholesterol 
9
. However, two 
other GWAS identified no genetic determinants of LDL-C response to statin therapy 
at a genome-wide significant level 
6;10
. 
Based on these studies, as well as previous candidate gene studies 
4;6
, the only 
genetic variants that have been consistently identified to be associated with 
variation in LDL-C response to statin therapy, irrespective of statin formulation, are 
located at or nearby APOE and LPA. To determine whether additional loci may 
influence LDL-C response to statins, we formed the Genomic Investigation of Statin 
Therapy (GIST) consortium and conducted a pharmacogenetic meta-analysis using 
GWAS datasets from randomized controlled trials (RCTs) and observational studies. 
We identify two loci not previously identified in GWAS, SORT1/CELSR2/PSRC1 and 
SLCO1B1. In addition, we confirm the associations within the APOE and LPA genes. 
These findings will extend the knowledge of the Pharmacogenetic architecture of 
statin response.  
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Methods 
Study populations 
The meta-analysis was conducted in the Genomic Investigation of Statin Therapy 
(GIST) consortium, which includes data from eight randomized controlled statin trials 
(RCTs) and eleven prospective, population-based studies. The initial analysis (first 
stage) was performed in 8,421 statin treated subjects from six randomized controlled 
trials (ASCOT, CARDS, CAP, PRINCE, PROSPER, and TNT) and 10,175 statin treated 
subjects from ten observational studies (AGES, ARIC, BioVU, CHS, FHS, GoDARTS I, 
GoDARTS II, Health ABC, HVH, and MESA). Further investigation (second stage) was 
performed in 21,975 statin treated subjects from two randomized trials (HPS and 
JUPITER) and one observational study (Rotterdam Study). Six SNPs were additionally 
genotyped in the Scandinavian participants of the ASCOT study. The details of the 
first and second stage studies can be found in the Supplementary Table 1 and 2 and 
Supplementary Note 1 and 2. 
Subjects 
Response to statin treatment was studied in statin treated subjects only and not in 
those treated with placebo. Subjects included in the observational studies analysis 
should be treated with statins and have LDL-C measurements before and after start 
of statin treatment. Subjects of reported or suspected non-European ancestry were 
excluded. All participants gave written informed consent and the study was approved 
by all institutional ethic committees. 
Outcome measurements 
The response to statin treatment was defined as the difference between the natural 
log transformed on- and off-treatment LDL-C levels. The beta of the corresponding 
regression thus reflects the fraction of differential LDL lowering in carriers vs. non-
carriers of the SNP. For observational studies the on-treatment LDL-C levels were 
taken into account for all kinds of prescribed statins, at any dosage, for any 
indication, and for at least four weeks prior to measurement. Characteristics of on- 
and off-treatment LDL-C levels and statins used in each study are shown in 
Supplementary Table 2. For each individual, at least one off-treatment LDL-C 
measurement and at least one on-treatment LDL-C measurement were required. 
When multiple on- or off-treatment measurements were available the mean of the 
cholesterol measurements was used. Subjects with missing on- or off-treatment 
measurements were excluded, with the exception of the GoDARTS cohorts for which 
missing off-treatment LDL-C levels were estimated using imputation methods 
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(Supplementary Note 2). In the HPS proportional LDL-C response was defined by the 
changes in natural log lipid levels from the screening visit prior to starting statin 
therapy to the randomization visit 
6
. 
Genotyping and imputation 
Genotyping, quality control, data cleaning and imputation was performed 
independently in each study using different genetic platforms and software as 
outlined in Supplementary Table 4. In all studies, genotyping was performed using 
Illumina, Affymetrix, or Perlegen genotyping arrays, and MACH, Impute, or BIMBAM 
software was used for imputation.  
GWAS analysis 
Each study independently performed the GWAS on the difference between natural 
log transformed on- and off-treatment LDL-C levels. To control for possible 
associations with off-treatment LDL-C levels, analyses were adjusted for the natural 
log transformed off-treatment LDL-C level. An additive genetic model was assumed 
and tested using a linear regression model. For imputed SNPs, regression analysis 
was performed onto expected allele dosage. Analyses were additionally adjusted for 
age, sex, and study specific covariates (e.g. ancestry PCs or country). Analyses in the 
observational studies were, if available, additionally adjusted for the statin dose by 
the natural logarithm of the dose equivalent as defined in Supplementary Table 3. 
This table shows the dose equivalent per statin type; dividing the statin dosage of an 
individual by the dose equivalent shown in Supplementary Table 3 will give the 
adjusted statin dosage.   
Quality control and Meta-analysis 
Centrally, within each study SNPs with minor allele frequency < 1% or imputation 
quality <0.3 were excluded from the analysis. QQ-plots were assessed for each study 
to identify between study differences (Supplementary Figure 1). The software 
package METAL was used for performing the meta-analysis 
11
. A fixed effects, inverse 
variance weighted approach was used. Using an inverse variance weighted meta-
analysis will give smaller weights to studies with large standard errors. To correct for 
possible population stratification, genomic control was performed by adjusting the 
within study findings and the meta-analysis results for the genomic inflation factor.  
Second stage  
SNPs with p-values <5x10
-4
 in the first stage meta-analysis were selected for further 
investigation in a second stage. A maximum of two SNPs per locus were selected, 
based on statistical significance, except for the APOE locus, for which all genome-
wide significant associated SNPs were selected for validation. A total of 246 SNPs, 
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within 158 independent loci, were selected for the second stage which was 
performed in the JUPITER trial, HPS study, and the Rotterdam Study, which all had 
GWAS data and response to statin treatment available. For two of the 246 SNPs a 
proxy was used in the JUPITER trial, and 31 SNPs were not available, nor was a proxy 
SNP. HPS provided data on 151 directly genotyped SNPs from GWAS and IPLEX 
experiments, including 48 of the requested SNPs and 103 proxy SNPs (r
2
>0.8). 
Analyses in HPS were not adjusted for ln baseline LDL-C levels. In addition, the 
number of subjects with data varied from SNP-to-SNP and ranges from ~4000 for 
variants with GWAS data to ~18000 for some candidate genes. Results of the first 
and second stage were combined using fixed effects, inverse variance weighted 





in the combined meta-analysis were selected for additional genotyping in 
the Scandinavian participants of the ASCOT study. Kaspar assays were designed for 
four of the SNPs using the KBioscience Primerpicker software, and oligos were 
provided by Intergrated DNA technologies (http://eu.idtdna.com/site). Full Kaspar 
methodology is available from LGC SNP genotyping (http://www.lgcgenomics.com/ 
genotyping/kasp-genotyping-reagents/). Two SNPs (rs981844 and rs13166647) were 
genotyped using Taqman assays supplied by Life technologies 
(http://www.lifetechnologies.com/uk/en/home.html) using the standard Taqman 
protocol. Results of the additional genotyping were combined with results from the 
first and second stages using a fixed effects, inverse variance weighted meta-analysis 
and analyzed by METAL. 
Determination of changes in LDL subfractions   
LDL subclasses were analyzed as described previously 
12
 using non-denaturing 
gradient gel electrophoresis of fasting plasma samples taken at baseline and after 6 
weeks of simvastatin 40 mg/d (CAP study, n=579) or 12 weeks of pravastatin 40 mg/d 
(PRINCE study, n=1284). Aliquots of 3.0 mL of whole plasma were mixed 1:1 with a 
sampling buffer of 20% sucrose and 0.25% bromophenol blue. Electrophoresis of 
samples and size calibration standards was performed using 2%–14% polyacrylamide 
gradients at 150 V for 3 hours following a 15-minute pre-run at 75 V. Gels were 
stained with 0.07% Sudan black for 1 hr and stored in a 0.81% acetic acid, 4% 
methanol solution until they were scanned by computer-assisted densitometry for 
determination of areas of LDL IVb (22.0–23.2 nm), LDL IVa (23.3–24.1 nm), LDL IIIb 
(24.2–24.6 nm), LDL IIIa (24.7–25.5 nm), LDL IIb (25.6–26.4 nm), LDL IIa (26.5–27.1 
nm), and LDL I (27.2–28.5 nm). The cholesterol concentrations of the subfractions 
(mg/dL plasma) were determined by multiplying percent of the total stained LDL area 
for each subfraction by the LDL cholesterol for that sample 
13
.  For genetic 
association analyses, subfractions were grouped into large LDL (LDL I+IIa), medium 
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LDL (LDL IIb), small LDL (LDL IIIa) and very small LDL (LDL IIIb+IVa+IVb) as described 
previously 
14
. A Generalized Estimating Equation method was used to test the 
association of log change with the interaction of the four SNPs by LDL subfraction. 
Effect of off-treatment LDL-C 
Effects of genetic variation on treatment response as measured by on-treatment LDL-
C could be mediated through effects on the off-treatment LDL-C. To evaluate 
whether genetic on-treatment LDL-C likely reflects residual effect on off-treatment 
LDL-C, it is necessary to adjust for the off-treatment LDL-C levels and to correct the 
maximum likelihood estimate of the adjusted effect of genotype on on-treatment 
value for the noise in off-treatment values (the noise is both random measurement 
error and intra-individual variation in usual LDL-C). This analysis was only carried out 
in CARDS in which multiple baseline measurements were available. From the rules of 
path analysis, we calculated the direct effect γ of genotype on an on-treatment trait 
value as β − αδ (1 − ρ) / ρ, where β is the coefficient of regression for on-treatment 
trait value on genotype adjusted for measured off-treatment value, α is the 
coefficient of regression of baseline LDL on genotype, ρ is the intraclass correlation 
between replicate measurements of off-treatment values,  and δ is the coefficient of 
regression for on-treatment value on observed off-treatment value 
8
. For these 
calculations, we used ρ = 0.8 as a plausible value for the intra-class correlation based 
on the within-person correlation in LDL-C values taken over two off-treatment visits 
in CARDS.  
The interaction of candidate SNPs with statin versus placebo allocation was assessed 
in the JUPITER trial, since this study was not involved in the first stage meta-analysis. 
Regression models were applied to the combined population of statin and placebo 
treated subjects by including extra terms encoding placebo allocation and the 
product of placebo allocation with SNP minor allele dose 
7
. 
Genome-wide conditional analysis (GWCA) using Genome-Complex Trait Analysis 
(GCTA) 
There may be multiple causal variants in a Gene and the total variation that could be 
explained at a locus may be underestimated if only the most significant SNP in the 
region is selected. To identify independent SNPS we ideally can perform a conditional 
analysis, starting with the top associated SNP, across the whole genome followed by 
a stepwise procedure of selecting additional SNPs, one by one, according to their 
conditional P values. Such a strategy would allow the discovery of more than two 
associated SNPs at a locus. To identify independent SNPs across the genome-wide 
data we used an approximate conditional and joint analysis approach implemented 
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in GCTA software 
15
. We used summary level statistics from the first and second 
stage combined meta-analysis and LD corrections between SNPs estimated from 
CARDS GWAS data. SNPs on different chromosomes or more than 10Mb distant are 
assumed to be in linkage equilibrium. The model selection process in GCTA starts 
with the most significant SNP in the single-SNP meta-analysis across the whole 
genome with P value<5 x 10
-7
. In the next step, it calculates the P-values of all the 
remaining SNPs conditional on the top SNP that have already been selected in the 
model. To avoid problems due to co-linearity, if the squared multiple correlations 
between a SNP to be tested and the selected SNP(s) is larger than a cut-off value, 
such as 0.9, the conditional P value for that SNP will be set to 1. Select the SNPs with 
minimum conditional P value that is lower than the cut-off P value. Fit all the 
selected SNPs jointly in a model and drop the SNPs with the P value that is greater 
than the cut-off P value. This process is repeated until no SNPs can be added or 
removed from the model. 
Pathway analysis and construction of a Statin Response Network 
Genes showing evidence of association (based on direct association or LD (HapMap 
CEU r
2
>0.8)) were reviewed for evidence of involvement in statin response at a 
pathway level using GeneGo Metacore (Thomson Reuters (portal.genego.com)). A 
statin response network was constructed in two stages. Firstly all genes with a 
literature reported involvement in statin response (based on Medical subject 
headings (MeSH) were identified using GeneGo MetaCore (Supplementary Data 3). 
Secondly these genes were combined with all genes in associated loci (including 
genes in LD) and a network was constructed based on direct interactions only. By 
including direct interactions only, we created a conservative network of direct gene 
interactions that have been consistently linked to statin response in the literature.  
Expression quantitative trait loci (eQTL) analysis 
LDL-C associated index SNPs (246 SNPs) were used to identify 1443 LD proxy SNPs 
displaying complete linkage disequilibrium (r
2
=1) across 4 HapMap builds in 
European ancestry samples (CEU) using the SNAP tool 
16
. The primary index SNPs and 
LD proxies were searched against a collected database of expression SNP (eSNP) 
results including the following tissues: fresh lymphocytes 
17
, fresh leukocytes 
18
, 
leukocyte samples in individuals with Celiac disease 
19
, whole blood samples 
20-23
, 
lymphoblastoid cell lines (LCL) derived from asthmatic children 
24;25
, HapMap LCL 
from 3 populations 
26
, a separate study on HapMap CEU LCL
27
, additional LCL 
population samples 
28-30
(Mangravite et al., unpublished), CD19+ B cells 
31
, primary 
PHA-stimulated T cells 
28
, CD4+ T cells 
32
, peripheral blood monocytes 
31;33;34
, CD11+ 
dendritic cells before and after Mycobacterium tuberculosis infection 
35
, omental and 
 





, endometrial carcinomas 
37
, ER+ and ER- 
breast cancer tumor cells 
38
, brain cortex 
33;39;40
, pre-frontal cortex 
41;42
, frontal cortex 
43






, three additional large studies of 
brain regions including prefrontal cortex, visual cortex and cerebellum, respectively 













. Micro-RNA QTLs were also queried for LCL 
50
, and gluteal and 
abdominal adipose 
51
. The collected eSNP results met the criteria for association with 
gene expression levels as defined in the original papers. In each case where a LDL-C 
associated SNP or proxy was associated with a transcript we further examined the 
strongest eSNP for that transcript within that dataset (best eSNP), and the LD 
between the best eSNP and GIST-selected eSNPs to estimate the concordance of the 
LDL-C and expression signals. 
Statin response connectivity map analysis 
The Connectivity Map (Cmap) data set is available at the Broad Institute 
(www.broadinstitute.org/cmap 
52
) and contains more than 7000 expression profiles 
representing 1309 compounds used on five different cultured human cancer cell lines 
(MCF7, ssMCF7, HL60, PC3 and SKMEL5). We selected (prostate tumor-derived) PC3 
cells as they showed the most responsiveness to statins at a genome wide level.  
Four statins were included in our analysis, including Pravastatin, Atorvastatin, 
Simvastatin and Rosuvastatin. PC3 Instance reference files for each statin treatment 
were extracted (as defined by Lamb et al.
52
), i.e. a treatment associated to its control 
pair. Transcripts were considered to show evidence of differential expression with a 
fold change >2. A fold change >1.5 was considered to be suggestive of differential 
expression only.   
Exploration of functional impact among directly and indirectly associated variants 
Genes and variants across all LDL-C associated loci were investigated for evidence of 
functional perturbation using a range of bioinformatics tools and databases. Variants 
showing LD (CEU r
2
>0.8) with associated variants were explored for impact on coding 
gene function using Annovar 
53
 and regulatory function using a combination of 
HaploReg 
54
 and Regulomedb 
55
, which both draw on comprehensive data from the 
Encyclopedia of DNA Elements (ENCODE) 
56
 and the NIH Roadmap Epigenomics 
consortium 
57
. Building on the functional annotation, we also identified variants 
which were shown to mediate eQTLs. Genes in associated loci were also used to 
query the NIH connectivity map for evidence of differential expression in PC3 cell 
lines treated with Pravastatin, Simvastatin and Rosuvastatin. By combining a wide 
range of functional data and pathway support we were able to build up a view of 
genes with the highest level of support in statin response. 
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Results 
First stage meta-analysis 
The GIST consortium includes six randomized controlled trials (n=8,421 statin 
recipients) and ten observational studies (n=10,175 statin recipients) that 
participated in the first stage (Methods, Supplementary Table 1 and 2 and 
Supplementary Note 1 and 2). To search for genetic variants associated with 
differential LDL-C response to statin therapy, each study independently performed a 
GWAS among statin users, using the difference between the natural log transformed 
LDL-C levels on- and off-treatment as the response variable (Methods).  
The first stage meta-analysis identified three loci, including 13 SNPs, that attained 
genome-wide significance (P<5x10
-8
) for association with LDL-C response to statin 
treatment (Figure 1 and Table 1). The most significant association was for a SNP on 
chromosome 19, at APOE (rs445925, MAF=0.098, β=-0.043, SE=0.005, P=1.58 x 10
-18
) 
(Figure 2A), indicating that carriers of the rs445925 SNP respond to statins with an 
additional 4.3% increase per allele in LDL-C lowering effect compared to non-carriers. 
 
Figure 1. Results of the GWAS meta-analysis. Manhattan plot presenting the –log10 P-values from the 
combined meta-analysis (n=40914) on LDL cholesterol response after statin treatment. P-values were 
generated using linear regression analysis.  
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The second strongest association was with a SNP at LPA on chromosome 6 
(rs10455872, MAF=0.069, β=0.041, SE=0.006, P=1.95 x 10
-11
) (Figure 2B), indicating a 
4.1% smaller LDL-C lowering per minor allele for carriers of the SNP compared to 
non-carriers. Associations at both loci have previously been described 
7;8
. A third 
genome-wide significant association was found with a SNP at RICTOR on 
chromosome 5 (rs13166647, MAF=0.230, β=-0.253, SE=0.046, P=4.50 x 10
-8
), 
although genotypes for this SNP were only available in two studies within the first 
stage (n=2,144).  
Second stage meta-analysis 
We selected 246 SNPs with P<5x10
-4
 from 158 loci for further investigation in three 
additional studies comprising up to 22,318 statin treated subjects (Methods, 
Supplementary Table 1 and 5 and Supplementary Note 3). This second stage 
Figure 2. Regional association plots of the genome-wide significant associations with LDL cholesterol 
response after statin treatment. The plots show the genome-wide significant associated loci in the 
combined meta-analysis (n=40914), the APOE locus (A), the LPA locus (B), the CELSR2 locus (C), and the 
SLCO1B1 locus (D) (generated using LocusZoom 
74
). The color of the SNPs is based on the LD with the lead 
SNP (shown in purple). The RefSeq genes in the region are shown in the lower panel. P-values were 
generated using linear regression analysis 
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confirmed the genome-wide significant associations between variations within the 
APOE and LPA loci and LDL-C response, as being observed in the first stage (Table 1, 
Supplementary Figure 2 and Supplementary Table 5). In addition, SNPs at two new 




 in the first phase, were shown to 
be significantly associated with statin induced LDL-C lowering after statin treatment 
in the total combined meta-analysis at a genome-wide level: SORT1/CELSR2/PSRC1 
(rs646776, β =-0.013, SE=0.002, P=1.05x10
-9
) and rs12740374, β=-0.013, SE=0.002, 
P=1.05x10
-9
) and SLCO1B1 (rs2900478, β=0.016, SE=0.003, P=1.22x10
-9
) (Figure 2C 
and 2D), indicating an additional 1.5% increase per allele in LDL-C lowering effect for 
carriers of the SORT1/CELSR2/PSRC1 SNP and a 1.6% smaller LDL-C lowering per 
minor allele for carriers of the SLCO1B1 SNP. 
The six next-ranked SNPs with p-values just below 5x10
-8 
in the combined meta-
analysis, including the two SNPs at RICTOR (rs13166647 and rs13172966) were 
selected for additional genotyping in the Scandinavian ASCOT participants 
(Methods). None of these six SNPs reached genome-wide significance after this 
additional genotyping (Supplementary Table 6). Therefore, our overall genome-wide 
significant findings were the SNPs at APOE, LPA, SORT1/CELSR2/PSRC1, and SLCO1B1.  
Subfraction analyses 
To extend our results for the novel GWAS finding SORT1/CELSR2/PSRC1 we 
performed additional association analyses, using measurements of cholesterol levels 
in four LDL subfractions (large, medium, small, and very small) from two of the trials 
in GIST; CAP and PRINCE (Table 2 and Methods). The minor allele of SORT1 rs646776 
was associated with greater statin-induced reductions in levels of all LDL 
subfractions, and there was a non-significant trend for larger effect sizes and greater 
statistical significance for lowering of small and very small LDL (Table 2). In contrast, 
the APOE SNP associated with greater LDL-C response to statins (rs445925) showed a 
small and non-significant association with change in very small LDL (Table 2). For the 
minor allele of rs2900478 (SLCO1B1), the borderline significant association with 
smaller magnitude of LDL-C reduction showed a trend for preferential association 
with larger versus smaller LDL subfractions. The lack of association of rs10455872 
(LPA) with changes in LDL subfractions is consistent with evidence discussed below 
that this locus affects levels of Lp(a) and not LDL particles. Using Generalized 
Estimating Equations, we tested the association of log change in each of the LDL 
subfractions with interactions of the four SNPs. For very small LDL, the association 
with the rs646776 minor allele was significantly different from that of the other 
minor alleles (P=0.03 after adjustment for multiple testing). 
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Effects of off-treatment LDL-C 
To demonstrate that our findings for LDL-C response to statin treatment are unlikely 
to be explained through associations with baseline LDL-C levels, we performed a 
number of additional analyses (Methods). First, Supplementary Table 7 shows 
regression coefficients for baseline-adjusted and measurement noise-corrected 
estimates of the direct effect of genotype on on-treatment LDL-C at the strongest 
SNPs in the GIST meta-analysis (P<1 x 10
-8
) which were available in the CARDS 
dataset. Correcting our effect size estimate further and modeling measurement noise 
at baseline reduced the apparent effect only slightly for all the markers, suggesting 
that there is little effect of measurement noise. Next, within the JUPITER trial, 
additional analyses were performed to determine whether there was an interaction 
between LDL-C change and statin or placebo allocation. Supplementary Table 8 
shows significant P-values for interaction (all <5x10
-2
) for SNPs at the four genome-
wide significant loci in the GIST meta-analysis, also suggesting that genetic effects on 
baseline LDL-C as manifest in the placebo group contribute at most only in part to 
genetic effects on LDL-C response in the statin group. 
Genome-Wide Conditional Analysis 
To investigate if there were multiple SNPs within any gene and multiple loci 
associated with differential LDL-C lowering to statin therapy we performed a 
conditional analysis across the genome using the summary statistics of the combined 
meta-analysis. The results of the Genome-Wide Conditional Analysis (GWCA) 
(Methods, Supplementary Table 9) showed 14 SNPs independently associated with 
statin response and these explained approximately 5% of the variation in LDL-C 
response to statin treatment. Of the 14 independent SNPs, six were genome-wide 
significant in the combined GWAS meta-analysis (Supplementary Table 5).  
Previous findings 
In Supplementary Table 10 we performed a look-up in our GWAS meta-analysis for 
SNPs previously described in the literature (NHGRI Catalogue 
58
 of Published GWAS 
and Candidate gene studies) to be associated with statin response, besides the loci 
associated at a genome-wide level in the current study. None of these SNPs was 
associated with statin response in our GWAS after correcting for multiple testing. 
Functional analyses 
Functional characterization of the 246 SNPs selected for the second stage was 
performed using a range of bioinformatics tools (Methods). A total of 420 eQTL 
associations were identified across a wide range of tissues (Supplementary Data 1), 
which comprised 67 independent gene eQTL associations. Eleven genes, including 
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APOE, SORT1, CELSR2 and PSRC1 showed eQTLs in liver, which considering its primary 
role in mediating statin-induced LDL reduction, may be particularly relevant to statin 
response. Putative gene eQTLs were combined with genes annotated to variants in 
LD with LDL-C response associated variants, resulting in a list of 185 candidate gene 
loci, defined by 2681 SNPs (Supplementary Data 2 and 3). In order to identify statin 
responsive genes among the candidate loci, gene expression data measured in 
response to statin treatment in a range of cell lines was retrieved from the 
Connectivity Map resource 
52
 (Methods). Five genes (APOE, BRCA1, GRPEL1, ADRB2 
and ETV1) showed convincing evidence of statin responsiveness on the basis of >2-
fold differential expression in response to statin treatment. Eight genes showed 
suggestive evidence (1.5-2-fold change; TOMM40, SREBP1, PSRC1, BCL3, BCAM, 
ANK3, SIVA1, and RANBP9) (Supplementary Data 3).  
Finally, involvement in statin response was investigated at a pathway level using 
GeneGo Metacore (Thomson Reuters 
59
). Briefly, 87 literature reported genes linked 
to statin response were combined with the 185 candidate gene loci reported here 
(Supplementary Data 3). A conservative network of direct interactions was 
constructed between query genes (Supplementary Data 4). The network included 24 
genes located in the LDL-C associated loci (Supplementary Figure 4). Collectively our 
functional and pathway analysis confirms a strong biological and functional role in 
statin response for several strongly associated gene loci, including 
APOE/TOMM40/PVRL2, and SORT1/CELSR2/PSRC2.  
Discussion 
We have performed a meta-analysis of GWAS including more than 40,000 subjects, 
investigating genetic variants associated with variation in LDL-C lowering upon statin 
treatment independent from associations with baseline LDL-C. We identified four loci 
at genome-wide significance, including the previously identified APOE and LPA, and 
the novel GWAS loci SORT1/CELSR2/PSRC1, and SLCO1B1. 
Nine SNPs in the APOE gene region reached genome-wide significance for LDL-C 
response. The minor allele of the lead SNP rs445925, which is a proxy for the apoE ε2 
protein variant defining SNP rs7412 
60
, was associated with a larger LDL-C lowering 
response to statins compared to carriers of the major allele. The magnitude and 
direction of the effect size was similar to previously reported findings for the 
rs445925 variant in the GWAS study performed in CARDS and ASCOT 
8
 and of the SNP 
rs7412 in JUPITER 
7
. Since the apoE ε2 protein results in increased hepatic 
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cholesterol synthesis, it may also predispose to stronger inhibition of cholesterol 
synthesis by statin treatment 
8;10
.  
Three independent SNPs at LPA were significantly associated with LDL-C response to 
statins. The minor G allele of the lead SNP rs10455872 was associated with smaller 
LDL-C reduction than the major allele. This result was similar to the previous GWAS 
findings for this SNP in the JUPITER trial and the combined ASCOT and CARDS study 
7;8
. The rs10455872 SNP was strongly associated with the KIV-2 copy number variant 
in lipoprotein(a) (Lp(a)), which encodes variability in apo(a) size and is responsible 
for approximately 30% of variance in Lp(a) levels 
8;61
. Furthermore, rs10455872 was 
shown to be strongly associated with plasma Lp(a) levels 
62
. Standard assays of LDL-C, 
as well as the Friedewald formula, include cholesterol that resides in Lp(a) 
6;8
. 
Carriers of this LPA variant are characterized by higher Lp(a) levels and a larger 
proportion of their measured LDL-C resides in Lp(a) particles 
8;10
. Since statin therapy 
does not reduce the number of Lp(a) particles 
63
, their presence attenuates the 
measured LDL-C response to statins.  
Two SNPs at SORT1/CELSR2/PSRC1 (rs646776 and rs12740374) on chromosome 1p 
were associated with an enhanced statin LDL-C response. A similar association was 
previously observed in a large candidate-gene study in HPS 
6
, however, we 
demonstrate this finding now first at a genome-wide significance level. The minor 
allele of rs12740374 has been shown to generate a binding site for the transcription 
factor C/EBPa 
14
. Transcription results in up-regulation of hepatic expression of three 
genes at this locus, SORT1, CELSR2 and PSRC1 
14
, which we also showed in our eQTL 
analysis (Supplementary Data 1). Of these, SORT1 is most notable, in that it encodes 
the multifunctional intracellular trafficking protein sortilin, which has been shown to 
bind tightly to apoB 
64
. Sortilin-induced lowering of plasma LDL-C results from two 
mechanisms: reduced secretion of apoB-containing precursors, and, perhaps of 
greater importance, increased hepatic LDL uptake via binding to sortilin at the cell 
surface, with subsequent internalization and lysosomal degradation 
64
. Notably, the 
minor allele of rs646776 is preferentially associated with lower levels of small and 
very small LDL (Table 2), suggesting that sortilin is of particular importance for 
regulating levels of these particles 
14
. Smaller LDL subfractions have been shown to 
be relatively enriched in particles with reduced LDL receptor binding affinity and 
cellular uptake 
65
, a property that may contribute to their associations with increased 
risk for cardiovascular disease 
13
. This property may also underlie the diminished 
efficacy of statins for reduction of these particles (Supplementary Figure 3) 
66
, since 
statins act to reduce LDL-C levels to a large extent by increasing LDL receptor 
expression as a result of upregulation of the transcription factor SREBP2, whereas 
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SORT1 is not regulated by this mechanism. Hence, the greater statin-mediated 
reduction of LDL-C among carriers of the rs646776 minor allele could be attributed to 
relative depletion of LDL particles dependent on sortilin for clearance and hence a 
residually greater proportion of those LDL particles whose uptake is more dependent 
on the LDL receptor than on sortilin. 
Notably, the strong association of rs646776 with statin-induced reductions in small 
and very small LDL particles contrasts to the weaker associations of changes in these 
particles with rs445925, likely the result of differing mechanisms underlying the 
effects of these SNPs on statin response. As noted above, rs445925 is a proxy for the 
SNP defining the apoE ε2 protein variant that is thought to predispose to heightened 
statin response as a result of greater statin inhibition of cholesterol synthesis and 
hence upregulation of SREBP and LDL receptor activity. 
The SLCO1B1 rs2900478 minor allele was associated with a smaller LDL-C reduction 
in response to statin treatment. SLCO1B1 encodes the organic anion-transporting 
polypeptide OATP1B1 and facilitates the hepatic uptake of statins 
67
. SNP rs2900478 
is in strong LD (r
2
=0.89) with rs4149056, which represents the Val174Ala substitution 
resulting in complete loss of function. In the HPS trial, which used simvastatin, this 
candidate-gene SNP was associated with a 1% lower LDL-C reduction per allele 
6
. 
Single-dose studies have shown that the observed area under the curve of plasma 
level of active simvastatin after a dose of 40mg was 221% higher in rs4149056 CC 
homozygotes compared with rs4149056 TT homozygotes, as compared to 
atorvastatin 20 mg (144% higher for CC vs TT) and rosuvastatin 40mg (117% higher 
for CC vs TT) 
68
. This finding results from the slower hepatic uptake of statins caused 
by the genetic variant, which would also be expected to result in a reduction of the 
cholesterol lowering effect 
69
. In a GWAS of the genetic risk factors for simvastatin-
induced myopathy, SLCO1B1 showed the strongest association 
69
. Homozygous 
carriers of the SLCO1B1 variant had a 16.9-times higher risk for myopathy compared 
to non-carriers. This might have led to a decrease in study medication adherence, 
and consequently a decreased effect on LDL-C in carriers of this SNP. In addition, 
previous analysis in the GoDARTS study showed that the effect of the SLCO1B1 gene 




GWCA identified three independent loci in the APOE gene region and two loci in the 
LPA gene region (Supplementary Table 9). GWCA also showed several other loci with 
P<5x10
-8
, that were not GWAS significant on single SNP analysis (HGD, RNF175, 
ISCA1L-HTR1A, GLIS3-SLC1A1, LOC100128657, NKX2-3-SLC25A28, and PELI2). These 
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findings will require replication in independent, larger datasets. The significant SNPs 
in the GWCA analysis explained approximately 5% of the variation in LDL-C response 
to statin treatment. Whether this 5% is clinically relevant should be investigated by 
other studies. For example it would be of interest to investigate if this differential 
LDL-C lowering is also associated with differential event reduction by statin 
treatment. 
In the current study we combined the results of six randomized clinical trials and ten 
observational studies in the first stage. This approach resulted also in combining 
several types of statins, since different statins were studied in the trials and within 
the observational studies (Supplementary Table 2). This, and the variation in statin 
dosage during follow-up for an individual, is a limitation of the current study, since 
for example the impact of the SLCO1B1 variant on statin pharmacogenetics is known 
to be highly dependent on statin type and dose 
68;71
. To overcome this limitation, the 
individual study analyses were adjusted for statin dose. Dividing the actual statin 
dose given by the statin specific dose equivalent (Supplementary Table 3) gives the 
statin adjusted equivalent based on the daily dosages required to achieve a mean 
30% LDL-C reduction. Using this table we made the different statin dosages and types 
comparable within the studies. To correct for between study variance we used a 
fixed effects meta-analysis with inverse variance weighting. Since we observed that 
the SLCO1B1 gene was genome-wide significantly associated with LDL lowering, this 
highlights the thoroughness of our analytical approach, in which the analyses were 
correctly adjusted for the type and dose of statins used (Supplementary Table 3). 
Moreover, a comparison of the estimates of the SNPs between the RCTs (where 
there are no intra-individual differences in dosages) with the estimates of the SNPs in 
the observational studies showed large homogeneity between the estimates in the 
various study designs (Supplementary Figure 2), indicating that our adjustment for 
dosage seems to be sufficient within this study. 
Another possible limitation of the current study is the influence of the identified 
genetic variants on baseline LDL-C levels. In pharmacogenetic studies investigating 
the LDL-C lowering response to statins it is important to eliminate the effect of 
association between the genetic variant and baseline LDL-C levels, since those 
findings may confound the response to treatment associations. Previous large GWAS 
studies have shown strong associations between baseline LDL-C levels and genetic 
variants in SORT1/CELSR2/PSRC1, APOE, and LPA 
72
. To eliminate those possible 
confounding effects our response to treatment analyses were adjusted for baseline 
LDL-C levels. In addition, additional analysis in CARDS and JUPITER suggests no or 
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little influence of genetic effects on baseline LDL-C on the genetic effects on LDL-C 
lowering response. 
In conclusion, this study is the largest meta-analysis of GWAS for LDL-C response to 
statin therapy conducted to date. Our results demonstrate that apart from the 
previously identified APOE and LPA loci, two new loci, SORT1/CELSR2/PSRC1 and 
SLCO1B1, also have a modest but genome-wide significant effect on LDL-C response. 
The minor alleles of the APOE rs445925 and SORT1/CELSR2/PSRC1 rs646776 SNPs 
were associated with a larger statin response, whereas the minor alleles of the LPA 
rs10455872 and SLCO1B1 rs2900478 SNPs, were associated with a smaller statin 
response. Our findings advance the understanding of the pharmacogenetic 
architecture of statin response.  
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Supplementary material 
Supplementary material is available at Nature Communications online. 
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Abstract 
Statin therapy is widely used in the prevention and treatment of cardiovascular 
events and is associated with significant risk reductions. However, there is 
considerable variation in response to statin therapy both in terms of LDL cholesterol 
reduction and clinical outcomes. It has been hypothesized that genetic variation 
contributes importantly to this individual drug response. In this study, we 
investigated the interaction between genetic variants and pravastatin or placebo 
therapy on the incidence of cardiovascular events by performing a genome-wide 
association study in the participants of the PROspective Study of Pravastatin in the 
Elderly at Risk for vascular disease – PHArmacogenetic study of Statins in the Elderly 
at risk (PROSPER/PHASE) study (n=5244). We did not observe genome-wide 
significant associations with a clinically meaningful differential cardiovascular event 
reduction by pravastatin therapy. In addition, SNPs with p-values lower than 1 x 10
-4
 
were assessed for replication in a case-only analysis within two randomized placebo 
controlled pravastatin trials, CARE (n=711) and WOSCOPS (n=522). rs7102569, on 
chromosome 11 near the ODZ4 gene, was replicated in the CARE study (p=0.008), 
however the direction of effect was opposite. This SNP was not associated in 
WOSCOPS. In addition, none of the SNPs replicated significantly after correcting for 
multiple testing. We could not identify genetic variation that was significantly 
associated at genome-wide level with a clinically meaningful differential event 
reduction by pravastatin treatment in a large prospective study. We therefore 
assume that in daily practice the use of genetic characteristics to personalize 
pravastatin treatment to improve prevention of cardiovascular disease will be 
limited.   
 
 
75 Chapter 5 
Introduction 
Cardiovascular disease is the leading cause of death in industrialized countries 
1
. 
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), are 
the most prescribed class of drug worldwide and are widely used in the prevention 
and treatment of cardiovascular disease. Statin therapy is in general associated with 
a low-density lipoprotein (LDL)-cholesterol lowering of 30-55% 
2
 and a reduction of 
cardiovascular events of 20-35% 
3
. However, there is considerable variation in 
response to statin therapy both in terms of LDL cholesterol lowering and clinical 
outcomes.  
Recently, results from six genome-wide association studies (GWAS) on the 
pharmacogenetics of statin therapy have been published 
4
, mainly focusing on the 
lipid lowering effects after statin therapy 
5-10
.  Evidence from the studies focusing on 
the lipid lowering response suggests that genetic variations in the apolipoprotein E 
(APOE) and apolipoprotein(a) (LPA) genes are associated with differential LDL 
cholesterol lowering after statin treatment 
5-8;10
. The GWAS in 85 myopathy subjects 
and 90 controls treated with simvastatin identified the SLCO1B1 gene variants to be 
associated with statin-induced myopathy 
9
. However, none of these GWAS studies 
reported the pharmacogenetic effects of statins on cardiovascular events. 
The association between genetic variants and the incidence of cardiovascular events 
after statin therapy has been investigated mainly by candidate gene studies. For 
example, several studies have reported an association between genetic variants in 
KIF6 and event reduction after statin treatment 
11-13
. However, these results are 
equivocal and could not be replicated in other studies 
14;15
. Within the WOSCOPS and 
CARE trials, a case-only GWAS was performed to identify genetic loci associated with 
differential cardiovascular event reduction by pravastatin therapy. Genetic variation 
within the DNAJC5B gene was significantly associated and replicated in the PROSPER 
study 
16
. To identify genetic variants associated with a clinically meaningful 
differential cardiovascular event reduction by pravastatin or placebo treatment on a 
genome-wide level, we conducted a GWAS in the PHArmacogenetic study of Statins 
in the Elderly at risk (PHASE) 
17
. The PHASE project is a GWAS conducted in the 
PROspective Study of Pravastatin in the Elderly at Risk for vascular disease (PROSPER) 
18
. The results were assessed for replication in two independent prospective 
pravastatin 40 mg trials, the Cholesterol and Recurrent Events (CARE) trial 
19
 and the 
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Methods 
Study population 
PROSPER was an investigator-driven, prospective multi-national randomized placebo-
controlled trial to assess whether treatment with pravastatin diminishes the risk of 
major vascular events in the elderly 
18;21
. Between December 1997 and May 1999, 
subjects in Scotland (Glasgow), Ireland (Cork) and the Netherlands (Leiden) were 
screened and enrolled. Men and women aged 70-82 years were recruited if they had 
pre-existing vascular disease or were at increased risk for such disease because of 
smoking, diabetes, or hypertension. A total number of 5804 subjects were randomly 
assigned to pravastatin or placebo. The primary endpoint in PROSPER was the 
combined endpoint of death from coronary heart disease (CHD), non-fatal 
myocardial infarction (MI), and occurrence of clinical stroke, either fatal or non-fatal. 
All endpoints were adjudicated by the study Endpoint Committee. The protocol of 
the PROSPER study was approved by the medical ethics committees of each 
participating institution. Written informed consent was obtained from all 
participating subjects. 
The PHASE project is a genome-wide association study (GWAS) in the participants of 
the PROSPER study, to investigate the genetic variation responsible for the individual 
variation in drug response, and has been described previously 
17
. The study was 
sponsored by the European Union’s Seventh Framework Programme (FP7/2007-
2013), under grant agreement number HEALTH-F2-2009-223004. 
Genotyping 
The genotyping and quality control performed in the PHASE project has been 
described previously 
17
. In brief, genotyping was conducted using the Illumina 660-
Quad beadchips following manufacturer’s instructions. After a stringent quality 
control (call rate< 95%) 557,192 SNPs in 5244 participants were available for analysis 
17
. Those SNPs were imputed up to 2.5 million autosomal CEPH HapMap SNPs using 
MaCH imputation software based on the HapMap built 36 release 22.  
Statistical Analysis 
Genome wide association analysis was performed with ProbABEL software 
specialized in genetic association analysis with imputed data taking the probability of 
the genotype into account 
22
. For the current analysis we assessed the interaction 
between genetic variants and statin treatment (pravastatin or placebo) on the 
incidence of the primary endpoint using a logistic regression model. To estimate the 
differential event reduction by pravastatin an interaction term between treatment 
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(pravastatin or placebo) and SNP was included in the model. By including this 
interaction term in the logistic regression model we can estimate the difference in 
statin treatment effect in carriers and non-carriers of a SNP. The model was adjusted 
for sex and age, and country to correct for the within-study population structure. To 
reduce the probability of false positive findings by multiple testing, a Bonferroni 
correction was used. The p-value threshold for genome-wide significant results was 




The main aim of the current study was to identify genetic variants associated with 
clinically meaningful differential event reduction after pravastatin therapy. To detect 
genetic variants relevant for clinical practice we used a relative large minor allele 
frequency (MAF), large genetic effect, and large interaction effect for the power 
calculation. Power calculations for detecting clinically meaningful interactions 
between genetic variants and pravastatin treatment were performed using Quanto 
software (http://hydra.usc.edu/gxe). Based on a total number of 800 cases with the 
primary endpoint, we calculated that with a MAF of 25% in a log additive model, a 
prevalence of 50% of the environmental factor (pravastatin use) and a baseline risk 
of the primary event of 10%, a pravastatin effect of 0.8, a gene effect of 1.5, and an 
interaction effect of 2.0, the statistical power to detect the interaction between gene 
and environment is 80% for a p-value threshold of 5 x 10
-7
.  
The power to detect smaller, but from the biological point of view perhaps also 
interesting effects (interaction effect of 1.2) was limited (<10%), and therefore this 
was not the purpose of the current investigation. 
Replication 
From each independent locus associated with p-values <1.0 x 10
-4
 for interaction 
from our logistic regression analysis, two SNPs were assessed for replication in two 
independent cohorts, the CARE trial 
19
 and the WOSCOPS study 
20
. The CARE trial was 
a double blind randomized placebo-controlled clinical trial in which 4159 post-
myocardial infarction patients (age range 21-75 years) were treated with 40 mg 
pravastatin (N=2081) or placebo (N=2078). The WOSCOPS study was a double blind 
randomized placebo-controlled clinical trial in which 6595 men (age range 45-64 
years) with hypercholesterolemia and no history of myocardial infarction were 
treated with 40 mg pravastatin (N=3302) or placebo (N=3293). For the current 
replication, we used data of the GWAS performed in all who had a cardiovascular 
disease event (a composite endpoint of death from CHD, non-fatal MI, 
revascularization procedures, or stroke) of the CARE (n=711) and WOSCOPS (n=522) 
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trials. In both CARE and WOSCOPS a case-only analysis was used to calculate the p-
value of the Synergy Index 
23
. The Synergy Index is an estimate for the interaction 
between pravastatin therapy and genotype that would be observed in a study that 
included both cases and non-cases. For 64 SNPs replication was requested, data was 
available for 47 SNPs, 22 with identical rs-number as the SNPs in PROSPER/PHASE 
and 25 SNPs in LD (r
2
>0.8). Of the remaining 17 SNPs, 10 SNPs were genotyped in 
CARE using PCR assays (9 identical to PROSPER/PHASE SNPs, 1 SNP in LD). Of these 10 
SNPs, one SNP was associated with an interaction p-value < 0.1 and was also 
genotyped in the entire WOSCOPS cohort. Seven of the 64 SNPs were not genotyped 
in either CARE or WOSCOPS.  
Results 
Table 1 shows the baseline characteristics of the 5244 subjects participating in the 
PROSPER/PHASE study, stratified by the allocation to pravastatin or placebo. Subjects 
allocated to pravastatin were similar compared to placebo treated subjects. The 
mean age of all subjects at study entry was 75.3 years and about 50% of the 






Continuous variables (mean, SD)   
 Age (years) 75.3 (3.3) 75.4 (3.4) 
 Systolic  blood pressure (mmHg) 154.6 (21.9) 154.5 (21.9) 
 Diastolic blood pressure (mmHg) 84.0 (11.7) 83.4 (11.1) 
 Body mass index (kg/m
2
) 26.8 (4.3) 26.8 (4.1) 
 Total cholesterol (mmol/L) 5.7 (0.9) 5.7 (0.9) 
 LDL cholesterol (mmol/L) 3.8 (0.8) 3.8 (0.8) 
 HDL cholesterol (mmol/L) 1.3 (0.3) 1.3 (0.4) 
 Triglycerides (mmol/L) 1.5 (0.7) 1.6 (0.7) 
Categorical variables (n, %)   
 Males 1267 (48.0) 1257 (48.3) 
 Current smoker 720 (27.3) 672 (25.8) 
 History of hypertension 1630 (61.8) 1627 (62.5) 
 History of diabetes 279 (10.6) 265 (10.2) 
 History of angina 682 (25.8) 742 (28.5) 
 History of claudication 173 (6.6) 181 (6.9) 
 History of myocardial infarction 361 (13.7) 347 (13.3) 
 History of stroke or TIA 291 (11.0) 295 (11.3) 
 History of vascular disease* 1145 (43.4) 1191 (45.7) 
* Any of stable angina, intermittent claudication, stroke, transient ischemic attack (TIA), 
myocardial infarction, peripheral artery disease surgery, or amputation for vascular disease more 
than 6 months before study entry. 
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participants were female. For the participants with GWAS data, the mean duration of 
follow-up was 3.2 years and the number of primary events was 798, 434 events in 
the placebo group and 364 events in the pravastatin group. Within the PHASE 
project, pravastatin reduced the incidence of primary events by 17% (age, sex, and 
country adjusted hazard ratio 0.83 [95% CI: 0.72-0.96]), which is comparable to the 




In figure 1 the QQ-plot of the interaction p-values is shown (lambda = 0.996). The QQ 
plot and lambda do not indicate an excess of significant results compared with those 
expected by chance, and indicate sufficient control for possible population 
stratification.  
Figure 1 shows the results of the GWAS assessing the interaction between genetic 
variants and statin treatment on the incidence of the primary endpoint depicted in a 
Manhattan plot. We did not observe genome wide significant associations, indicating 
that all estimates for the cardiovascular event reduction by pravastatin treatment 
were similar between SNP carriers and non-carriers. Furthermore, none of the SNPS 
reached the p-value of 5 x 10
-7
, for which the power (as indicated) would have been 
80%. Loci with low p-values (p-value <1 x 10
-5
) were found around ADAMTS14 (chr 
10) and PPP2R5E (chr 14), and near ODZ4 (chr 11), XKR4 (chr 8), METTL4 (chr 18),  
Figure 1. Q-Q and Manhattan plot for GWAS on the interaction between genotype and pravastatin 
treatment on the primary endpoint in the PROSPER/PHASE study. The left panel shows the quantile-
quantile (QQ) plot of the observed versus expected p-values. The right panel shows the Manhattan plot, 
presenting the –log10 p-values of the interaction p-values. 
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Table 2. Genomic loci interacting with statin treatment with a p-value smaller than 1E-04 
CHR Position  Top SNP A1 A2 Frq A1 Beta SE p-value Gene or nearby genes 
1 107319828 rs12725107 A C 0.80 0.57 0.14 4.50E-05 LOC126987, PRMT6 
2 13334109 rs453359 C A 0.57 -0.57 0.14 7.05E-05 TRIB2, FAM84A 
2 67604877 rs17633730 G T 0.96 1.49 0.37 6.59E-05 ETAA1, LOC402076 
2 143476854 rs352887 A G 0.47 -0.43 0.11 9.18E-05 KYNU 
2 182620241 rs1913896 T C 0.76 -0.58 0.13 1.47E-05 PPP1R1C 
2 206775723 rs17223074 C T 0.96 -1.42 0.36 9.60E-05 GPR1 
2 222230114 rs1519483 C T 0.72 0.55 0.14 9.67E-05 LOC402120, LOC646444 
3 37487651 rs11709385 C G 0.65 -0.50 0.12 1.37E-05 ITGA9 
3 48706491 rs3172494 G T 0.87 -0.64 0.16 9.70E-05 IHPK2 
3 74427932 rs502114 A T 0.53 -0.48 0.11 1.12E-05 CNTN3 
4 126962141 rs12501068 G T 0.96 -1.48 0.35 1.98E-05 LOC645841, LOC132817 
5 55445178 rs160919 A G 0.27 -0.52 0.12 2.43E-05 ANKRD55 
5 158689546 rs6894567 A G 0.80 -0.61 0.14 1.71E-05 IL12B 
7 43414315 rs10255565 T C 0.82 -0.78 0.18 2.35E-05 HECQ1 
8 9374196 rs6601319 T C 0.26 0.57 0.14 2.73E-05 LOC100129150, TNKS 
8 56077010 rs3934874 G A 0.81 -0.68 0.15 4.43E-06 LOC100128419, XKR4 
8 62975272 rs1116816 C T 0.69 0.52 0.12 2.10E-05 ASP, LOC645551 
9 5520017 rs7870226 G A 0.38 0.45 0.11 7.63E-05 PDCD1LG2 
9 25629941 rs6475859 A C 0.79 0.59 0.14 4.70E-05 C9orf134, TUSC1 
9 32878825 rs10971182 G A 0.92 1.18 0.27 8.87E-06 TMEM215, ASSP12 
9 43582384 rs10907653 T C 0.71 -2.68 0.64 2.52E-05 FAM75A6, CNTNAP3B 
10 72186144 rs2791188 A G 0.82 0.67 0.15 8.76E-06 ADAMTS14 
10 127991998 rs868589 T C 0.75 0.48 0.12 9.71E-05 ADAM12 
11 6384682 rs1079199 T C 0.69 0.52 0.12 1.38E-05 APBB1 
11 69857496 rs655130 C T 0.94 -1.32 0.34 9.43E-05 PPFIA1 
11 78862547 rs7102569 G A 0.35 0.55 0.12 1.65E-06 ODZ4, LOC646112 
11 86414173 rs7927570 G T 0.84 -0.64 0.16 4.80E-05 FZD4, TMEM135 
11 116182933 rs1263167 A G 0.81 0.56 0.14 7.16E-05 APOA5, APOA4 
12 56811397 rs17120361 G A 0.96 -1.45 0.35 2.88E-05 XRCC6BP1, LOC100127973 
12 102208363 rs10778228 G A 0.66 0.48 0.12 4.25E-05 LOC728545, C12orf42 
12 115701524 rs4767452 C T 0.91 -0.88 0.21 2.37E-05 RNFT2 
12 130358787 rs7135770 C T 0.74 0.79 0.20 8.06E-05 LOC100128002, LOC338797 
13 80897164 rs9545683 C T 0.90 -0.75 0.19 7.86E-05 LOC100129023, PTMAP5 
13 101074718 rs1436260 A G 0.28 -0.49 0.13 9.76E-05 ITGBL1 
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and TMEM215 (chr 9) (Table 2). Overall we observed 43 loci, including 140 SNPs, 
possibly associated with differential event reduction after pravastatin or placebo 
treatment (p-values <1 x 10
-4
). None of those loci were previously reported to be 
associated with cardiovascular diseases. Stratifying the analysis for participants with 
and without a history of vascular disease before participating in the PROSPER study 
did not change the results (data not shown). 
In supplementary table 1 we show all loci with p-values for the interaction term (SNP 
x drug) <1x10
-4
 and the corresponding p-values for the intrinsic SNP effect.  None of 
the SNPs with a p-value for interaction term < 1x10
-4
 reached genome-wide 
significance for the intrinsic SNP effect. In supplementary table 2 we show all loci 
with p-values for the intrinsic SNP effect <1x10
-4
 and the corresponding p0values for 
the interaction term (SNP x drug). No SNPs reached genome-wide significance for the 
intrinsic SNP effect. 
Loci associated with p-values <1 x 10
-4
 were assessed for replication in the CARE trial 
and the WOSCOPS study. The results of the replication are shown in table 3. Only 
rs7102569 was significantly associated in the CARE trial (p=0.008). Rs7102569 is 
present on chromosome 11 and close to the ODZ4 gene and LOC646112 pseudo-
gene. In PROSPER/PHASE rs7102569 was associated with p=1.65 x 10
-6
, in CARE a 
proxy for this SNP, rs11237851, was used and associated with a p-value of 0.008. 
However, the direction of the effects was opposite in CARE compared to PROSPER 
and after correcting for multiple testing the association did not remain significant. 
  
Table 2. Genomic loci interacting with statin treatment with a p-value smaller than 1E-04 (continued) 
CHR Position  Top SNP A1 A2 Frq A1 Beta SE p-value Gene or nearby genes 
14 63044403 rs1271562 A T 0.88 0.77 0.17 9.68E-06 PPP2R5E 
14 95377650 rs1885155 C A 0.23 0.52 0.13 7.55E-05 LOC100133207, LOC730125 
17 21932776 rs11654492 A C 0.49 -0.46 0.11 3.28E-05 LOC100131001 
18 2384986 rs7242734 G T 0.88 -0.84 0.19 7.05E-06 LOC100128360, METTL4 
18 4403363 rs281018 C T 0.94 -2.12 0.50 2.58E-05 LOC284215, PPIAP14 
18 58924818 rs8092360 C T 0.81 0.58 0.14 5.12E-05 PHLPP, BCL2 
19 18203477 rs271828 C A 0.62 -0.49 0.12 2.55E-05 PDE4C 
19 61187205 rs306468 A T 0.55 0.47 0.11 2.51E-05 NLRP8 
Abbreviations: A1, coding allele; A2, non-coding allele; CHR, Chromosome; SNP, Single Nucleotide 
Polymorphism; Frq coding allele, Frequency non-reference allele; SE, standard error. 
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We assessed the explained variance in clinical events by our top SNP rs7102569. The 
Nagelkerke R square of the logistic regression analysis without the SNP and 
interaction term was 0.020. Including rs7102569 and the interaction term between 
SNP and pravastatin treatment gave a Nagelkerke R square of 0.028.  
In supplementary table 3 we performed a look-up in our GWAS for SNPs previously 
described in the literature to be associated with a differential event reduction after 
statin treatment. Only the DNAJC5B SNP rs13279522 was significantly associated 
with differential event reduction after correcting for multiple testing (p=0.002).  
Discussion 
This GWAS was set out to assess for clinically meaningful interactions between 
genetic variants and pravastatin treatment on the incidence of cardiovascular events 
on a genome-wide level. We did not observe any genetic variant genome-wide 
significantly associated with a clinically meaningful differential event reduction by 
pravastatin, taking the power of our study into account (p<5x10
-7
). For loci that had 
an interaction p<1x10
-4
 in PROSPER, we investigated them further in two 
independent pravastatin cohorts (CARE and WOSCOPS), which showed no consistent 
evidence for a significant pharmacogenetic effect for pravastatin.   
In the current study, we investigated the interaction between genetic variants and 
statin treatment on the incidence of cardiovascular events at a GWAS level. 
Previously the CARE and WOSCOPS trial conducted a GWAS study to identify genetic 
variants associated with differential CHD event reduction by pravastatin therapy, 
however for this GWAS a case-only approach was used 
16
. CARE and WOSCOPS 
identified a SNP in the DNAJC5B gene associated with a different event reduction by 
pravastatin therapy. Other studies have investigated variation in clinical events after 
statin therapy mainly via candidate gene approaches. For example, genetic variations 
in CETP and APOE have been suggested to interact with statin treatment on 
cardiovascular event reduction 
24-29
. However most of those results are equivocal and 
could not be replicated in large meta-analysis or other studies 
30-32
. In addition, none 
of those SNPs were associated with the differential event reduction during statin 
therapy in our study, not even to a level of p<1x10
-4
.  
Although we did not find any genetic variants significantly associated with 
differential event reduction by pravastatin treatment, the GWAS in the 
PROSPER/PHASE study should have the statistical power to detect clinically 
meaningful interactions (interaction effect of 2.0) between genes and treatment at a 
p-value threshold of 5x10
-7
 (80% power). The power to detect smaller but from the 
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biological point of view perhaps also interesting effects (interaction effect of 1.2), or 
less common SNPs, was however limited (<10%) and not the purpose of this study. 
However, we assume that publishing underpowered results, like our SNPs with a 
MAF<0.25, is not always senseless. Non-significant but promising findings might be 
indications for further candidate gene studies, or might be useful in larger meta-
analysis. Although for the GWAS approach the PROSPER/PHASE study may not be 
large enough, the PROSPER study is one of the largest studies of this kind, with 
prospective data on more than 5000 subjects. Also, the mean duration of follow-up 
was 42 months with virtually no loss to follow-up and an incidence of almost 800 
primary events.  
A possible limitation of the current study is the replication in the CARE trial and 
WOSCOPS study. Both studies had performed a case-only approach to investigate the 
possible interaction between SNP and pravastatin treatment. This approach is valid 
only if SNP and treatment are independent of each other, but since both CARE and 
WOSCOPS were a randomized controlled trial they are independent by design.  
The aim of pharmacogenetic research is to identify the genetic variants associated 
with variable drug responses. Finding those genetic variants should lead to 
improvements in the use of drug therapy through selection of the most appropriate 
drug based on an individual’s genetic make-up 
33
. In some areas of disease this has 
proven to work 
34
. For example, genetic variation in the cytochrome P450 2C9 
(CYP2C9) and vitamin K epoxide reductase (VKORC1) genes explain up to 35% of the 
variability in required warfarin starting dose
35
. Therefore, since 2010, the United 
States Food and Drug Administration has required dose recommendations based on 
CYP2C9 and VKORC1 genotypes into the warfarin product label 
35
. Another possible 
area where pharmacogenetics might be of clinical value is antiplatelet therapy 
36
. The 
COX1 – 842A>G and CYP2C19*2 polymorphisms, reported to be associated to aspirin 
and clopidogrel resistance, are determinants of thrombotic complications in ST-
segment elevation myocardial infarction patients treated with percutaneous 
coronary intervention and seem of clinical significance
37
. With regard to the 
pharmacogenetics of statin therapy, most GWA studies have focused on the lipid 
lowering effects of statins. The only genetic variants that have been consistently 
identified to associate with variation in LDL cholesterol response are within the APOE 
and LPA genes
4
. Currently a large meta-analysis is being performed within the 
Genomic Investigation of Statin Therapy (GIST) consortium, which potentially will 
identify more loci associated with variation in LDL cholesterol response to statin 
therapy 
4
.  A possible target for pharmacogenetic testing in statin treatment is the 
SLCO1B1 gene. Variants in this gene were strongly associated with the risk of high 
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dose simvastatin-induced myopathy and more than 60% of the myopathy cases could 
be attributed to the minor SLCO1B1 allele 
9
. This SCLCO1B1 variant seems to be only 
relevant for simvastatin-associated myopathy, and not for subjects treated with 
other statin types 
38
. This implicates that our findings might not be generalizable to 
other statins. In our pharmacogenetic of pravastatin study however, our most 
significant SNP rs7102569 explained only less than 1 percent of the variance in 
clinical events, which seems not clinically meaningful.  
Since we were not able to detect a clinically meaningful differential event reduction 
by any SNP within this relative large sample of 5200 participants and 800 primary 
events, one might wonder how pharmacogenetics of pravastatin therapy can be of 
any clinically relevant use for individual patients in clinical care. Therefore we should 
ask ourselves the question whether personalized medicine should still be an aim of 
pharmacogenetic research with regard to (prava) statin therapy. With the GWA 
studies usually common SNPs with small effect sizes are found in relation to the 
outcome, however exome sequencing may still reveal rare genetic variant of larger 
effect sizes that can be used in pharmacogenetic research, but these results then 
would only apply for a small subset of patients. Pooling of more large studies may 
lead to significant findings. For the pooling of more studies, collaboration in large 
consortia is necessary. Within the Genomic Investigation of Statin Therapy (GIST) 
consortium, meta-analysis will be performed to identify possible SNPs associated 
with differential event reduction after statin therapy. But even when we then will be 
able to identify associations in such a large consortium, the question remains if those 
findings are relevant for the individual patient to guide therapy in daily practice. 
However, the possibility to identify SNPs of lower effect sizes in such meta-analysis 
may still be beneficial in identifying novel mechanisms/pathways for protection. 
Alternatively, they could be used to identify potential new drug targets. A possible 
positive implication of our findings might be that our findings do not suggest any 
evidence for differential treatment with statins according to genotype sub-groups. 
In conclusion, we could not identify genetic variation that was significantly 
associated at a genome-wide level with a clinically meaningful differential event 
reduction by pravastatin treatment in a large prospective study. We therefore 
assume that in daily practice the use of genetic characteristics to personalize 
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Supplementary material 
Supplementary material is available at Athereosclerosis online. 
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Abstract 
In pharmacogenetic research, genetic variation in non-responders and high-
responders are compared with the aim to identify the genetic loci responsible for this 
variation in response. However an important question is whether the non-responders 
are true non-responders or whether they actually are non-adherent? Therefore, we 
describe, within the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER) the characteristics of both non-responders and high-responders of statin 
treatment in order to possibly discriminate non-responders from the non-adherers. 
Here, we demonstrate that subjects that do not respond to statin therapy are 
younger (p=0.001), more often smoke (p<0.001), have a higher alcohol consumption 
(p<0.001), have lower total cholesterol levels (p<0.001), have a lower prevalence of 
hypertension (p<0.001), and have lower cognitive function (p=0.035) compared to 
subjects who highly respond to pravastatin treatment. Moreover, we showed that 
excluding non-responders and/or non-adherers in pharmacogenetic studies provides 
more robust results, since standard errors are lower. Our results suggest that non-
responders to statin therapy are more likely to be non-adherers, since they have 
more characteristics that we assume to be indicators of high self-perceived health 
and low disease awareness, making the subjects less adherent to study medication. 
We suggest that in pharmacogenetic research, extreme non-responders are excluded 
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Introduction 
Hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
(statins) are the most commonly prescribed drugs for the prevention of 
cardiovascular disease worldwide. Statins lower plasma cholesterol levels with 30-
50% and are associated with a reduction of cardiovascular events of 20-40% 
1
. Statins 
are generally well tolerated and are believed to have relatively few side effects 
2
. 
However, clinical response is highly variable and not all subjects appear to benefit 
from statin therapy, only about a third of treated patients achieve the international 
guideline specified lipid lowering goals 
1
.  
Pharmacogenetic studies aim to find genetic variation that is responsible for the 
variable response to drug treatment. For that purpose genome-wide genetic 
variation in high responders and non-responders is usually compared with the aim to 
identify genetic loci associated with the variation in response 
3;4
. Especially in whole 
genome sequencing studies, only the two extreme phenotypes e.g. the extremely 
good responders and the non-responders are chosen to reduce costs and enhance 
efficiency 
5
. However, for correct interpretation of this comparison it is essential to 
be sure that non-responders have actually taken the drug and are not non-
responders due to non-adherence.  
Pharmacogenetic research is usually best executed in randomized controlled trials, 
since adherence to medication is closely monitored, by for example, questionnaires,  
pill count and nowadays electronic medication monitoring devices 
6
. However, this 
monitoring system does not provide certainty that subjects are actually adherent to 
their medication. Non-adherers can relatively easily work around the control 
mechanisms, e.g. by discarding drugs before the pill count. Moreover, assessing 
plasma levels of drugs does not guarantee adherence, apart from the last days 
before the study blood drawn. In other words, are we capable in discriminating non-
responders from non-adherers in pharmacogenetic research? And how should we 
optimally deal with this problem in pharmacogenetic analyses? 
Using data of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) 
7;8
, we here describe baseline characteristics of differential responder groups to 
statin treatment in order to find discriminatory factors between likely non-
responders and likely non-adherers. Furthermore, we propose how to deal with the 
misclassification of false non-responders in pharmacogenetic analyses. 
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Methods 
We used data from the PROSPER study 
7;8
. In short, the PROSPER study is a 
prospective multicenter randomized placebo-controlled trial to assess whether 
treatment with 40 mg daily pravastatin diminishes the risk of major vascular events 
in elderly. Men and women aged 70-82 years were recruited if they had pre-existing 
vascular disease or increased risk of such disease because of smoking, hypertension, 
or diabetes. A total number of 5,804 subjects were randomly assigned to pravastatin 
(n=2,891) or placebo treatment (n=2,913). At baseline, a brief medical history was 
taken, vital signs were recorded, and a fasting venous blood sample was collected for 
biochemical and hematological checks and for lipoprotein quantification. In addition, 
a Mini-Mental State Examination was conducted to test for cognitive function. 
Adherence was measured by pill count every three months. 
From the pravastatin users (n=2,891), we excluded all subjects who were withdrawn 
from the PROSPER study in follow-up because they refused study medication or did 
not attend the follow-up visits (n=346). From the remaining subjects (n= 2,545) the 
percentage achieved LDL lowering after statin treatment was calculated by taking the 
mean LDL level for all post statin treatment measurements at month 3, 6, 12, 24 and 
36, minus the baseline LDL level, divided by the baseline LDL level and multiplied by 
100. If data of one of the measurements for one individual was missing, we took the 
mean of only the available measurements of that individual as post statin treatment 
measurement. These data were available for 2,519 subjects.  
We then created five groups of achieved LDL lowering (=<10%; 10-20%; 20-30%; 30-
40%; >40% LDL lowering) and compared baseline characteristics between these 
groups. Based on clinical experience, non-responders were defined as =<10% 
decrease in LDL cholesterol levels and high-responders were defined as >40% 
decrease in LDL cholesterol levels.  
First, we assessed whether there were differences in baseline characteristics 
between the five groups of achieved LDL lowering using ANOVA. Baseline 
characteristics included sex, age, education, smoking, alcohol use, BMI, blood 
pressure, cholesterol level, history of hypertension, diabetes, and vascular disease, 
and cognitive function. We also assessed differences in baseline characteristics 
between the non- and high-responders with a student’s t-test for continuous 
variables or the Pearson Chi-square test for categorical variables. 
Second, we used binary logistic regression to assess the relative risk of being a non-
responder based on the clinical characteristics that were significantly different 
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between the high and low groups in the first analysis. Continuous measurements 
were dichotomized based on sex-specific medians. All analyses were adjusted for age 
and country of origin, and where necessary additionally adjusted for sex. Third, we 
calculated the number of risk factors per subject and assessed the association 
between the number of risk factors and non-responder status with binary logistic 
regression analysis adjusted for age, sex, and country of origin. The sum of the risk 
scores was not available in seven subjects of the high-responders and in one subject 
of the non-responders because of missing data of one of the clinical characteristics. 
Fourth, we compared the non-adherers based on the pill count with the non-
responders based on LDL lowering for baseline characteristics with a student’s t-test 
for continuous variables or the Pearson Chi-square test for categorical variables. 
Subjects were defined as a non-adherer if they returned more than 18 (20%) pills in 
the preceding 90 days before their study visit (mean pill count over maximum 
number of study visits per individual) 
9
. Non-responders were those with LDL 
lowering <10%. There were 24 subjects in both groups, who were excluded from this 
analysis to facilitate statistical comparison. 
Finally, we performed a Genome-Wide Association Study (GWAS) to analyze the 
genetic variation associated with variation in LDL lowering in all subjects (n=2272) 
and repeated this analysis with the exclusion of the subjects classified as non-
responders (leaving n=2167), with the exclusion of the non-adherers (leaving 
n=2160) and with the exclusion of both non-responders and non-adherers (leaving 
n=2078). The total number of subjects is lower in this analysis since the GWAS has 
not been executed in all PROSPER subjects, since genotyping failed or they were 
excluded based on the GWAS quality control criteria 
10
. No subjects were excluded 
based on phenotypic outliers. For this analysis, we used 2.5 million imputed SNPs 
within the PHASE study (the PHArmacogenetic study of Statins in the Elderly) 
10
. The 
analysis was performed with ProbABEL software (http://www.genabel.org/), adjusted 




Table 1 shows the baseline characteristics of the five groups of percentage LDL 
lowering after pravastatin treatment. There were significant differences between the 
groups for sex, current smoker, history of hypertension, age, education, cognitive 
function, alcohol use, and level of total cholesterol. Moreover, when we compared 
the baseline characteristics of the 114 non-responders with the characteristics of the 
734 high-responders to pravastatin therapy, we found that subjects who did not 
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respond to pravastatin therapy were by average 1 year younger (p=0.001), more 
often smoked and drank more alcohol (both p<0.001), had lower total cholesterol 
levels (p<0.001), had lower prevalence of hypertension (p<0.001), and had lower 
cognitive function (p=0.035) compared to subjects who highly responded to 
pravastatin therapy.  
Table 1. Association between groups of % LDL lowering to statin treatment and clinical variables 
 % LDL lowering in response to pravastatin treatment  
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Continuous variables  
(mean, se) 




 Education (years) 
 MMSE (points) 
 Alcohol (units/week) 
 Total cholesterol (mmol/L) 
 SBP (mmHg) 





























































Abbreviations: BMI, Body Mass Index; MMSE, Mini Mental State Examination; SBP, systolic blood 
pressure; DBP, diastolic blood pressure. 
*significant difference between the groups of <=10% and >40% LDL lowering (all p<0.05) 
Next, we calculated the relative risk of being a non-responder for the characteristics 
that significantly differed between high and non-responders with a binary logistic 
regression model (table 2). The largest relative risk was found for subjects that were 
current smokers (OR 3.96, 95% CI 2.60-6.03, p=1.4 x 10
-10
). We also found a higher 
risk of being a non-responder in subjects without a history of hypertension (OR 2.01, 
95%CI 1.32-3.04, p=0.001), with a lower cognitive function (OR 1.46, 95%CI 0.97-
2.20, p=0.068), with higher alcohol intake (OR 1.73, 95%CI 1.15-2.59, p=0.008), and 
with lower total cholesterol levels (OR 3.12, 95%CI 2.02-4.81, p=2.6 x 10
-7
). The 
association between number of characteristics in the non-responders compared to 
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the high responders is also shown in table 2. Compared to subjects with none or 1 
risk factor, the relative risk of being a non-responder increased gradually to 14.66 
(95%CI 5.51-39.02, p=7.6 x 10
-8
) for subjects with 5 characteristics. When the 
summary score was included in the model as a continuous variable, the risk of being 
a non-responder increased with 1.99 (95%CI 1.65-2.38, p=1.7 x 10
-13
) per additional 
characteristic. 





OR (95%CI)* p-value 
Baseline characteristics     
Smoking 126 (17) 54 (47) 3.96 (2.60-6.03) 1.43 x 10
-10 
 No history of hypertension 231 (32) 56 (49) 2.01 (1.32-3.04) 0.001 
 Low MMSE 379 (52) 68 (60) 1.46 (0.97-2.20) 0.068 
 High Alcohol 270 (37) 58 (51) 1.73 (1.15-2.59) 0.008 
 Low TC 318 (43) 81 (71) 3.12 (2.02-4.81) 2.58 x 10
-7
 
Number of characteristics     
 <=1 297 (41) 20 (18) 1.0 (ref) - 
 2 256 (35) 26 (23) 1.53 (0.83-2.83) 0.170 
 3 126 (17) 36 (32) 4.15 (2.28-7.55) 3.22 x 10
-6 
 4 38 (5) 20 (18) 7.25 (3.53-14.87) 6.54 x 10
-8
 
 5 10 (1) 11 (10) 14.66 (5.51-39.02) 7.57 x 10
-8
 
 Trend   1.99 (1.65-2.38) 1.65 x 10
-13 
*The OR represents the risk of being a non-responder when you are in the risk category. 
The continuous factors are dichotomized based on sex-specific medians. Adjusted for age and country, 
the analyses for smoking and hypertension are additionally adjusted for sex. 
Abbreviations: OR, Odds Ratio; TC, total cholesterol; SBP, Systolic blood pressure; MMSE, Mini Mental 
State Examination. 
Based on pill count, we defined a non-adherer if they returned more than 18 (20%) 
pills in the preceding 90 days before their study visit (mean pill count over maximum 
number of study visits per individual). Within the subjects that highly respond to 
pravastatin therapy 99.5% were adherent to their study medication based on pill 
count, whereas in the non-responders group this was reduced to 78.6%. Table 3 
shows the comparison between non-adherers of the PROSPER study based on pill 
count and the non-responders based on LDL lowering. Compared to the non-
adherers, non-responders smoked more often (p=0.085) and had higher alcohol 
intake (p=0.117), lower total cholesterol levels (p=0.020), lower systolic blood 
pressure (p=0.034), and had less often a history of hypertension (p=0.001) and 
diabetes (0.273) although not all comparisons were statistically significant different. 
A major difference between the two groups was the number of subjects with a 
history of vascular disease. Within the non-adheres, there were no subjects with a 
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history of vascular disease whereas in the non-responder group, 46 (51%) had a 
history of vascular disease (p<0.001).  
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Subjects who were both non-responder and non-adherer were removed from the analysis to facilitate 
statistical comparison. 
Finally, we compared the results of the GWA studies on the influence of genetic 
variation of the LDL lowering response after pravastatin treatment in all subjects 
(n=2272) and in the sample excluding non-responders (n=2167), in the sample 
excluding non-adherers (n=2160) and in the sample excluding both non-responders 
and non-adherers (n=2078). The results of the GWA studies are depicted in figure 1. 
None of the Manhattan plots show any genome wide significant results (all p>5.0 x 
10
-8
). From 4 SNPs known to be associated with statin response the results for the 
four different analyses are compared in table 4. The main message of this 
comparison is that by excluding non-responders or non-adherers, the standard error 
decreases, indicating that probably noise is removed from the analysis. The beta 
stays more or less consistent in the analysis in the three restricted study samples, 
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Figure 1. Manhattan plots showing the results of GWA studies on the influence of genetic variation of 
the LDL lowering response after pravastatin treatment in all subjects (A) and in the sample excluding 
non-responders (B), in the sample excluding non-adherers (C) and in the sample excluding both non-
responders and non-adherers (D). 
Discussion 
In this study we showed that non-responders to statin treatment differ depending on 
baseline clinical characteristics from high-responders. Non-responders were more 
often smokers, drank more alcohol, had a lower cognitive function, were less likely to 
have hypertension and had lower total cholesterol levels. These characteristics can 
be considered as indicators of higher self-perceived health and lower disease 
awareness, indicating that non-responders are less aware of the benefits of using the 
study medication and are therefore more likely to be non-adherers than non-
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responders. Also, compared to the non-adherers based on pill count, non-responders 
were more likely to be non-adherers since they have more characteristics that 
correspond with high self-perceived health and low disease awareness. Moreover, 
we showed that exclusion of the non-responders in the GWAS yielded more robust 
results, since the standard errors decreased after exclusion. All these results 
together indicate that pharmacogenetic studies that compare extreme phenotypes 
might be at least partially biased by the phenomenon of some, perhaps many, non-
adherers probably being misclassified as non-responders.   
Table 4. Comparison of four SNPs associated with statin response in four different study samples 
 N Beta SE p-value 
rs10455872 (LPA) 
   All subjects 
   Excl. non-responders 
   Excl. non-adherers 
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Only a few studies have investigated differences between non-responders and high-
responders of statin therapy 
12-15
. Each study showed that characteristics that are 
indicators of better self-perceived health like age, the number of comorbidities and 
diet habits are different between non- and high-responders and are therefore more 
indicators of non-adherence 
16;17
.  However, we cannot rule out the possibility that 
these characteristics are actually real factors that determine whether a subject 
responds biologically different to statin therapy. For example, high-responders of 
statin therapy have higher baseline cholesterol levels, probably since subjects with 
higher baseline cholesterol levels could also decrease more in cholesterol level 
(simply because a greater absolute but also relative change is achievable) after statin 
therapy compared to subjects with low baseline cholesterol. In this case it is still not 
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certain if this variable can help us to discriminate between non-responders and non-
adherers. However, in various subgroup analyses within the PROSPER study we found 
no evidence that there is an interaction between any of the clinical characteristics 
and statin response 
8
. 
The comparison with the actual non-adherers of the PROSPER study based on pill 
count at each study visit also does not give a conclusive answer. Adherence to study 
medication in randomized controlled trials like the PROSPER study, is closely 
monitored by for example questionnaires and by pill count 
6
. However, this 
monitoring system does not provide certainty that subjects are actually adherent to 
their study medication. Non-adherers can relatively easily work around the control 
mechanisms, e.g. by discarding a reasonable number of pills before the study visit. 
Since we showed that the non-responders of pravastatin therapy based on the 
clinical outcome LDL lowering had more characteristics that we think coincide with 
high self-perceived health and low disease awareness, we think we have missed non-
adherers by using the pill count monitoring system. On the contrary, none of the 
non-adherers had a history of vascular disease compared to 51% of the non-
responders, which indicates that in the non-responder group subjects are included, 
s.a. those with a history of vascular disease, that likely are adherent and therefore 
biologically non-responders to the drug.   
In many pharmacogenetic studies, non-responders are compared to high-responders 
to investigate which genetic variation is responsible for this difference in response 
5
. 
However we believe that by using this comparison the best power and most 
efficiency is reached, there is the possibility that actually the non-adherent 
phenotype is investigated. Hence, instead of finding genetic variation responsible for 
the variation in response to therapy, genetic variation for adherence is assessed. 
Therefore we assessed the difference in analyses when we perform pharmacogenetic 
research in all subjects compared to pharmacogenetic research excluding the non-
responders and/or non-adherers.  Our results suggest that in all analyses excluding 
non-responders and/or non-adherers the noise of the possible non-adherence is 
reduced since the standard errors were decreased, which cannot be the result of a 
larger sample size. 
Our suggestion is that in pharmacogenetic research, another strategy should be 
followed to find the genetic variation responsible for the difference in response to 
(statin) therapy instead of comparing the extreme phenotypes (high- vs. non-
responders). We propose three different strategies that may be followed to exclude 
the problem of investigating non-adherence instead of non-responsiveness. First, all 
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subjects should be investigated with a total range of responsiveness as a continuous 
phenotype. In this way the extreme non-responsive cases which are possible non-
adherers will not have large weight in the analyses compared to an analysis where 
non-responders and high-responders are compared. The second proposed strategy is 
to exclude subjects with non-responsiveness and/or non-adherence and investigate 
the moderate-responders to the high-responders to be sure that the non-adherence 
phenotype is excluded from the analysis. And the third, most sophisticated, strategy 
is to use a propensity score based on various clinical characteristics associated with 
non-adherence to match high-responders to non-responders. This analysis will 
exclude any possible confounding from non-adherence from the study. 
Unfortunately, we could not perform such analysis due to low statistical power.  
In conclusion, pharmacogenetic studies that are investigating the difference between 
non- and high-responders were almost certainly in part investigating the non-
compliant phenotype, since non-responders have clinical characteristics that coincide 
with high self-perceived health and low-disease awareness and that are also very 
common in non-adherers. Other strategies, as proposed herein, should be used to 
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Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD accounts 
for 17.3 million deaths per year, a number that is expected to grow to over 23.6 
million by the year 2030 
1;2
. During the last decades the CVD death rates have 
declined in several developed countries, however in low- and middle-income 
countries the rates of CVD have risen 
2;3
. Eighty percent of the CVD deaths worldwide 
occur nowadays in the low- and middle-income countries, usually at younger age and 
involve women more frequently 
4
. An important risk factor for CVD is 
hypercholesterolemia. Many studies have proven the effectiveness of lipid-lowering 
therapy, predominantly statins, in reducing the incidence of CVD 
5
. The 
successfulness of statin therapy is dependent on the decrease in low-density 
lipoprotein cholesterol (LDLc) 
5
, therefore achieving the recommended lipid levels is 
essential in the treatment of CVD. 
In this issue of Current Medical Research and Opinion, Lee et al. investigated the 
achievement of the recommended LDLc goals and factors associated with this 
achievement of 1851 Korean patients with hypercholesterolemia treated with 
rosuvastatin 
6
. The LDLc target was defined according to National Cholesterol 
Education Program – Adult Treatment Panel III guidelines 
7
, patients were divided 
into four groups based on their coronary heart disease risk: low, moderate, high, and 
very high. The LDLc target was dependent on the risk category, < 130 mg/dL for low 
or moderate risk subjects, < 100 mg/dL for high-risk subjects, and < 70 mg/dL. The 
attainment rates were relatively high; overall, 88% of the patients reached their LDLc 
goal. Next, the authors investigated which factors influenced the achieved targets. It 
was shown that good adherence with medication was a strong predictor of target 
achievement.  
Lee et al. have investigated the target achievement in a Korean population, but are 
there indications that this would be different in other regions of the world? The 
INTERHEART study was an international case-control study to assess the importance 
of risk factors for coronary heart disease worldwide 
3
. Although the relative 
importance of every risk factor varied and was dependent on its prevalence, the 
effect of the risk factors was consistent across different geographic regions and by 
ethnic background. Since risk factors are comparable around the world, it would 
seem logical that treatment strategies for the prevention of CVD are also similar in 
every country. Statins are used worldwide to lower LDLc levels and thereby 
decreasing CVD risk. But is the success rate comparable in different geographical 
regions? The Lipid Treatment Assessment Project 2 (L-TAP 2) was a survey performed 
in nine countries worldwide, and evaluated the proportion of patients achieving the 
LDLc treatment goals with statins 
8
. The proportion of patients attaining the 
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treatment goal ranged from 47 to 84% across the different countries, with the 
highest success rate in Korea en the lowest in Spain. The success rate was dependent 
on the CVD risk, the higher the risk, the lower the achievement of the LDLc goal, 
being 86% in low-risk patients, 74% in moderate-risk patients, 67% in high-risk 
patients, and only 30% in the very-high-risk patients, indicating that it is especially 
difficult to reach the stringent goals in very-high-risk patients.  
The slightly observed differences in success rates between countries are likely due to 
differences in guidelines, patient characteristics, and healthcare systems among the 
countries. But pharmacokinetic factors may also influence the rate of goal 
achievement. A study performed in four different ethnic groups living in Singapore 
investigated the pharmacokinetics of rosuvastatin 
9
. Plasma exposure of rosuvastatin 
and its metabolites was significantly higher in the Asian groups compared with the 
white subjects. This higher plasma exposure in Asian subjects might be associated 
with the higher LDLc goal achievement in Korean subjects as observed in the study of 
Lee et al. and L-TAP 2 
6;8
. Differences in genetic background may also be associated 
with differences in statin response. For example, the occurrence of genetic risk 
variants or the allele frequencies can be different across populations 
10
. An example 
of racial differences in statin pharmacogenetics was shown in the Cholesterol and 
Pharmacogenetics (CAP) study. In the CAP study the association between haplotypes 
in the Low-density lipoprotein receptor (LDLR) gene and lipid-lowering response to 
simvastatin was assessed in blacks and whites 
11
. The LDLR haplotype 5 was 
associated with smaller LDLc reduction in black but not in the white participants. 
Recent genome-wide association studies (GWAS) have investigated genetic variants 
associated with the lipid lowering effects of statins, in which the Lipoprotein(a) and 
apolipoprotein E genes revealed to be associated with statin response 
12
. Another 
study has investigated genetic variants associated with differential coronary heart 
disease event reduction after statin therapy 
13
. However, until now, the majority of 
the GWAS studies were performed in Caucasian participants 
14
. Since there are 
differences in genetic background, findings from the current GWA studies may not be 
generalizable to non-Caucasian patients. 
Although there seem to be slight differences in goal achievement rates between 
ethnicities, overall the achievement rates are reasonable, especially in low-risk 
patients. The overall success rate in the L-TAP 2 survey was 73%, and even 88% in the 
study by Lee et al. 
6;8
. The JUPITER (Justification for Use of statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin) trial assessed if there were ethnical 
differences in the effectiveness of rosuvastatin in reducing first-ever cardiovascular 
 
 
110 Statins around the world 
events 
15
. In this trial rosuvastatin was similarly effective in reducing events among 
whites and nonwhites, including blacks, Hispanics and Asians.  
To summarize, statins are used worldwide as lipid-lowering therapy in the prevention 
of CVD. Despite the many different ethnicities worldwide, the most important risk 
factors for CVD are for all populations the same. Furthermore, statins seem on 
average to be effective in all studied populations and thus seem to work all around 
the world.   
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Abstract 
Observational studies in older subjects have shown no or inverse associations 
between cholesterol levels and mortality. However, in old age plasma low density 
lipoprotein cholesterol (LDL-C) may not reflect the life-time level due to reverse 
causality and hence the risk may be underestimated. In the current study, we used 
an LDL genetic risk score (GRS) to overcome this problem. A weighted GRS was 
created using 37 single nucleotide polymorphisms associated with LDL-C levels. The 
LDL GRS was calculated in three Dutch cohorts, the Leiden Longevity Study (LLS) 
(n=3282), the Leiden 85-plus study (n=317), and the Rotterdam Study (n=4035). We 
assessed the association between the LDL GRS and LDL-C levels, chronological age, 
familial longevity, and mortality. In all age strata, individuals with high LDL GRS had 
higher LDL-C levels (p=0.012 to p=8.5x10
-15
). The frequency of LDL increasing alleles 
decreased with increasing age (β=-0.027 (SE=0.01) per year, p=0.010). Moreover, 
individuals with a genetic predisposition for longevity had significantly lower LDL GRS 
compared to age-matched individuals of the general population (LLS nonagenarians 
versus >90 years: β=0.93 (SE=0.39), p=0.018, LLS offspring versus partners: β=0.23 
(SE=0.10), p=0.019). In longitudinal analysis, high GRS was associated with increased 
all-cause mortality in individuals >90 years; with a 19% increased risk in individuals 
with the highest LDL GRS (p-trend=0.008). Results of the current study indicate that a 
genetic predisposition to high LDL-C levels contributes to mortality throughout life, 
also in the oldest old and a beneficial LDL genetic risk profile is associated with 
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Introduction 
Observational studies including middle-aged individuals have shown a positive 
association between cardiovascular disease and cholesterol levels.
1;2
 In addition, 
lowering cholesterol levels with statins reduces the risk of cardiovascular disease at 
all ages.
1
 However, at older ages above 75 years, the contribution of high cholesterol 
as a cardiovascular risk factor is controversial. Mortality from disease in old age has 
been shown to be independent of total cholesterol and low-density lipoprotein 
cholesterol (LDL-C) levels 
3;4
, whereas low total cholesterol levels have been 
associated with higher all-cause mortality in the oldest old.
3;5;6
 At old age, LDL-C 
levels in plasma may not reflect life-time LDL-C level due to comorbidities.
3
 This 
inverse health relation in old age raises the question whether lipid levels represent 
causal factors affecting cardiovascular/metabolic health at all ages. Fortunately, the 
use of genetic variants as an instrumental variable provides a possibility to 
investigate the associations free of biases such as reverse causality. In recent years, 
genome-wide association studies (GWAS) have identified several new genetic loci 
that are associated with lipoprotein levels. The largest GWAS meta-analysis, 
including 46 studies comprising more than 100,000 individuals, found 95 loci to be 
associated with cholesterol levels.
7
  
Characteristics of lipid metabolism have further been linked to human lifespan 
regulation by association to familial longevity. For example, offspring of long-lived 
individuals have larger LDL particle sizes compared to their spouses or age- and 
lifestyle-matched controls.
8-10
 Moreover, older people who carry the apolipoprotein 
E gene ε3/ε3 variant and have lower plasma levels of apoE, have a decreased 
mortality risk compared to carriers of the ε3/ε3 variant with high levels .
11
  
In this study we created a genetic risk score (GRS), based on single nucleotide 
polymorphisms (SNPs) associated with LDL-C levels.
7
 Using this GRS as instrumental 
variable, we evaluated the association between LDL-C and mortality in participants of 
three Dutch studies (figure 1).  In addition, we assessed the association between the 
LDL GRS and familial longevity. 
Methods 
Study populations 
To assess the associations between the LDL GRS and the various outcomes we made 
use of three Dutch cohort studies including 7634 participants, the Leiden Longevity 
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Study (LLS), the Leiden 85-plus study, and the Rotterdam Study. All cohorts had GWA 
data available and are briefly described here. 
Leiden Longevity study 
For the LLS, long-lived siblings of European descent were recruited together with 
their offspring and the spouses of the offspring (partners). Families were included if 
at least two long-lived siblings were alive and fulfilled the age criterion of 89 years or 
older for men and 91 years or older for women, representing less than 0.5% of the 
Dutch population in 2001.
12
 In total, 931 long-lived siblings with a mean age of 94 
years (range 89-104), 1671 offspring (mean age 61 years, range 39-81), and 744 
partners (mean 60 years, range 36-79) were included. DNA from the participants of 
the LLS was extracted from samples at baseline using conventional methods. 
13
 
Leiden 85-plus study 
Participants of the Leiden 85-plus study were inhabitants of Leiden, the Netherlands, 
who reached the age of 85 years between September 1, 1997, and September 1, 
1999. There were no selection criteria on health, functioning or demographic 
characteristics. A total of 705 inhabitants reached the age of 85 years and a total of 
599 individuals participated.
14
 Individuals were visited at their place of residence and 
annual follow up visits were performed until death or age 90 years. Information 
about mortality was available until December 31, 2009. The date of death was 
obtained from the civic registry of Leiden. 
Rotterdam Study 
The Rotterdam Study is a population-based cohort study, including 7983 participants 
living in Ommoord, a district of Rotterdam, the Netherlands. All inhabitants aged 55 
and over, were invited to participate in the study (n = 10275). The Rotterdam Study 
started in the early 1990s and periodical examinations were performed every three 
to five years. Analyses of this study are based on data from the third round of the 
Figure 1. Graphical presentation of the research question in the current study 
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study which was performed between 1997-1999 (n=4035). The study was approved 
by the medical ethical committee of the Erasmus Medical Center and written 




In offspring and partners from the LLS non-fasting venous blood samples were taken. 
Total and HDL cholesterol levels were determined using fully automated equipment 
(the Hitachi Modular or the Cobas Inergra 800 both from Roche, Almere, the 
Netherlands).  
In the Leiden 85-plus study lipoprotein levels were obtained at the follow-up visit at 
age 90 years. Total cholesterol, triglyceride, and HDL cholesterol levels were 
analysed with fully automated computerized analyzers (Hitachi 747 and 911, Hitachi, 
Ltd, Tokyo, Japan).  
In the Rotterdam Study, total cholesterol, HDL cholesterol, and triglyceride 
concentrations were measured from serum or plasma extracted from whole blood, 
using an automated enzymatic procedure (Boehringer Mannheim System). 




In the Leiden Longevity study genotyping was performed with Illumina Human660W-
Quad and OmniExpress BeadChips (Illumina, San Diego, CA, USA). Individuals were 
removed if they showed a mismatch in gender or familial relatedness based on 
genotype and phenotype, leaving 931 nonagenarians, 1610 offspring and 741 
partners for the analysis. In addition, SNPs which were not measured on both 
platforms and with a call rate <0.95, MAF <0.01 and PHWE < 10
-4
 were excluded, 
leaving 288635 (nonagenarians) and 298538 (offspring and partners) SNPs as input 
for the imputation. Imputation was performed separately for the LLS nonagenarians 
and LLS offspring and partners using IMPUTE2 with reference HapMap Phase I + II 
CEU release 22 (hg18/build36). 
In the Leiden 85-plus study genotyping was performed with Illumina OmniExpress 
BeadChips (Illumina) in participants aged 90 years. Individuals were removed if they 
showed a mismatch in gender based on genotype and phenotype, leaving 317 
individuals for the analysis. In addition, SNPs with a call rate <0.95, MAF <0.01 and 
PHWE <10
-4
 were excluded, leaving 603301 SNPs as input for the imputation. 
Imputation was performed using IMPUTE2 with reference HapMap Phase I + II CEU 
release 22 (hg18/build36). 
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In the Rotterdam Study genotyping was conducted using the Illumina Infinium II 
HumanHap 550K array among self-reported Caucasian individuals. Individuals were 
excluded if they had excess autosomal heterozygosity, mismatch between called and 
phenotypic gender, or recognized as being outlier with IBS clustering analysis. In 
addition, SNPs with a MAF ≤1%, PHWE <10
-5
, or call rate ≤90% were excluded, leaving 
530683 SNPs. Imputation was performed using the maximum likelihood method 
implemented in MaCH (version 1.0.15) with reference to HapMap Phase I + II CEU 
release 22 (hg18/build36).  
Weighted genetic risk score 
To create the LDL GRS we used the SNPs identified in the GWAS meta-analysis 
reported by Teslovich et al..
7
 We included all 37 SNPs associated with LDL-C levels 
(and possibly with total cholesterol, HDL cholesterol, and/or triglycerides).To build 
the LDL GRS, we first determined the number (or dosage in case of imputed SNPs) of 
unfavourable alleles for each individual, whereby the unfavourable allele was 
associated with higher LDL-C levels in the GWAS meta-analysis.
7
 The number of 
unfavourable alleles was multiplied by the absolute effect size as published in the 
original paper.
7
 Next, we calculated the GRS for each individual by summing the 
estimates (number of unfavourable alleles x absolute effect size) of all SNPs and 
divided it by the average of all effect sizes. In the final step the GRS was rescaled into 
a percentage of the maximum number of risk alleles (individuals GRS / maximum GRS 
score) x 100%. To use the GRS as a categorical variable, the GRS % was divided into 
three groups, using 47.5% and 52.5% as cut off values. 
Statistical analysis 
First, to assess the association between LDL GRS categories and LDL-C levels we 
combined the data of general population subjects (LLS partners, Leiden 85-plus 
study, and Rotterdam Study) and divided the individuals in age strata of 10 years. 
Data of LLS nonagenarians and offspring were excluded from this analysis since they 
have a genetic predisposition for longevity and to exclude possible familial effects. A 
general linear model was used adjusted for age, sex, and cohort. The explained 
variance in LDL-C levels by the LDL GRS was assessed by calculating the R
2
 per cohort 
using a linear regression model.  
Second, we assessed the cross-sectional association between the LDL GRS and 
chronological age. Individual level data from the LLS partners, Leiden 85-plus study, 
and the Rotterdam Study were combined to have a wide variation in age range. A 
general linear model was used adjusted for sex and cohort. Additional analyses were 
performed using only the individuals aged ≥ 50 years, and ≥70 years.  
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Differences in LDL GRS between LLS nonagenarians and individuals ≥90 years, and LLS 
partners and offspring were tested using a general linear model adjusted for age, 
sex, and, if necessary, familial relations.  
Finally, the longitudinal association between LDL GRS categories and mortality in 
individuals ≥90 years was assessed using Poisson analysis to calculate incidence rate 
ratios. For this analysis, data of the LLS nonagenarians, Leiden 85-plus study and 
Rotterdam Study participants aged ≥90 years was used. Incidence rate ratios were 
adjusted for age, sex, and, if necessary, cohort and familial relations.   
All statistical analyses were performed using IBM SPSS Statistics program for 
Windows (Version 20.0, USA) and Stata/SE version 12.1 for Windows. P-values ≤0.05 
were considered statistically significant. 
Results 
The LDL GRS was calculated for 3282 participants (931 nonagenarians, 1610 
offspring, and 741 partners) of the Leiden Longevity Study, 317 participants of the 
Leiden 85-plus study, and 4035 participants of the Rotterdam study. In table 1, the 
baseline characteristics are shown for the six age strata including the general 
population participants (LLS partners, Leiden 85-plus study, and Rotterdam Study), 
the LLS nonagenarians and offspring.  Baseline characteristics per cohort are 
provided in supplementary table 1.  
Figure 2: LDL cholesterol levels per GRS category in different age strata, using individual level data of LLS 
partners, Leiden 85-plus study, and the Rotterdam Study. Means and standard errors (SE) were assessed 
using a general linear model adjusted for age, sex, and cohort. P-values were assessed using the 
continuous values of the LDL GRS.  
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In each age stratum there was a linear association between the LDL GRS and LDL-C 
levels (figure 2), with individuals in the highest LDL GRS group having the highest 
LDL-C level (p=0.012 to p=8.5x10
-15
). Associations between the LDL GRS and LDL-C 
levels in the separate cohorts are provided in supplementary figure 1, showing a 
linear association in each cohort. The LDL GRS explained 7.1% of the variance in LDL-
C levels in the LLS offspring, 4.4% in the LLS partners, 6.0% in the Leiden 85-plus 
study, and 3.8% in the total Rotterdam Study.  
The next step was to assess the association between the LDL GRS and chronological 
age. Figure 3 shows the cross-sectional relation between the LDL GRS and age. With 
increasing age, the LDL GRS decreased. Regression analysis showed a significant 
association between LDL GRS and chronological age (β=-0.27 (SE=0.1) per 10-year 
increase in age, p=0.010, adjusted for sex and cohort). Additional separate analyses 
were performed in participants aged ≥50 years and in participants aged ≥70 years. In 
both age groups the significant association between the LDL GRS and age remained 
when excluding the younger participants (≥50 years: β=-0.26 (SE=0.11) per 10-year 
increase in age, p=0.015; ≥70 years: β=-0.52 (SE=0.18) per 10-years increase in age, 
p=0.005).  
Next, we investigated if the LDL GRS was associated with familial longevity. For this 
purpose, we compared the mean LDL GRS in the LLS nonagenarians versus the 
individuals aged ≥90 years from the Leiden 85-plus study and the Rotterdam Study 
(figure 4A), and in the LLS offspring versus the LLS partners (figure 4B). The mean 
Figure 3: Mean percentage of LDL GRS for each age category, including LLS partners, participants of the 
Leiden 85-plus study, and the Rotterdam Study. The LDL GRS is plotted as mean percentage with 
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GRS was significantly lower for individuals with a predisposition for longevity 
compared to the individuals from the general population within the same age range. 
LLS nonagenarians had a mean LDL GRS of 48.8% (SD=0.2) compared to a mean LDL 
GRS of 49.7% (SE=0.3) for the individuals aged ≥90 years from the general population 
(pdifference=0.018). LLS offspring had a mean LDL GRS of 50.0% (SE=0.1), while the 
partners had a mean LDL GRS of 50.7% (SE=0.2) (pdifference=0.019).   







































Figure 4: Mean percentage of LDL GRS in participants of the general population (dark grey) and 
genetically enriched for longevity (light grey). A: Subjects aged ≥90 years from the Leiden 85-plus study 
and Rotterdam Study versus Leiden Longevity study (LLS) nonagenarians; B: LLS partners versus 
offspring. GRS plotted as mean with standard error, adjusted for age, sex, and familial relations. 
Finally, we investigated the association between the LDL GRS and mortality in the 
elderly. For this purpose, we used the data of the LLS nonagenarians and of 
participants aged ≥ 90 years from the Leiden 85-plus study and the Rotterdam Study. 
The combined analysis of the three studies showed a significant association between 
the LDL GRS and increased all-cause mortality (table 2). Individuals in the middle LDL 
GRS group had 4% increased mortality risk (IRR 1.04, 95% CI: 0.90-1.19), and 
individuals in the highest group had 19% increased mortality risk (IRR 1.19, 95% CI: 
1.02-1.37), compared to individuals in the lowest LDL GRS group (p-trend=0.008).  
Analyses in the individual studies showed a significant association between LDL GRS 
and mortality in the LLS nonagenarians (p=0.010), with 25% increased mortality risk 
(95% CI: 1.04-1.49) for individuals in the highest LDL GRS group, compared to 
individuals in the lowest group. Within the Leiden 85-plus study and the Rotterdam 
Study, the LDL GRS was not significantly associated with mortality (p=0.445 and 
p=0.962, respectively).    
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Discussion 
In old age, the importance of high LDL-C levels as risk factor for mortality is unclear 
since observational studies have shown no or inverse associations. Due to 
confounding or reversed causality, the plasma LDL-C levels may not reflect the life-
time level. To overcome the potential influences of reverse causality and 
confounding we used in the current study the LDL GRS as an instrumental variable. 
The LDL GRS was strongly associated with LDL-C levels and the number of LDL 
increasing alleles decreased with increasing age. Furthermore, individuals with a 
genetic predisposition for longevity had a lower LDL GRS compared to age-matched 
controls. Finally, we showed that the LDL GRS was associated with all-cause mortality 
above 90 years in the pooled analysis of three independent populations, although 
this effect was mainly driven by one study. All these results indicate that a genetic 
predisposition to high LDL-C levels contributes to mortality throughout life, also in 
the oldest old, and a beneficial LDL genetic profile is associated with familial 
longevity. 
Observational studies have repeatedly shown a positive association between high 
cholesterol levels and increased mortality risks.
17
 However, it is unclear whether this 
positive association remains in the elderly. Several studies in people aged 80 years 
and over showed an association between low total cholesterol levels and increased 
mortality.
5
 Previously reported analysis of the Leiden 85-plus study did not observe 
any association between high LDL-C levels and mortality, and high total cholesterol 
levels were associated with longevity.
3;4
 Cholesterol levels of elderly aged 85 years 
and over might not reflect their life-time cholesterol level, due to reverse causality 
and possible selective survival.
3
 Our results using the LDL GRS as an instrumental 
variable indicate that the results from observational studies in elderly using plasma 
cholesterol as a reflection of risk were probably biased. 
The observed association between the LDL GRS and mortality was only significant in 
the LLS siblings and the combined analysis. This might be explained by the lower 
number of individuals aged 90 years and over in the Leiden 85-plus and Rotterdam 
study compared to the LLS siblings. We did observe that the level of LDL GRS 
decreased by increasing age, this was however not reflected in all prospective 
studies. A similar phenomenon was observed earlier for the APOE gene. A lower 
frequency of the APOE ε4 allele with increasing age was reported already in 1988.
18
 
However, associations between the APOE gene and mortality were reported since 
1994 in large studies. 
19;20
 Nowadays, the association between genetic variation in 
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the APOE gene and longevity has repeatedly been validated in large prospective 
studies with sufficient statistical power. 
20;21
    
Genetic risk scores based on SNPs associated with cholesterol levels have been used 
previously. Within the CARDIoGRAM consortium, including more than 53146 
myocardial infarction cases and controls, the association between cholesterol levels 
and the risk of myocardial infarction (MI) was compared to the association between 
GRS and the risk of MI.
22
 An increase in both plasma LDL-C levels as well as LDL-C 
conferred by the GRS was associated with an increased risk of MI. Increased HDL 
cholesterol was associated with a decreased risk for MI, although the HDL GRS was 
not associated with the risk for MI, indicating that HDL cholesterol is not a causal risk 
factor for MI.
22
 Recently, a GRS based on LDL-C SNPs was tested in two British 
prospective studies, including middle-aged men and women.
23
 Participants in the top 
quintile of the genetic score distribution tended to have a 36-49% increased risk of 
having a high CVD risk, determined by the Framingham 10-year CVD risk more than 
20%, compared to individuals in the lowest quintile. Our study shows that an 
association with mortality is still present at old age. 
In the current study we observed a difference in LDL GRS between offspring of 
nonagenarians and their spouses and between LLS nonagenarians and individuals 
aged ≥90 years. Individuals with a genetic predisposition for longevity had a lower 
LDL GRS, indicating the beneficial effects of low LDL cholesterol levels. This finding is 
the first difference in genetic risk scores observed between the LLS offspring and 
partners. Previous studies found a lower prevalence of diabetes mellitus, 
hypertension, and myocardial infarction in LLS offspring compared to their 
partners.
24
 Furthermore, the offspring had a more beneficial metabolic profile.
25
 A 
GRS based on diabetes risk alleles has previously been tested in the LLS partners and 
offspring, and despite the better glucose tolerance of the offspring, this was not 
associated with differences in GRS.
25
  
To summarize, previous observational studies including older individuals have shown 
no or inverse associations between cholesterol levels and mortality, suggesting that 
the causal relation between LDL and (cardiovascular) disease is absent at old age. 
Results of the current study indicate that a genetic predisposition to high LDL-C 
contributes to mortality throughout life, also in the oldest old and a beneficial LDL 
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Abstract 
Proprotein convertase subtilisin like/kexin type 9 (PCSK9) is a protein involved in the 
LDL-cholesterol metabolism. The single nucleotide polymorphism (SNP) rs11591147 
has been associated with lower LDL-cholesterol levels and a lower risk of coronary 
heart disease. Since PCSK9 has high affinity to the LDL receptor, inhibiting PCSK9 is a 
testable therapeutic target for lipid-lowering therapy. Currently, several approaches 
to inhibit PCSK9 are under development, but it is unknown what the effects of those 
inhibitors will be on cognition or noncardiovascular clinical events. In this study we 
assessed the association between rs11591147 and cognitive performance, activities 
of daily living (ADL), and noncardiovascular clinical events within 5777 participants of 
the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Rs11591147 
was associated with 10 to 16% lower LDL-cholesterol levels (p=3.62 x 10
-12
), but was 
not associated with cognitive performance, ADL, or noncardiovascular clinical events 
in the PROSPER study. Our findings suggest that lower cholesterol levels due to 
genetic variation in the PCSK9 gene are not associated with cognitive performance, 
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Introduction 
Elevated plasma concentration of low-density lipoprotein (LDL)-cholesterol is a major 
causal risk factor for cardiovascular disease. Lowering LDL-cholesterol levels is one of 
the primary goals of therapy in its prevention and treatment 
1
. Present lipid lowering 
therapy mainly depends on treatment with HMG-CoA reductase inhibitors (statins), 
but new lipid lowering drugs are under development that can decrease circulating 
lipid levels even more 
2
. A promising new therapeutic target for lipid-lowering 
therapy is proprotein convertase subtilisin-like/kexin type 9 (PCSK9), a protein 
involved in LDL-cholesterol metabolism 
3-5
. PCSK9 modulates plasma LDL-cholesterol 
levels by promoting the degradation of LDL receptor (LDLR) 
6
.  
Several “loss of function” and “gain of function” mutations have been described in 
the PCSK9 gene 
4
. Within the Atherosclerosis Risk in Communities (ARIC) Study “loss 
of function” mutations, for example rs11591147, were associated with lower LDL-
cholesterol levels through increased LDLR levels, resulting in a lower prevalence of 
peripheral arterial disease, and a reduced risk of coronary heart disease 
7;8
. A recent 
meta-analysis showed 12% lower LDL-cholesterol levels and 28% lower ischemic 
heart disease risk among carriers of the rs11591147 mutation in the PCSK9 gene 
9
.  
On the other hand, PCSK9 may be involved in processes associated with 
neurodegenerative disorders like Alzheimer’s disease. A Canadian study found a two-
fold increased expression of the PCSK9 in the human frontal cortex of autopsy-
confirmed Alzheimer’s disease cases compared with age-matched controls 
10
. 
Furthermore, men carrying either the rs2483205-C, rs483462-A, or rs662145-T allele 
showed a significant increased risk for Alzheimer’s disease. However, those single 
nucleotide polymorphisms (SNPs) are not known to be associated with LDL-
cholesterol levels or with cardiovascular disease risk.  
Several approaches to inhibit PCSK9 are currently under development, but it is not 
known whether those inhibitors will influence cognitive performance or clinical 
events. In old age, cholesterol levels are not associated with cognitive performance, 
and it has previously been shown in the PROspective Study of Pravastatin in the 
Elderly at Risk (PROSPER), that pravastatin therapy in old age did not affect cognitive 
decline over a median follow-up of 3.2 years 
11;12
. However, to investigate whether 
lipid lowering via PCSK9 inhibition might have other clinical effects besides lipid 
lowering, we assessed the relation between lower LDL levels associated with genetic 
variation within the PCSK9 SNP rs11591147 and cognitive function, ADL, and 
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All data come from the PROSPER study. Detailed descriptions of PROSPER have been 
published elsewhere 
13;14
.   Briefly, PROSPER was an investigator-driven, prospective 
multi-national randomized placebo-controlled trial to assess whether treatment with 
pravastatin reduces the risk of major vascular events in the elderly. Between 
December 1997 and May 1999, subjects in Scotland (Glasgow), Ireland (Cork) and the 
Netherlands (Leiden) were screened and enrolled. Men and women aged 70-82 years 
were recruited if they had pre-existing vascular disease or were at increased risk for 
such disease because of smoking, diabetes, or hypertension. A total number of 5804 
subjects were randomly assigned to pravastatin or placebo. The protocol of the 
PROSPER study was approved by the Medical Ethics Committees of each participating 
institution. Written informed consent was obtained from all participating subjects. 
Endpoints 
Mean follow-up duration was 3.2 years (range 2.8-4.0) and participants were 
reviewed every 3 months. During those visits all endpoints were adjudicated by a 
study Endpoint Committee. The primary outcome in PROSPER was the combined 
endpoint of definite or suspected death from coronary heart disease, nonfatal 
myocardial infarction, and fatal or nonfatal stroke. Furthermore several 
noncardiovascular clinical events were recorded. Cancer incidence was a tertiary 
study endpoint. Infections and diabetes were reported as serious adverse effects. 
Since the association between PCSK9 and cardiovascular events has been 
investigated previously in PROSPER the focus in the present paper was on 
noncardiovascular events, functional status, and cognitive performance. 
Cognitive performance and activities of daily living (ADL) 
The Mini-Mental State Examination (MMSE) was used to measure global cognitive 
performance. The MMSE scores range from 0 (very severe cognitive impairment) to 
30 points (optimal cognitive function). Participants with poor cognitive performance 
(MMSE <24) were not eligible for inclusion in the PROSPER study. Four 
neuropsychological performance tests were used to measure various cognitive 
domains. The Stroop color-word test for attention and the Letter-Digit Coding test 
(LDT) for processing speed were used to measure executive function. The outcome 
parameter for the Stroop test was the total number of seconds to complete the third 
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Stroop card containing 40 items. The outcome variable for the LDT was the total 
number of correct entries in 60 seconds. Memory was assessed with the 15-Picture 
Learning test (PLT) testing immediate and delayed recall. The main outcome 
parameters were the accumulated number of recalled pictures over the three 
learning trials and the number of pictures recalled after 20 minutes. To assess 
change of functional status, the 20 point Barthel and Instrumental Activities of Daily 
Living (IADL) questionnaires, using a modified version of the OARS questionnaire, 
were performed. The Barthel index is a measure of basic ADL and the IADL measures 
extended ADL. The reliability and sensitivity of these tests in an elderly population 
have been published elsewhere 
15
.  
Cognitive performance and ADL was tested at six different time-points during the 
study, before randomization, at baseline, after 9, 18 and 30 months, and at the end 
of the study. The time point of this last measurement was between 36 and 48 
months and different for the participants, therefore we performed the analyses with 
their individually varying time-point but report the results for the mean of these 
time-points (42 months). The pre-randomized measurement was discarded in the 
analysis to preclude possible learning effects.  
Genotyping 
Rs11591147 of the PCSK9 gene was genotyped previously in PROSPER using Taq 
Man® SNPs genotyping assay (Applied Biosystems, Foster City, CA, United States). A 
detailed description of the genotyping has been published elsewhere 
16
. Rs11591147 
genotyping succeeded in 5777 of the 5804 PROSPER participants. ApoE phenotype 
was determined on plasma samples by western blotting, using the method of 
Havekes et al. 
17
.  
To assess the association between other PCSK9 SNPs and cholesterol levels, cognitive 
performance and clinical events we used data of the PHArmacogenetic study of 
Statins in the Elderly at risk (PHASE), a genome-wide association study (GWAS) in the 
PROSPER participants 
18
. The GWAS was conducted using the Illumina 660-Quad 
beadchips following manufacturer’s instructions. After a stringent quality control 
557,192 SNPs were available for analysis. To maximize the availability of genetic data 
and coverage of the genome, imputation up to 2.5 million autosomal CEPH HapMap 
SNPs was performed with MACH imputation software based on the Hapmap built II 
release 23. Detailed descriptions of the PHASE project have been published 
elsewhere 
18
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Statistical analysis 
Cross-sectional associations between rs11591147 and cognitive function were 
assessed using a general linear model adjusted for age, sex, country, education, ApoE 
phenotype and where appropriate version of test used. Repeated cross-sectional 
associations with cognitive function were assessed with a linear mixed model for 
repeated measurements and were additionally adjusted for follow-up time. Cross-
sectional associations between rs11591147 and history of clinical events were 
assessed with logistic regression analysis, which was adjusted for age, sex, and 
country. Longitudinal associations were assessed with Cox regression and were 
additionally adjusted for pravastatin use. Power calculation was performed using 
Quanto version 1.2.4, May 2009. The study had 99% power to detect a 2% increased 
incidence of diabetes by the rs11591147 variant, assuming a 5% incidence rate in the 
rs11591147 wild-type carriers. PASW statistics software (version 17.0.2, SPSS Inc., 
Chicago, IL) was used for all statistical analyses. P-values <0.05 were considered 
statistically significant. 
Table 1. Baseline characteristics of PROSPER participants stratified by country 
 Scotland Ireland the Netherlands 
 (n=2516) (n=2166) (n=1095) 
Continuous variables (mean, SD)    
 Age (years) 75.3 (3.4) 75.5 (3.3) 75.1 (3.3) 
 Body mass index (kg/m
2
) 26.7 (4.2) 27.0 (4.4) 26.7 (3.8) 
 Total cholesterol (mmol/l) 5.7 (0.9) 5.6 (0.9) 5.8 (0.9) 
 LDL-cholesterol (mmol/l) 3.8 (0.8) 3.7 (0.8) 3.9 (0.8) 
 HDL cholesterol (mmol/l) 1.3 (0.4) 1.3 (0.4) 1.2 (0.3) 
Categorical variables (n, %)    
 Males 1237 (49.2) 980 (45.2) 577 (52.7) 
 Current smoker 707 (28.1) 580 (26.8) 267 (24.4) 
 History of hypertension 1443 (57.4) 1430 (66.0) 703 (64.2) 
 History of diabetes 213 (8.5) 220 (10.2) 184 (16.8) 
 History of angina 811 (32.2) 518 (23.9) 222 (20.3) 
 History of claudication 229 (9.1) 113 (5.2) 46 (4.2) 
 History of myocardial infarction 379 (15.1) 255 (11.8) 139 (12.7) 
 History of stroke or TIA 265 (10.5) 222 (10.2) 161 (14.7) 
 History of vascular disease* 1239 (49.2) 842 (38.9) 473 (43.2) 
Genotype, MAF (%)    
 Rs11591147 (GT) 2.1 1.8 1.2 
* Any of stable angina, intermittent claudication, stroke, transient ischemic attack (TIA), myocardial 
infarction, peripheral artery disease surgery, or amputation for vascular disease more than 6 months 
before study entry. Abbreviations: TIA, transient ischemic attack; MAF, Minor allele frequency 
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Results 
Table 1 shows the baseline characteristics of study subjects, stratified by country of 
origin. The mean age of all subjects was 75.3 years and about 50% of the participants 
were female. The association between the PCSK9 SNP rs11591147 and lipoprotein 
levels and vascular events has previously been described 
16
. To summarize these 
findings, carriers of one rs11591147 variant had 10% lower LDL-cholesterol levels 
(p=3.62 x 10
-12
) (Table 2) and a non-significant 9% reduced risk of vascular disease 
16
.  
Table 2 shows the association between rs11591147 and cognitive performance and 
functional status. There were no associations between rs11591147 and cognitive 
performance and functional status, either at baseline or during follow-up (all p>0.1). 
Table 2. Rs11591147, cholesterol levels, cognitive performance, and functional status at baseline and 
during follow-up 
 Rs11591147  
 Wt/Wt Wt/Var Var/Var  
 (n=5337) (n=193) (n=2) P-trend 
Baseline     
 Cholesterol levels     
 Total cholesterol (mmol/l) 5.64 (0.03) 5.30 (0.07) 5.04 (0.59) 1.18 x 10
-8 
 LDL-cholesterol (mmol/l) 3.66 (0.03) 3.29 (0.06) 3.08 (0.52) 3.62 x 10
-12 
 Functional status     
 Barthel score 19.77 (0.03) 19.70 (0.06) 19.57 (0.51) 0.21 
 Instrumental activities of daily living score 13.61 (0.04) 13.63 (0.08) 12.98 (0.70) 0.90 
 Cognitive performance     
 Mini mental state examination score 28.00 (0.05) 28.05 (0.12) 28.14 (1.04) 0.67 
 Stroop-Colour-Word test 65.73 (0.90) 63.87 (1.97) 65.72 (16.63) 0.31 
 Picture Learning test immediate 9.41 (0.07) 9.26 (0.15) 10.03 (1.22) 0.32 
 Picture Learning test delayed 10.27 (0.09) 10.13 (0.21) 10.41 (1.74) 0.48 
 Letter-digit Coding test 23.44 (0.25) 23.24 (0.54) 21.39 (4.57) 0.63 
Repeated cross-sectional      
 Functional status     
 Barthel score 19.61 (0.03) 19.55 (0.08) 19.40 (0.66) 0.37 
 Instrumental activities of daily living score 13.29 (0.05) 13.32 (0.10) 11.24 (0.88) 0.90 
 Cognitive performance     
 Mini mental state examination score 28.04 (0.05) 28.12 (0.12) 28.37 (1.02) 0.40 
 Stroop-Colour-Word test 66.48 (0.86) 63.96 (1.89) 66.91 (17.19) 0.16 
 Picture Learning test immediate 9.37 (0.06) 9.29 (0.13) 9.20 (1.16) 0.51 
 Picture Learning test delayed 10.01 (0.08) 9.96 (0.18) 10.94 (1.63) 0.86 
 Letter-digit Coding test 22.85 (0.23) 23.12 (0.49) 22.45 (4.44) 0.57 
Estimates and p-values at baseline were assessed with general linear model adjusted for sex, age, and 
country. Analyses on cognition were additional adjusted for education, APOE genotype, and were 
appropriate, version of test used. Repeated cross-sectional estimates and p-values were assessed with 
linear mixed model and additional adjusted for follow-up time. Values are means (SE). 
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Next, we assessed the association between rs11591147 and history of diabetes and 
hypertension at baseline. Carrying a variant of rs11591147 was not associated with a 
history of diabetes or hypertension (both p>0.4) (Table 3). Also during follow-up, 
there was no association between rs11591147 and the incidence of cancer, diabetes 
and infections (Table 3).  
Table 3. Rs11591147 and history or incidence of noncardiovascular clinical events 
  Rs11591147  
  Wt/Wt Wt/Var Var/Var  
  (n=5571) (n=204) (n=2*)  
 N events OR (95% CI) OR (95% CI) OR (95% CI) P-trend 
History of diabetes 617 1 (ref) 0.82 (0.49-1.36) NA 0.44 
History of hypertension 3575 1 (ref) 1.08 (0.80-1.45) NA 0.63 
      
  HR (95% CI) HR (95% CI) HR (95% CI)  
Serious cancer 441 1 (ref) 0.86 (0.49-1.49) NA 0.59 
Incident diabetes 291 1 (ref) 1.39 (0.81-2.39) NA 0.23 
Incident infection  313 1 (ref) 0.90 (0.48-1.68) NA 0.73 
Odds ratios (OR) and corresponding p-values were assessed with logistic regression analysis adjusted for 
age, sex, and country. Hazard ratios (HR) and p-values were assessed with Cox-proportional hazard 
models adjusted for age, sex, country, and pravastatin use. 
* not possible to perform logistic or Cox regression with n=2. 
To cover the whole PCSK9 gene, we also assessed the association between other 
PCSK9 tag SNPs (rs2094470, rs2479415, rs7525649, rs17111495, rs10888896, 
rs4927193, rs2479411, rs499718, rs10888897, rs529787, rs562556, rs615563, 
rs10465832, rs505151, rs662145, rs9326034) and cholesterol levels, cognitive 
performance, functional status, and clinical events using data of the PHASE study 
18
. 
Three SNPs, rs2479415, rs2182833, and rs11206514, were associated with LDL-
cholesterol levels (all p<0.01). However, none of these SNPs were also associated 
with cognitive performance, functional status, or noncardiovascular clinical events 
(supplementary tables 1-2). Also, when we combined the PCSK9 SNPs into haplotypes 
there were no associations between the haplotypes, cholesterol levels, cognitive 
performance, functional status, or clinical events (data not shown).  
Discussion 
In this study we assessed the association between the PCSK9 SNP rs11591147, 
cognitive performance, functional status and noncardiovascular clinical events in the 
PROSPER study. No association between rs11591147 and cognitive performance, 
functional status or non-vascular clinical events was observed. As the SNP was 
significantly associated with lower cholesterol and with cardiovascular disease 
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protection 
7;9;16
, these data do not lend arguments that drugs inhibiting PCSK9 will 
have other (adverse) effects. 
The association between the PCSK9 SNP rs11591147 and lipid levels and vascular 
disease risk has been investigated previously in PROSPER 
16
. In this analysis carriers 
of the rare variant of rs11591147 had significantly 10% lower LDL-cholesterol levels 
(P<0.001). These lower LDL-cholesterol levels are well in line with the findings of a 
meta-analysis including seven general population studies with a total of 1,639 
carriers of the rs11591147 minor allele and 59,298 non-carriers 
9
. In this meta-
analysis, rs11591147 was associated with 12% lower LDL-cholesterol levels in 
carriers. The same article also reported a meta-analysis combining studies which 
investigated the risk of ischemic heart disease (IHD), including 11,339 cases and 
55,359 control subjects. The rs11591147 SNP was associated with a reduction in risk 
of IHD of 28 percent (fixed effect OR: 0.72, 95% CI: 0.62-0.84). This effect is higher 
than the previously reported results in PROSPER where rs11591147 was associated 
with a non-significant reduced risk of vascular disease of 9%. 
The LDLR plays an important role in cholesterol metabolism by mediating the uptake 
of apoB containing lipoprotein from the blood into liver cells 
2
. PCSK9 is involved in 
the cholesterol metabolism by promoting the degradation of LDLR 
6
. There are 
indications that cholesterol metabolism is associated with cognitive performance. 
High total serum cholesterol levels have been shown to associate with lower cerebral 
spinal fluid levels of β-amyloid and larger amounts of β-amyloid deposition in brain 
autopsy studies 
11
. Since PCSK9 is involved in the cholesterol metabolism this raises 
the question if PCSK9 is also associated with cognitive function. A Canadian study 
investigated the relation between PCSK9 and Alzheimer’s disease. In this study 
variations in rs2483205, rs483462, and rs662145 were associated with an increased 
Alzheimer’s disease risk 
10
. However, those SNPs are not known to be associated with 
cholesterol levels or in linkage disequilibrium with one of our SNPs associated with 
LDL-cholesterol. A study with Japanese Alzheimer’s disease patients found no 
association between the PCSK9 SNPs rs11583680 and rs662145 and Alzheimer’s 
disease 
20
. In our study, rs11591147 was not associated with cognitive performance. 
Since PCSK9 has high affinity for the LDLR, inhibiting PCSK9 might be a promising 
therapeutic target for lipid lowering therapy in addition to statin therapy. Several 
approaches to inhibit PCSK9 are currently under development, but it is unknown 
what the influences of those inhibitors will be on cognitive function or 
noncardiovascular events 
2
. In our study rs11591147, associated with LDL-cholesterol 
levels, did not affect cognitive performance, functional status, or noncardiovascular 
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clinical events. Based on our results one may expect that drugs inhibiting PCSK9 
21-23
, 
to an extend comparable to the rs11591147 mutation, administered to an age group 
70 to 82 years with a history or increased risk of cardiovascular disease are not likely 
to affect cognitive performance. This suggests that cholesterol lowering by PCSK9 
inhibition may be a valid and safe way to reduce cardiovascular disease risk. 
However, because the inhibitors in development may cause larger LDL-cholesterol 
reductions compared with the rs11591147 mutation, definite conclusions about the 
adverse effects of cholesterol lowering due to PCSK9 inhibition cannot be assessed 
by this study.  
One of the strengths of our study is our population size. We have prospective data of 
over 5000 subjects on lipid parameters, cognitive function, and clinical endpoints. 
Also we have a follow-up of 42 months with very little lost to follow-up. 
Furthermore, our population is an appropriate study population to measure cognitive 
function, since only subjects with a MMSE above 24 points were eligible for 
participation, which makes it a homogenous study group suitable for investigating 
cognitive function.  
A possible limitation of our study is the limited power to detect subtle differences. 
Although the PROSPER study is one of the largest studies to investigate the 
association between genetic variations and lipid levels, cognitive function, and 
clinical events, we do not have infinite power to detect small effects. But we assume 
that it is unrealistic that we have missed clinically relevant effects. Another possible 
limitation is the ceiling effect of the ADL measurements. This may have restricted our 
ability to find significant associations between the PCSK9 mutation and ADL 
performance. However, previous analysis on apolipoprotein E genotype have proven 
that the PROSPER study is suitable for investigating genetic influences on cognition 
and ADL 
24
. A last possible limitation is the selection of the PROSPER participants. 
Participants were recruited when they had existing vascular disease or increased risk 
of such disease 
13
. Individuals especially susceptible to the mutation leading not only 
to low LDL-cholesterol but also protective for cardiovascular disease may have been 
under represented in our study. 
In conclusion, it has previously been shown that the PCSK9 SNP rs11591147 is 
associated with lower LDL-cholesterol levels and lower cardiovascular risk. In our 
study we failed to find associations between the variant and cognitive phenotypes. 
The implication of our finding is that it is unlikely that medication lowering LDL-
cholesterol via inhibiting PCSK9 to an extent comparable to the effect of the 
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mutation in our study population, will affect cognitive performance, functional 
status, or noncardiovascular clinical events.  
Supplementary Material 
Supplementary material is available at Journal of Lipid research online. 
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Main findings and general discussion 
The main aim of this thesis was to investigate pharmacogenetic effects on response 
to statin treatment and the genetics of lipid metabolism and cardiovascular disease 
(CVD). Since CVD is one of the leading causes of death worldwide, it is important to 
identify factors that influence the response to treatment 
1;2
. Identifying genetic 
variants associated with response to statin treatment could possible allow for 
personalized treatment or the development of new drugs to reduce the burden of 
CVD. 
Chapter 2 described the current state of the pharmacogenetic studies investigating 
the response to statin treatment. In previous decades mainly candidate gene studies 
were used to investigate the efficiency and clinical effectiveness of statin therapy. 
Based on these candidate gene studies, which investigated only one or a few genes 
per study, genes regulating pharmacokinetic and pharmacodynamic properties of 
statins appear to be the most promising target genes 
3
. The more recent genome-
wide association studies (GWAS) give the possibility to investigate the whole genome 
with no a priori assumptions, facilitating new discoveries. Although multiple 
pharmacogenetic GWAS have investigated the response to statin treatment, only two 
genetic loci, APOE and LPA, have been consistently found to be associated with 
variation in low-density lipoprotein cholesterol (LDL-C) response to statin therapy 
4;5
. 
To assess pharmacogenetic associations within the PROSPER study we conducted the 
PHArmacogenetic study of Statins in the Elderly at risk (PHASE). In chapter 3 we 
presented the first GWAS performed in PHASE, replicating the previously identified 
genetic variants associated with LDL-cholesterol levels. 
Due to the large number of statistical test performed in a GWAS analysis, large 
sample sizes are required to provide adequate statistical power to detect small effect 
sizes. Therefore, to identify novel genetic variants associated with response to statin 
treatment, it is necessary to collaborate with other studies. In chapter 4 the results 
of the first analyses performed within the Genomic Investigation of Statin Therapy 
(GIST) consortium were shown. More than 40,000 statin treated subjects from both 
randomized controlled trials and observational studies were included in the analysis. 
We identified and validated two novel GWAS loci associated with LDL-C response at 
SORT1/CELSR2/PSRC1 and the SLCO1B1 loci. Furthermore, we confirmed the 
previously described associations within the LPA and APOE gene loci. These findings 
advance the understanding of the pharmacogenetic architecture of statin response.  
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Most of the pharmacogenetic studies with regard to statin therapy have focused on 
the lipid lowering response, while relatively little is known about the genetic 
variation associated with variability in clinical event reduction by statins. As only one 
GWAS study had investigated this association 
6
, we performed a GWAS on 
differential event reduction by pravastatin therapy in chapter 5. However, we did not 
identify any genetic variants significantly associated at a genome-wide level with a 
clinically meaningful differential event reduction by pravastatin treatment in the 
PROSPER/PHASE study. These results indicate that in daily practice the use of genetic 
characteristics to personalize pravastatin treatment to improve prevention of CVD 
will be limited. However, as mentioned before, GWA studies require large sample 
sizes to provide adequate statistical power to detect small effect sizes. To increase 
the chance of identifying genetic variants associated with differential event 
reduction by statin therapy, the GIST consortium is currently performing a meta-
analysis of GWAS studies investigating differential cardiovascular event reduction by 
statins. 
Together, the genetic variants assessed within the GIST GWAS meta-analysis 
explained 5% of the variance in LDL-cholesterol lowering response (chapter 4). 
Whether this 5% is clinically relevant is as yet unclear and should be tested in new 
research studies. Within the PROSPER study we were not able to identify any genetic 
variant associated with a clinically meaningful differential CVD event reduction by 
pravastatin (chapter 5). Therefore we might wonder how pharmacogenetics of 
(prava) statin therapy can be of any clinically relevant use for individual patients in 
clinical care.  However, newer research methods such as whole genome sequencing 
may reveal rare genetic variants with larger effect sizes 
7
. The aim of sequencing 
studies is to identify rare variants, present in <1% of the population. It will therefore 
be difficult to apply these results in the clinical setting. Combining several genetic 
variants with small effects into a genetic risk score (GRS) might be another option to 
use pharmacogenetic research in clinical practice.  
In pharmacogenetic research, non-responders to a drug are often compared to high-
responders, with the aim of identifying the genetic loci responsible for this variation 
in response 
8;9
. In chapter 6 we tried to answer the question whether the non-
responders are true non-responders or whether they are actually non-adherent. Our 
results suggest that many of the so called non-responders are more likely to be non-
adherers, since they have more clinical characteristics related to high self-perceived 
health and low disease awareness. In addition, these results indicate that other 
strategies should be used to investigate the relation between genetic variation and 
responsiveness to statin treatment. In chapter 7 we discuss whether there are 
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indications that statins work differently around the world. Despite the many 
different ethnicities worldwide, the most important risk factors for CVD are the same 
for, and statins seem to be similarly effective in, all studied populations around the 
world. However, this does not suggest that different ethnicities can be combined in 




In chapter 8 we focused on the question whether high LDL-C levels are still a risk 
factor for mortality in the elderly. To overcome the problems of confounding and 
reverse causality we used a LDL genetic risk score (GRS) based on the Mendelian 
randomization concept 
11
. The level of this GRS decreased by increasing age and was 
significantly associated with mortality in the participants aged 90 years and older. In 
addition we showed that participants with a genetic predisposition for longevity had 
a lower GRS compared to participants from the general population. These results 
indicate that a genetic predisposition to high LDL-C contributes to mortality 
throughout life also in the oldest old. These results are supported by the fact that 
statin therapy is still beneficial in the treatment of CVD in the elderly 
12
. 
In the first chapters of this thesis we showed that there is currently limited evidence 
for a role of genetics in the individual variability in statin response. In chapter 8 we 
showed that a genetic predisposition to high LDL-C contributes to mortality even in 
the oldest old, therefore lowering LDL-C levels should remain an important goal in 
reducing CVD risk. New drugs to lower LDL-C levels are currently in development. 
One of those promising drugs are the PCSK9 inhibitors 
13
, however it is currently 
unknown what the effect of those inhibitors will be on cognition or non-
cardiovascular clinical events. In chapter 9 we investigated whether genetic variation 
within the PCSK9 gene was associated with cognitive performance and non-
cardiovascular clinical events in the PROSPER study. We showed that a genetic 
variant in the PCSK9 gene was associated with lower LDL-C levels, but not with 
cognitive performance or non-cardiovascular events. This suggests that it is unlikely 
that lowering of cholesterol levels through the inhibition of PCSK9 will affect 
cognitive performance and non-cardiovascular clinical events.   
Future perspectives 
In the past few years, genome-wide association studies have become a popular 
approach for investigating associations between response to drugs and genetic 
variants. The ultimate aim of pharmacogenetic studies is to improve and personalize 
individual drug treatment 
14;15
.  This thesis shows that there is currently limited 
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evidence for a role of genetics in the individual variability in statin response. In other 
disease areas pharmacogenetic research has shown promising results 
8
. For example, 
genetic variation in the cytochrome P450 enzyme CYP2C9 and vitamin K epoxide 
reductase genes explained up to 35% of the variability in required warfarin starting 
dose 
16
. However, three new clinical trials assessing the role of pharmacogenetics in 
the dosing of vitamin K antagonists have shown disappointing results 
17-19
. The 
results of the three trials show that the usefulness of pharmacogenetic testing for 
the initial dose of vitamin K antagonists is absent or marginal 
20
. 
Although the PROSPER/PHASE study is one of the largest randomized clinical trials to 
investigate the pharmacogenetics of statins, the sample size might still be too small. 
To increase the sample size for pharmacogenetic studies, collaborating in large 
consortia is necessary. To this end, the GIST consortium was formed (chapter 4). 
Within this consortium the pharmacogenetic effects of statins on CVD event 
reduction are also investigated. Other ongoing studies investigate statin 
pharmacogenetics on C-reactive protein (CRP) response. Statin treatment is 
associated with reduction in CRP levels in a LDL-C-independent manner, reflecting 
the anti-inflammatory properties of statins 
21
. Possible, these analyses will lead to 
the discovery of new genetic variants that might be beneficial in novel 
mechanisms/pathways for the treatment of CVD.  
Recent developments such as whole genome sequencing methods and the 1000 
genomes imputation will give new opportunities for the genetic research field 
7;22
. 
Compared to methods using the HapMap haplotypes as reference panel 
23
, the more 
recent 1000 Genomes Project allows for much denser imputations 
22
. However, using 
the 1000 Genomes imputation will probably mainly refine the previously identified 
associations and identify genetic variants that are in high linkage disequilibrium with 
the variants identified in the previous GWAS based on HapMap imputations 
24
.  
Sequencing studies aim to identify rare variants, present in less than 1% of the 
population. These rare variants are not present on the chips currently used in GWAS, 
which contain far less genetic variants and only the more common ones. It remains 
the question whether the variants identified using sequencing, the rare variants with 
large effect sizes, will explain the missing heritability 
25
.   
Mendelian randomization is another method increasingly used in genetic research. 
For example, the use of a genetic risk score has helped to unravel the question of 
causality with regard to HDL-C levels and CVD 
26
. Based on observational studies in 
middle-aged populations, high LDL-C and low HDL-C levels appeared to be important 
risk factors for CVD 
26
. LDL-C lowering treatments such as statins are therefore 
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effective in the reduction of the CVD risk 
27
. However, thus far, increasing HDL-C 
levels with pharmacological therapies have not lead to clinical beneficial results 
28
. 
Using Mendelian randomization analysis, it was shown that HDL-C was not causally 
associated with the risk for myocardial infarction, whereas LDL-C was 
26
. Most studies 
investigating the association between LDL-C and CVD or mortality were performed in 
middle-aged populations, as was the Mendelian randomization analysis, while the 
few studies performed in older aged subjects showed inverse or no associations 
29
. 
This thesis shows that a genetic predisposition to high LDL-C contributes to mortality, 
also in the oldest old. However, the power of this analysis was limited as the results 
were mainly driven by one of the three studies. To increase the evidence that high 
LDL-C is still a risk factor for CVD in the elderly, the LUMC will start a large meta-
analysis of Mendelian randomization studies investigating a LDL genetic risk score in 
various age groups and assess the association with cardiovascular events.   
Conclusions 
LDL-cholesterol is an important risk factor for CVD, even at old age. Reducing LDL-
cholesterol levels is therefore essential in the treatment of CVD. To improve the 
current treatment, new drugs such as the PCSK9 inhibitors, are in development. 
Another option to improve treatment is to personalize treatment based on an 
individual’s genetic make-up, thereby reducing polypharmacy and the risk of adverse 
events. With the currently available research approaches to investigate statin 
pharmacogenetics, only four genetic variants have been found to be associated with 
the LDL-cholesterol response. As shown in this thesis, these four genetic variants 
explain only 5% of the observed variation in LDL-cholesterol lowering response to 
statins. Therefore the possibilities to personalize statin treatment based on genetic 
variants remain limited. New research methods will hopefully give new opportunities 
to improve CVD treatment and give more insight into the biological mechanisms of 
statin treatment.  
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Hoofdbevindingen 
Doel van dit proefschrift was het vinden van genetische varianten welke een rol 
spelen in de respons op statine behandeling. Daarnaast is de genetische achtergrond 
van het lipide metabolisme en hart- en vaatziekten (HVZ) verder uitgezocht. 
Aangezien HVZ een van de belangrijkste doodsoorzaken wereldwijd zijn, is het 
belangrijk om factoren te vinden welke de respons op behandeling beïnvloeden. Het 
vinden van genetische varianten geassocieerd met statine respons kan mogelijk 
leiden tot gepersonaliseerde behandeling of de ontwikkeling van nieuwe medicatie 
om de gevolgen van HVZ te verminderen. 
Hoofdstuk 2 beschrijft de tot aan dat moment uitgevoerde farmacogenetische 
studies naar de respons op statine behandeling. In de voorgaande jaren zijn 
voornamelijk kandidaat gen studies uitgevoerd om de efficiëntie en klinische 
effectiviteit van statines te onderzoeken. Gebaseerd op de resultaten van deze 
studies, die maar enkele genen per studie onderzochten, lijken met name genen 
welke de farmacokinetische en farmacodynamische eigenschappen van statines 
beïnvloeden de meest belovende target genen. Met de recentere genoom wijde 
associatie studies (GWAS) kan het gehele genoom hypothese-vrij geanalyseerd 
worden, wat nieuwe ontdekkingen mogelijk maakt. Hoewel al meerdere 
farmacogenetische GWAS de respons op statines hebben onderzocht, zijn er maar 
twee genetische varianten gevonden die consistent geassocieerd zijn met de variatie 
in LDL-cholesterol respons. Om ook farmacogenetisch onderzoek te kunnen doen in 
de PROSPER studie, is de PHArmacogenetic study of Statins in the Elderly at risk 
(PHASE) uitgevoerd. In hoofdstuk 3 tonen we resultaten van de eerste GWAS 
uitgevoerd in PHASE, hierin repliceren we de eerder gevonden associaties met LDL-
cholesterol levels. 
Een gevolg van het grote aantal statistische testen dat wordt uitgevoerd in een 
GWAS, is dat je een grote studiepopulatie nodig hebt om met genoeg statistische 
power kleine effecten aan te tonen. Voor het vinden van nieuwe associaties tussen 
genetische varianten en respons op statine behandeling is het essentieel om samen 
te werken met andere studies. Met dit doel is het Genomic Investigation of Statin 
Therapy (GIST) consortium gevormd, waarvan we in hoofdstuk 4 de eerste resultaten 
presenteren. Data van meer dan 40.000 met statine behandelde personen zijn 
meegenomen in deze analyse. We hebben twee nieuwe GWAS loci geassocieerd met 
LDL-cholesterol respons gevonden en gevalideerd, de SORT1/CELSR2/PSRC1 en 
SLCO1B1 loci. Daarnaast hebben we de eerder beschreven associaties met APOE en 
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LPA bevestigd. Deze bevindingen geven meer inzicht in de farmacogenetica van 
statine respons.   
De meeste farmacogenetische studies met betrekking tot statine therapie waren 
gericht op LDL-cholesterol verlaging. Daarentegen is weinig bekend over de 
genetische variatie geassocieerd met variabiliteit in cardiovasculaire event reductie 
na statine behandeling. In de PROSPER/PHASE studie konden wij geen genetische 
varianten vinden die geassocieerd zijn met een klinisch relevante differentiële event 
reductie na statine behandeling (hoofdstuk 5). Deze resultaten indiceren dat het nut 
van het gebruik van genetische informatie om statine behandeling  te personaliseren 
in de dagelijkse praktijk klein zal zijn. Echter, zoals eerder aangegeven, is voor het 
uitvoeren van een GWAS een grote studiepopulatie nodig voor het genereren van 
voldoende statistische power om kleine effecten aan te tonen. Voor het vergroten 
van de kans op het vinden van genetische varianten geassocieerd met differentiële 
event reductie, voert het GIST consortium momenteel een meta-analyse van 
verschillende GWA studies uit.  
De gevonden genetische varianten in de GIST GWAS meta-analyse verklaren 
gezamenlijk 5% van de variatie in LDL-cholesterol verlaging na statine behandeling 
(hoofdstuk 4). Of deze 5% klinisch relevant is, is nog onduidelijk en moet in nieuwe 
studies onderzocht worden.  In de PROSPER studie waren we niet in staat om 
genetische varianten te vinden welke geassocieerd zijn met een klinisch relevante 
differentiële event afname na pravastatine behandeling (hoofdstuk 5). Daarom 
kunnen we ons afvragen of het gebruik van farmacogenetica van (prava) statine 
therapie enige klinische relevantie zal hebben voor de individuele patiënt. Echter, 
nieuwe onderzoeksmethoden zoals exome sequencing kunnen zeldzame varianten 
met grotere effecten aan het licht brengen. Het doel van sequencing studies is het 
vinden van zeldzame varianten die in minder dan 1% van de bevolking voorkomen. 
Waarschijnlijk zal het lastig zijn deze resultaten toe te passen in de klinische praktijk. 
Het combineren van verschillende genetische varianten met kleine effecten in een 
genetische risico score (GRS) kan een andere optie zijn voor het gebruik van 
farmacogenetica in de klinische praktijk. 
In farmacogenetische studies worden non-responders vaak vergeleken met de high-
responders, met het doel om genetische varianten te identificeren welke 
geassocieerd zijn met de variatie in respons. In hoofdstuk 6 hebben we geprobeerd 
de vraag te beantwoorden of deze non-responders werkelijk non-responders zijn of 
dat zij therapie ontrouw zijn. Onze resultaten suggereren dat vele van de 
zogenoemde non-responders waarschijnlijk therapie ontrouw zijn, aangezien zij meer 
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klinische karakteristieken hebben die samen gaan met een laag ziekte bewustzijn. 
Verder geven deze resultaten aan dat andere strategieën gebruikt moeten worden 
voor het onderzoeken van de relatie tussen genetische varianten en respons op 
statine behandeling. In hoofdstuk 7 bespreken we of er indicaties zijn dat statines 
wereldwijd anders werken. Ondanks de vele verschillende bevolkingsgroepen 
wereldwijd, zijn de belangrijkste risicofactoren voor HVZ gelijk en zijn statines even 
efficiënt in alle onderzochte bevolkingsgroepen. Dit suggereert echter niet dat 
verschillende bevolkingsgroepen gecombineerd kunnen worden in farmacogenetisch 
onderzoek, aangezien de frequentie van genetische varianten kan variëren tussen 
bevolkingsgroepen.  
In hoofdstuk 8 hebben we geprobeerd de vraag te beantwoorden of verhoogde LDL-
cholesterol levels op hoge leeftijd nog steeds een risico factor zijn voor mortaliteit. 
Om problemen als confounding en omgekeerde causaliteit te voorkomen hebben we 
gebruik gemaakt van een LDL genetische risico score (GRS) gebaseerd op het 
Mendeliaanse randomisatie concept. De LDL GRS nam af met toenemende leeftijd en 
was significant geassocieerd met mortaliteit in de deelnemers van 90 jaar en ouder. 
Daarnaast hebben we aangetoond dat deelnemers met een genetische aanleg voor 
langlevendheid een lagere GRS hebben in vergelijking met deelnemers van de 
algemene populatie. Deze resultaten suggereren dat een genetische aanleg voor een 
hoog LDL-cholesterol ook op hoge leeftijd een risico factor is voor mortaliteit. Deze 
resultaten worden ondersteund door het feit dat statines ook in ouderen efficiënt 
zijn in de behandeling van HVZ. 
In de eerste hoofdstukken van dit proefschrift hebben we laten zien dat er 
momenteel weinig bewijs is voor een grote rol voor de genetica in het verklaren van 
de individuele variatie in respons op statine behandeling. In hoofdstuk 8 hebben we 
laten zien dat een genetische aanleg voor een hoog LDL-cholesterol een risico factor 
voor mortaliteit is, zelfs op hoge leeftijd. Daarom moet het verlagen van LDL-
cholesterol levels een belangrijk doel blijven bij het verlagen van het risico op HVZ. 
Momenteel zijn er nieuwe medicijnen om LDL-cholesterol te verlagen in 
ontwikkeling. Een van de veelbelovende medicijnen zijn de PCSK9 remmers. Wel is 
het nog onbekend wat het effect van deze medicijnen zal zijn op de cognitie en niet-
cardiovasculaire events. In hoofdstuk 9 hebben we onderzocht of genetische 
varianten in het PCSK9 gen geassocieerd zijn met de cognitieve functie en niet-
cardiovasculaire events in de PROSPER studie. We hebben aangetoond dat de 
genetische variant in het PCSK9 gen geassocieerd is met lagere LDL-cholesterol 
levels, maar niet met cognitieve functie en niet-cardiovasculaire events. Deze 
resultaten suggereren dat het niet waarschijnlijk is dat cholesterol verlaging door 
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middel van PCSK9 remmers invloed zal hebben op het cognitief functioneren of niet-
cardiovasculaire events.  
Toekomstperspectieven 
Genoom-wijde associatie studies zijn gedurende de laatste jaren een populaire 
methode geworden voor het onderzoeken van associaties tussen genetische 
varianten en de respons op medicatie. Het ultieme doel van farmacogenetische 
studies is het verbeteren en personaliseren van medicijn gebruik. In dit proefschrift 
laten we zien dat er momenteel weinig bewijs is voor een grote rol van de genetica in 
het verklaren van de individuele variatie in respons op statine behandeling. Voor een 
aantal andere medicijnen lijken de resultaten van farmacogenetisch onderzoek 
veelbelovend. Genetische varianten in de cytogroom P450 enzym CYP2C9 en 
vitamine K epoxide reductase genen verklaren tot 35% van de benodigde warfarine 
startdosering. Echter, de resultaten van drie recente klinische studies 
gebruikmakende van genetische informatie in de bepaling van de vitamine K 
antagonist dosering zijn teleurstellend. Deze laten zien dat de toepasbaarheid van 
genetisch testen voor de initiële vitamine K antagonist dosering minimaal of afwezig 
is.  
Hoewel de PROSPER/PHASE studie een van de grootste gerandomiseerde studies is 
voor het onderzoeken van statine farmacogenetica, is de populatie grootte mogelijk 
nog te klein. Voor het vergroten van de studiepopulatie is het samenwerken in grote 
consortia noodzakelijk. Om dit te bewerkstelligen is het GIST consortium gevormd 
(hoofdstuk 4). Binnen dit consortium zal ook gezocht worden naar genetische 
varianten die invloed hebben op de reductie van HVZ events na statine behandeling. 
In een andere analyse zal gezocht worden naar farmacogenetische effecten op C-
reactief proteïne (CRP) respons na statine behandeling. Statine behandeling is 
geassocieerd met een verlaging van CRP waarden onafhankelijk van LDL-cholesterol, 
dit weerspiegeld de ontstekingsremmende eigenschappen van statines. Mogelijk 
zullen deze analyses leiden tot de ontdekking van nieuwe genetische varianten welke 
betrokken kunnen zijn bij nieuwe mechanismes in de behandeling van HVZ. 
Recente ontwikkelingen als de sequencing van het gehele genoom en de 1000 
genomen imputatie zullen nieuwe mogelijkheden bieden voor het genetisch 
onderzoek. Met deze nieuwe methoden kan het genoom in nog meer detail 
geanalyseerd worden. Maar waarschijnlijk zal het gebruik van de 1000 genomen 
imputatie vooral leiden tot de verfijning van de eerder gevonden associaties doordat 
veel van de nieuwe associaties sterk gerelateerd zullen zijn aan de eerder gevonden 
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associaties met de HapMap imputaties. Het doel van sequencing studies is het vinden 
van zeldzame genetische varianten, aanwezig in minder dan 1% van de bevolking. 
Deze varianten zijn niet aanwezig op de chips welke momenteel gebruikt worden 
voor de GWAS, welke minder varianten bevatten en alleen de gebruikelijke 
varianten. Het is nog de vraag of de genetische varianten welke gevonden worden 
met sequencing, de zeldzame varianten met grote effecten, de nog ontbrekende 
verklaring van erfelijkheid zullen verklaren.  
In het genetisch onderzoek worden meer en meer analyses uitgevoerd die gebruik  
maken van Mendeliaanse randomisatie. Een genetische risico score is bijvoorbeeld 
gebruikt om de relatie tussen HDL-cholesterol en HVZ te onderzoeken. Gebaseerd op 
resultaten uit observationele studies, lijken een hoog LDL-cholesterol level en een 
laag HDL-cholesterol level belangrijke risico factoren te zijn voor HVZ. Bovendien zijn 
LDL-cholesterol verlagende behandelingen, bijvoorbeeld met statines, effectief in het 
verlagen van het HVZ risico. Daarentegen zijn HDL-cholesterol verhogende 
therapieën tot op heden nog niet effectief gebleken in de behandeling van HVZ. Door 
middel van Mendeliaanse randomisatie analyse is aangetoond dat HDL-cholesterol 
niet causaal geassocieerd is met het risico op het krijgen van een hartinfarct. LDL-
cholesterol bleek hier wel causaal mee geassocieerd te zijn. De meeste studies die de 
associatie tussen LDL-cholesterol en HVZ of mortaliteit hebben onderzocht zijn 
uitgevoerd in populaties van middelbare leeftijd. De enkele studies welke uitgevoerd 
zijn in ouderen hebben omgekeerde of geen associaties aangetoond. In dit 
proefschrift hebben we door middel van een Mendeliaanse randomisatie analyse 
aangetoond dat ook in ouderen een genetische aanleg voor een hoog LDL-cholesterol 
bijdraagt aan een verhoogd mortaliteitsrisico. Echter, de power van deze analyse was 
beperkt, de resultaten werden met name gedreven door een van de drie studies. Om 
het bewijs dat LDL-cholesterol ook in de ouderen een risicofactor is te vergroten, zal 
er vanuit het LUMC een meta-analyse uitgevoerd worden. In deze meta-analyse zal 
de associatie tussen LDL-cholesterol en HVZ worden onderzocht doormiddel van een 
LDL-cholesterol genetische risico score in verschillende leeftijdscategorieën.  
Conclusie 
LDL-cholesterol is een belangrijke risico factor voor HVZ, ook op hoge leeftijd. Het 
verlagen van LDL-cholesterol levels is daarom belangrijk in de behandeling van HVZ. 
Om de huidige behandeling te verbeteren zijn nieuwe medicijnen, zoals de PCSK9 
remmers, in ontwikkeling. Een andere mogelijkheid om de huidige behandeling te 
verbeteren, is door de behandeling te personaliseren aan de hand van iemands 
genetisch profiel. Door het personaliseren van de behandeling zal de polyfarmacie en 
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de kans op bijwerkingen verlaagd worden. Met de huidige genetische 
onderzoeksmethoden zijn vier genetische varianten gevonden welke geassocieerd 
zijn met de mate van LDL-cholesterol verlaging na statine behandeling. In dit 
proefschrift hebben we laten zien dat deze vier varianten slechts 5% van de 
geobserveerde variatie in LDL-cholesterol respons verklaren. Hierdoor zijn de 
mogelijkheden om statine behandeling te personaliseren op basis van iemands 
genetisch profiel tot op heden beperkt. Mogelijk bieden nieuwe 
onderzoeksmethoden nieuwe mogelijkheden tot het verbeteren van de behandeling 
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promotietraject stond onder leiding van prof. J.W. Jukema (afdeling Cardiologie) en 
prof. R.G.J. Westendorp (afdeling Ouderengeneeskunde). De resultaten hiervan staan 










Met dit proefschrift rond ik mijn promotieonderzoek af. Ik heb dit onderzoek 
natuurlijk niet alleen gedaan en hierbij wil ik iedereen bedanken die heeft 
bijgedragen aan de totstandkoming van dit proefschrift.  
Als eerste wil ik mijn promotoren, Professor Jukema en Professor Westendorp, 
bedanken voor de kans om te promoveren. Vier jaar geleden had ik niet gedacht dat 
promoveren iets voor mij zou zijn. Maar mede door jullie vertrouwen en begeleiding 
hebben we een aantal mooie artikelen geschreven en heb ik het promoveren leuk 
gevonden. Ook wil ik graag mijn co-promotor Dr. de Craen noemen. Beste Ton, jouw 
epidemiologische inzichten en kritische blik op ons onderzoek heb ik de afgelopen 
jaren zeer gewaardeerd. Stella, jou wil ik niet alleen bedanken voor alle begeleiding 
in het genetisch-epidemiologisch onderzoek, maar ook voor het gezelschap tijdens 
de diverse congressen.  
I would like to thank all members of the GIST consortium. Thanks for all the 
discussions during the conference calls. Hopefully a lot of nice papers will follow the 
Nature Communication publication. Daarnaast wil ik ook de collega’s van de afdeling 
Moleculaire epidemiologie bedanken voor al jullie inbreng op mijn onderzoek tijdens 
de gezamenlijke meetings.  
Ik wil alle promovendi en studenten van de afdeling ouderengeneeskunde bedanken. 
Jullie hebben er voor gezorgd dat dit proefschrift niet het enige aandenken is aan 
mijn tijd als promovendi, maar dat ik ook terug kan kijken op een aantal leuke en 
gezellige jaren.  
Als laatste wil ik Bart bedanken voor alles. Ze zeggen wel eens, promoveren is 
trouwen in je eentje. Ik ben blij dat ik eerst met jou heb mogen ‘oefenen’! 
 
 
 
  
 
 
 
